
<html lang="en"     class="pb-page"  data-request-id="7fda9956-f537-4635-9bd9-e1485948f6b5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2016.59.issue-5;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.5b01633"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants" /></meta><meta name="dc.Creator" content="Hengmiao  Cheng" /></meta><meta name="dc.Creator" content="Sajiv K.  Nair" /></meta><meta name="dc.Creator" content="Brion W.  Murray" /></meta><meta name="dc.Creator" content="Chau  Almaden" /></meta><meta name="dc.Creator" content="Simon  Bailey" /></meta><meta name="dc.Creator" content="Sangita  Baxi" /></meta><meta name="dc.Creator" content="Doug  Behenna" /></meta><meta name="dc.Creator" content="Sujin  Cho-Schultz" /></meta><meta name="dc.Creator" content="Deepak  Dalvie" /></meta><meta name="dc.Creator" content="Dac M.  Dinh" /></meta><meta name="dc.Creator" content="Martin P.  Edwards" /></meta><meta name="dc.Creator" content="Jun Li  Feng" /></meta><meta name="dc.Creator" content="Rose Ann  Ferre" /></meta><meta name="dc.Creator" content="Ketan S.  Gajiwala" /></meta><meta name="dc.Creator" content="Michelle D.  Hemkens" /></meta><meta name="dc.Creator" content="Amy  Jackson-Fisher" /></meta><meta name="dc.Creator" content="Mehran  Jalaie" /></meta><meta name="dc.Creator" content="Ted O.  Johnson" /></meta><meta name="dc.Creator" content="Robert S.  Kania" /></meta><meta name="dc.Creator" content="Susan  Kephart" /></meta><meta name="dc.Creator" content="Jennifer  Lafontaine" /></meta><meta name="dc.Creator" content="Beth  Lunney" /></meta><meta name="dc.Creator" content="Kevin K.-C.  Liu" /></meta><meta name="dc.Creator" content="Zhengyu  Liu" /></meta><meta name="dc.Creator" content="Jean  Matthews" /></meta><meta name="dc.Creator" content="Asako  Nagata" /></meta><meta name="dc.Creator" content="Sherry  Niessen" /></meta><meta name="dc.Creator" content="Martha A.  Ornelas" /></meta><meta name="dc.Creator" content="Suvi T. M.  Orr" /></meta><meta name="dc.Creator" content="Mason  Pairish" /></meta><meta name="dc.Creator" content="Simon  Planken" /></meta><meta name="dc.Creator" content="Shijian  Ren" /></meta><meta name="dc.Creator" content="Daniel  Richter" /></meta><meta name="dc.Creator" content="Kevin  Ryan" /></meta><meta name="dc.Creator" content="Neal  Sach" /></meta><meta name="dc.Creator" content="Hong  Shen" /></meta><meta name="dc.Creator" content="Tod  Smeal" /></meta><meta name="dc.Creator" content="Jim  Solowiej" /></meta><meta name="dc.Creator" content="Scott  Sutton" /></meta><meta name="dc.Creator" content="Khanh  Tran" /></meta><meta name="dc.Creator" content="Elaine  Tseng" /></meta><meta name="dc.Creator" content="William  Vernier" /></meta><meta name="dc.Creator" content="Marlena  Walls" /></meta><meta name="dc.Creator" content="Shuiwang  Wang" /></meta><meta name="dc.Creator" content="Scott L.  Weinrich" /></meta><meta name="dc.Creator" content="Shuibo  Xin" /></meta><meta name="dc.Creator" content="Haiwei  Xu" /></meta><meta name="dc.Creator" content="Min-Jean  Yin" /></meta><meta name="dc.Creator" content="Michael  Zientek" /></meta><meta name="dc.Creator" content="Ru  Zhou" /></meta><meta name="dc.Creator" content="John C.  Kath" /></meta><meta name="dc.Description" content="First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients’ disease progresses, often..." /></meta><meta name="Description" content="First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients’ disease progresses, often..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 28, 2016" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01633" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2016 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01633" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01633" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01633" /></link>
        
    
    

<title>Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01633" /></meta><meta property="og:title" content="Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0010.jpeg" /></meta><meta property="og:description" content="First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients’ disease progresses, often driven by a second-site mutation in the EGFR kinase domain (T790M). Another liability of the first generation drugs is severe adverse events driven by inhibition of WT EGFR. As such, our goal was to develop a highly potent irreversible inhibitor with the largest selectivity ratio between the drug-resistant double mutants (L858R/T790M, Del/T790M) and WT EGFR. A unique approach to develop covalent inhibitors, optimization of reversible binding affinity, served as a cornerstone of this effort. PF-06459988 was discovered as a novel, third generation irreversible inhibitor, which demonstrates (i) high potency and specificity to the T790M-containing double mutant EGFRs, (ii) minimal intrinsic chemical reactivity of the electrophilic warhead, (iii) greatly reduced proteome reactivity relative to earlier irreversible EGFR inhibitors, and (iv) minimal activity against WT EGFR." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01633"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01633">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01633&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01633&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01633&amp;href=/doi/10.1021/acs.jmedchem.5b01633" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 5</span><span class="cit-fg-pageRange">, 2005-2024</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/5" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01618" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01629" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of 1-{(3<i>R</i>,4<i>R</i>)-3-[({5-Chloro-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hengmiao++Cheng">Hengmiao Cheng</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sajiv+K.++Nair">Sajiv K. Nair</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brion+W.++Murray">Brion W. Murray</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chau++Almaden">Chau Almaden</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Bailey">Simon Bailey</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sangita++Baxi">Sangita Baxi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Doug++Behenna">Doug Behenna</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sujin++Cho-Schultz">Sujin Cho-Schultz</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Deepak++Dalvie">Deepak Dalvie</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dac+M.++Dinh">Dac M. Dinh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martin+P.++Edwards">Martin P. Edwards</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jun+Li++Feng">Jun Li Feng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Rose+Ann++Ferre">Rose Ann Ferre</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ketan+S.++Gajiwala">Ketan S. Gajiwala</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michelle+D.++Hemkens">Michelle D. Hemkens</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Amy++Jackson-Fisher">Amy Jackson-Fisher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mehran++Jalaie">Mehran Jalaie</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ted+O.++Johnson">Ted O. Johnson</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+S.++Kania">Robert S. Kania</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan++Kephart">Susan Kephart</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jennifer++Lafontaine">Jennifer Lafontaine</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Beth++Lunney">Beth Lunney</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+K.-C.++Liu">Kevin K.-C. Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Zhengyu++Liu">Zhengyu Liu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jean++Matthews">Jean Matthews</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Asako++Nagata">Asako Nagata</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sherry++Niessen">Sherry Niessen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Martha+A.++Ornelas">Martha A. Ornelas</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Suvi+T.+M.++Orr">Suvi T. M. Orr</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mason++Pairish">Mason Pairish</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Simon++Planken">Simon Planken</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shijian++Ren">Shijian Ren</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Richter">Daniel Richter</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kevin++Ryan">Kevin Ryan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Neal++Sach">Neal Sach</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Shen">Hong Shen</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tod++Smeal">Tod Smeal</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jim++Solowiej">Jim Solowiej</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Sutton">Scott Sutton</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Khanh++Tran">Khanh Tran</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elaine++Tseng">Elaine Tseng</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William++Vernier">William Vernier</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Marlena++Walls">Marlena Walls</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuiwang++Wang">Shuiwang Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott+L.++Weinrich">Scott L. Weinrich</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuibo++Xin">Shuibo Xin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Haiwei++Xu">Haiwei Xu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Min-Jean++Yin">Min-Jean Yin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Zientek">Michael Zientek</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ru++Zhou">Ru Zhou</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+C.++Kath">John C. Kath</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">La Jolla Laboratories, Pfizer Worldwide Research and Development, 10770 Science Center Drive, San Diego, California 92121, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">Wuxi AppTec, 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China</span></div><div class="corresp-info"><strong>*</strong>H.C.: e-mail, <a href="/cdn-cgi/l/email-protection#2149444f53580f4249444f46615147485b44530f424e4c"><span class="__cf_email__" data-cfemail="127a777c606b3c717a777c755262747b6877603c717d7f">[email protected]</span></a>; phone, 858-622-3208.</div><div class="corresp-info"><strong>*</strong>S.K.N.: email, <a href="/cdn-cgi/l/email-protection#0c7f6d66657a226722626d657e4c7c6a6576697e226f6361"><span class="__cf_email__" data-cfemail="5724363d3e21793c7939363e251727313e2d32257934383a">[email protected]</span></a>; phone, 858-526-4894.</div><div class="corresp-info"><strong>*</strong>B.W.M.; e-mail, <a href="/cdn-cgi/l/email-protection#305242595f5e1e5d4542425149704056594a55421e535f5d"><span class="__cf_email__" data-cfemail="7d1f0f1412135310080f0f1c043d0d1b1407180f531e1210">[email protected]</span></a>; phone, 858-622-6038.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01633&amp;href=/doi/10.1021%2Facs.jmedchem.5b01633" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 5</span><span class="cit-pageRange">, 2005–2024</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 12, 2016</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 October 2015</li><li><span class="item_label"><b>Published</b> online</span>28 January 2016</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 10 March 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01633" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01633</a></div><div class="article_header-article-copyright"><strong>Copyright © 2016 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2005%26pageCount%3D20%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DHengmiao%2BCheng%252C%2BSajiv%2BK.%2BNair%252C%2BBrion%2BW.%2BMurray%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D5%26contentID%3Dacs.jmedchem.5b01633%26title%3DDiscovery%2Bof%2B1-%257B%25283R%252C4R%2529-3-%255B%2528%257B5-Chloro-2-%255B%25281-methyl-1H-pyrazol-4-yl%2529amino%255D-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%257Doxy%2529methyl%255D-4-methoxypyrrolidin-1-yl%257Dprop-2-en-1-one%2B%2528PF-06459988%2529%252C%2Ba%2BPotent%252C%2BWT%2BSparing%252C%2BIrreversible%2BInhibitor%2Bof%2BT790M-Containing%2BEGFR%2BMutants%26numPages%3D20%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2024%26publicationDate%3DMarch%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01633"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">5142</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">57</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01633" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Hengmiao&quot;,&quot;last_name&quot;:&quot;Cheng&quot;},{&quot;first_name&quot;:&quot;Sajiv&quot;,&quot;last_name&quot;:&quot;K. Nair&quot;},{&quot;first_name&quot;:&quot;Brion&quot;,&quot;last_name&quot;:&quot;W. Murray&quot;},{&quot;first_name&quot;:&quot;Chau&quot;,&quot;last_name&quot;:&quot;Almaden&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Bailey&quot;},{&quot;first_name&quot;:&quot;Sangita&quot;,&quot;last_name&quot;:&quot;Baxi&quot;},{&quot;first_name&quot;:&quot;Doug&quot;,&quot;last_name&quot;:&quot;Behenna&quot;},{&quot;first_name&quot;:&quot;Sujin&quot;,&quot;last_name&quot;:&quot;Cho-Schultz&quot;},{&quot;first_name&quot;:&quot;Deepak&quot;,&quot;last_name&quot;:&quot;Dalvie&quot;},{&quot;first_name&quot;:&quot;Dac&quot;,&quot;last_name&quot;:&quot;M. Dinh&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;P. Edwards&quot;},{&quot;first_name&quot;:&quot;Jun&quot;,&quot;last_name&quot;:&quot;Li Feng&quot;},{&quot;first_name&quot;:&quot;Rose&quot;,&quot;last_name&quot;:&quot;Ann Ferre&quot;},{&quot;first_name&quot;:&quot;Ketan&quot;,&quot;last_name&quot;:&quot;S. Gajiwala&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;D. Hemkens&quot;},{&quot;first_name&quot;:&quot;Amy&quot;,&quot;last_name&quot;:&quot;Jackson-Fisher&quot;},{&quot;first_name&quot;:&quot;Mehran&quot;,&quot;last_name&quot;:&quot;Jalaie&quot;},{&quot;first_name&quot;:&quot;Ted&quot;,&quot;last_name&quot;:&quot;O. Johnson&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;S. Kania&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;Kephart&quot;},{&quot;first_name&quot;:&quot;Jennifer&quot;,&quot;last_name&quot;:&quot;Lafontaine&quot;},{&quot;first_name&quot;:&quot;Beth&quot;,&quot;last_name&quot;:&quot;Lunney&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;K.-C. Liu&quot;},{&quot;first_name&quot;:&quot;Zhengyu&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Jean&quot;,&quot;last_name&quot;:&quot;Matthews&quot;},{&quot;first_name&quot;:&quot;Asako&quot;,&quot;last_name&quot;:&quot;Nagata&quot;},{&quot;first_name&quot;:&quot;Sherry&quot;,&quot;last_name&quot;:&quot;Niessen&quot;},{&quot;first_name&quot;:&quot;Martha&quot;,&quot;last_name&quot;:&quot;A. Ornelas&quot;},{&quot;first_name&quot;:&quot;Suvi&quot;,&quot;last_name&quot;:&quot;T. M. Orr&quot;},{&quot;first_name&quot;:&quot;Mason&quot;,&quot;last_name&quot;:&quot;Pairish&quot;},{&quot;first_name&quot;:&quot;Simon&quot;,&quot;last_name&quot;:&quot;Planken&quot;},{&quot;first_name&quot;:&quot;Shijian&quot;,&quot;last_name&quot;:&quot;Ren&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Richter&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;Ryan&quot;},{&quot;first_name&quot;:&quot;Neal&quot;,&quot;last_name&quot;:&quot;Sach&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Shen&quot;},{&quot;first_name&quot;:&quot;Tod&quot;,&quot;last_name&quot;:&quot;Smeal&quot;},{&quot;first_name&quot;:&quot;Jim&quot;,&quot;last_name&quot;:&quot;Solowiej&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Sutton&quot;},{&quot;first_name&quot;:&quot;Khanh&quot;,&quot;last_name&quot;:&quot;Tran&quot;},{&quot;first_name&quot;:&quot;Elaine&quot;,&quot;last_name&quot;:&quot;Tseng&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;Vernier&quot;},{&quot;first_name&quot;:&quot;Marlena&quot;,&quot;last_name&quot;:&quot;Walls&quot;},{&quot;first_name&quot;:&quot;Shuiwang&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;L. Weinrich&quot;},{&quot;first_name&quot;:&quot;Shuibo&quot;,&quot;last_name&quot;:&quot;Xin&quot;},{&quot;first_name&quot;:&quot;Haiwei&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Min-Jean&quot;,&quot;last_name&quot;:&quot;Yin&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Zientek&quot;},{&quot;first_name&quot;:&quot;Ru&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;C. Kath&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2016&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;28&quot;,&quot;issue&quot;:&quot;5&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;2005-2024&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01633&quot;},&quot;abstract&quot;:&quot;First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients’ disease progresses, often driven by a second-site mutation in the EGFR kinase domain (T790M). Another liability of the first generation drugs is severe adverse events driven by inhibition of WT EGFR. As such, our goal was to develop a highly potent irreversible inhibitor with the largest selectivity ratio between the drug-resistant double mutants (L858R/T790M, Del/T790M) and WT EGFR. A unique approach to develop covalent inhibitors, optimization of reversible binding affinity, served as a cornerstone of this effort. PF-06459988 was discovered as a novel, third generation irreversible inhibitor, which demonstrates (i) high potency and specificity to the T790M-containing double mutant EGFRs, (ii) minimal intrinsic chemical reactivity of the electrophilic warhead, (iii) greatly reduced proteome reactivity relative to earlier irreversible EGFR &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01633&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01633" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01633&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01633" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01633&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01633" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01633&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01633&amp;href=/doi/10.1021/acs.jmedchem.5b01633" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01633" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01633" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (3 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26pmid%3D26756222%26genre%3Darticle%26aulast%3DCheng%26date%3D2016%26atitle%3DDiscovery%2Bof%2B1-%257B%25283R%252C4R%2529-3-%255B%2528%257B5-Chloro-2-%255B%25281-methyl-1H-pyrazol-4-yl%2529amino%255D-7H-pyrrolo%255B2%252C3-d%255Dpyrimidin-4-yl%257Doxy%2529methyl%255D-4-methoxypyrrolidin-1-yl%257Dprop-2-en-1-one%2B%2528PF-06459988%2529%252C%2Ba%2BPotent%252C%2BWT%2BSparing%252C%2BIrreversible%2BInhibitor%2Bof%2BT790M-Containing%2BEGFR%2BMutants%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D5%26spage%3D2005%26epage%3D2024%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (3)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291316" title="Mixtures">Mixtures</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291352" title="Screening assays">Screening assays</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/5" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/jmcmar.2016.59.issue-5/20160310-01/jmcmar.2016.59.issue-5.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">First generation EGFR TKIs (gefitinib, erlotinib) provide significant clinical benefit for NSCLC cancer patients with oncogenic EGFR mutations. Ultimately, these patients’ disease progresses, often driven by a second-site mutation in the EGFR kinase domain (T790M). Another liability of the first generation drugs is severe adverse events driven by inhibition of WT EGFR. As such, our goal was to develop a highly potent irreversible inhibitor with the largest selectivity ratio between the drug-resistant double mutants (L858R/T790M, Del/T790M) and WT EGFR. A unique approach to develop covalent inhibitors, optimization of <i>reversible binding affinity</i>, served as a cornerstone of this effort. PF-06459988 was discovered as a novel, third generation irreversible inhibitor, which demonstrates (i) high potency and specificity to the T790M-containing double mutant EGFRs, (ii) minimal intrinsic chemical reactivity of the electrophilic warhead, (iii) greatly reduced proteome reactivity relative to earlier irreversible EGFR inhibitors, and (iv) minimal activity against WT EGFR.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec fnGroup"><div class="fnGroupItem" id="extra"><span><h4></h4></span><span><p class="last">Compound <b>1</b> (PF-06459988) is commercially available via Sigma-Aldrich (catalog no. PZ0296).</p></span></div></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32466" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32466" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Lung cancer is the leading cause of cancer-related death worldwide, with an estimated over 1 million new cases diagnosed and over 1 million deaths each year.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In non-small-cell lung cancer (NSCLC), which accounts for 85% of lung cancer, patients harboring mutations in EGFR constitute between 10% and 30% of the overall patient population. Two frequent and mutually exclusive primary mutations occur either in the activation loop as a point mutation (EGFR L858R) or by short deletion in exon 19 (EGFR-Del), together accounting for approximately 85% of all cases.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> These somatic EGFR mutants enable constitutive activation and are strong predictive biomarkers of response to first generation EGFR TKIs (gefitinib<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> and erlotinib<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a>) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). In contrast, these drugs are dose-limited by potent inhibition of their originally intended target wild type (WT) EGFR, which causes epithelium-based toxicities by blocking its role in normal adult physiology.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> Treatment of EGFR mutant NSCLC patients with the first generation EGFR TKIs provides excellent response rates and disease control for 11–14 months, but patients invariably become resistant to these therapies, and their disease progresses. Of the drug-resistant EGFR mutant NSCLC patients, approximately 60% harbor an additional mutation in the EGFR kinase domain (T790M) in <i>cis</i> with the primary activating mutation<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> that renders the receptor insensitive to inhibition by the EGFR TKIs and thus restoring constitutive EGFR signaling. The resistance mechanism derived from T790M mutation is believed to come from a number of components, including the increased ATP binding affinity for T790M mutants, the steric clash between the Met790 gatekeeper side chain and the aniline moiety that is utilized by the first generation EGFR TKIs to bind in the kinase back-pocket, and the altered catalytic domain conformation.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8-10)</a></div><div class="NLM_p">The first generation of EGFR drugs relied on reversible affinity to achieve potency. More recently, a covalent inhibition strategy has been used because it delivers distinct pharmacological properties. Irreversible kinase inhibitors can achieve advantages over reversible compounds by delivering complete and sustained target engagement in the presence of high intracellular concentrations of ATP in the cells and by requiring the physical turnover of kinase proteins to restore inhibited signaling pathways.<a onclick="showRef(event, 'ref11 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref11 ref12 ref13">(11-13)</a> Indeed, second generation, irreversible inhibitors of EGFR WT (canertinib (CI-1033);<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> dacomitinib;<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> afatinib<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a>) (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) which covalently modify EGFR Cys797 demonstrate increased cellular potency against T790M mutants relative to their reversible counterparts. However, because these compounds maintain the aniline moiety that clashes with Met790 side chain, their T790M activity is less than their activity against the primary activating EGFR mutants. As a result, their clinical efficacy to treat T790M patients is limited due to dose-limiting toxicity associated with inhibition of WT EGFR.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0012.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Summary of first generation and second generation EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In response to this unmet need and because irreversible inhibitors demonstrated better potency against EGFR T790M mutants than reversible inhibitors, an effort was initiated to discover highly potent irreversible inhibitors of the drug resistant T790M mutants that spare EGFR WT activity to the greatest extent as a means to minimize mechanism-based toxicities. Others have pursued irreversible inhibitors of EGFR T790M, resulting in the identification of WZ-4002<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> (<b>7</b>), rociletinib<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> (CO-1686, <b>8</b>), and osimertinib<a onclick="showRef(event, 'ref19 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref19 ref20 ref21">(19-21)</a> (AZD9291, <b>9</b>) (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Both rociletinib and osimertinib have progressed to advanced clinical trials. In addition, there are several recent publications discussing the design and SAR for novel third generation irreversible EGFR inhibitors.<a onclick="showRef(event, 'ref22 ref23 ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24 ref25 ref26">(22-26)</a> The discovery of 1-{(3<i>R</i>,4<i>R</i>)-3-[({5-chloro-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988,<b>1</b>),<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> a highly potent inhibitor of EGFR T790M with unprecedented selectivity over EGFR WT, is described in this manuscript.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0013.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Summary of third generation EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10010" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10010" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Objective</h3><div class="NLM_p">The inactivation of EGFR occurs through a two-step process that begins with reversible binding to EGFR followed by covalent bond formation with the thiol of Cys797 to form a covalent adduct (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Therefore, irreversible inhibitor potency can be increased by maximizing the reversible binding affinity (<i>K</i><sub>i</sub> = <i>k</i><sub>off</sub>/<i>k</i><sub>on</sub>), the specific reactivity (<i>k</i><sub>inact</sub>), or the inherent chemical reactivity of the electrophile. In addition to optimizing T790M potency and selectivity over WT, an equally significant emphasis was placed on reducing warhead reactivity to minimize proteome-wide reactivity and decrease the probability of idiosyncratic toxicity. To achieve these multiple objectives, a key strategy was to optimize the potency of inhibitors based on their reversible (noncovalent) binding affinity to EGFR T790M as opposed to the chemical reactivity of the warhead. To effectively carry out this strategy, a high capacity binding kinetics assay was developed which is capable of separating the reversible binding affinity from the inactivation rate. Typically, irreversible kinetic analysis to determine reversible affinity (<i>K</i><sub>i</sub>) and specific reactivity <i>k</i><sub>inact</sub> is low throughput and labor intensive. However, to truly leverage binding affinity SAR, it was essential to be able to test all new inhibitors on a weekly basis. To do so, a high throughput irreversible kinetics screening assay capable of coarsely defining reversible binding affinity (<i>K</i><sub>i</sub><sup>est</sup>) and overall irreversible inactivation (<i>k</i><sub>obs</sub>/I) was developed. Specialized reaction conditions were used to enhance the predictability of this method.<a onclick="showRef(event, 'ref29 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31">(29-31)</a> Since an inhibitor’s inactivation rate is governed by a pseudo-second-order rate constant (<i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>), it is highly dependent on the inhibitor concentration and its chemical properties. It was recognized that in any given week a range of inhibitors would be tested from weak binders to highly optimized inhibitors. To address this issue, five inhibitor concentrations (0.01, 0.05, 0.1, 1, and 5 μM) were selected to ensure at least one or two are in the proper range to measure the initial reversible binding event (between 25% and 80% inhibition of the initial linear (60–120 s) portion of the inactivation time-course). When the initial region of the inactivation time course is linear, then the dominant contribution to inhibition is reversible binding affinity. Placing a constraint on the observed percent inhibition (25–80%) kept the measurement in an accurate region, enough inhibition to be confident in the binding affinity but not too much that there is a large contribution from reactivity or too slow of an enzymatic rate to be accurate. The full inactivation time course for a given inhibitor concentration is defined by a rate constant (<i>k</i><sub>obs</sub>). To normalize the contribution of the inhibitor concentration to the observed inactivation rate, it is divided by the inhibitor concentration (<i>k</i><sub>obs</sub>/I). This value encompasses contributions from both reversible binding affinity and chemical reactivity. Under the assay conditions, <i>k</i><sub>obs</sub>/I is correlated to <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>. To determine the correlation between <i>K</i><sub>i</sub><sup>est</sup> and <i>K</i><sub>i</sub>, both established and absolute values were generated for a structurally diverse set of compounds using the L858R/T790M enzyme (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). The correlation between these values supported the use of <i>K</i><sub>i</sub><sup>est</sup> for inhibitor design.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0014.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinetic mechanism for two-step covalent inhibition of EGFR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0015.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Correlation between absolute and estimated <i>K</i><sub>i</sub> values, <i>R</i><sup>2</sup> = 0.68.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The irreversible screening assay provides two important pieces of data from an appropriate progression curve: (1) the percent inhibition value at the drug concentration used to generate that curve which provides the <i>K</i><sub>i</sub><sup>est</sup> and (2) the <i>k</i><sub>obs</sub>/I value (which is proportional to <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub>) from that same progression curve which provides a measure of enzyme inactivation. The assay consistently provided data for multiple compounds each week (medium number of compounds per week = 14; maximum number of compounds run in 1 week = 91) and became the primary assay used throughout the duration of the program.</div><div class="NLM_p last">The irreversible screening assay was supplemented with two additional assays to round out the set of primary screens used to fully characterize irreversible inhibitor SAR. To further assist in minimizing warhead reactivity, a glutathione (GSH) conjugation assay was developed which monitored parent compound loss in the presence of GSH to establish a half-life.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Canertinib was used as a control, and the half-lives of test compounds were normalized to that of canertinib (<i>t</i><sub>1/2</sub> ≈ 21 min), to describe the intrinsic chemical reactivity of the warhead. To drive toward the critical objective of achieving the high levels of selectivity for EGFR T790M over EGFR WT, a pair of cellular ELISA assays were used which measure the ability of a compound to inhibit phosphorylation of EGFR L858R/T790M (H1975 cells) relative to EGFR WT (A549 cells).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Establishing Early Leads</h3><div class="NLM_p">The critical structural difference in the surface of the ATP binding pocket between EGFR WT and the T790M mutant resides at the gatekeeper residue. This mutation changes the amino acid residue from the polar threonine to a nonpolar methionine. Therefore, to attain the largest difference in potency between EGFR T790M and EGFR WT, optimizing hydrophobic interactions between an inhibitor and the Met790 side chain may provide high levels of T790M potency and selectivity. Modeling studies indicated that the pyrrole portion of a pyrrolopyrimidine (PP) core would achieve effective hydrophobic interactions with the Met790 side chain and provide an additional hydrogen bond interaction with the backbone carbonyl of Gln791 (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>).</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0016.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Modeled interactions of PP core with Met790 and hinge residue of monomeric L858R/T790M EGFR. Hydrophobic surface of the binding site is near the hinge, and T790M is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Initial designs with the PP core led to the identification of an early lead, compound <b>10</b> (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). This compound had a high binding affinity to the L858R/T790M double mutant (DM) with a <i>K</i><sub>i</sub><sup>est</sup> of 2 nM (43% inhibition at 0.05 μM) and a substantial inactivation rate with <i>k</i><sub>obs</sub>/I of 51 300 M<sup>–1</sup> s<sup>–1</sup>. The <i>k</i><sub>obs</sub>/I value was obtained at 0.05 μM inhibitor concentration. The substantial inactivation rate for <b>10</b> was confirmed by the measured <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> rate of 59 123 000 M<sup>–1</sup> s<sup>–1</sup>. Compound <b>10</b> was an attractive lead, potently inhibiting EGFR L858R/T790M autophosphorylation (IC<sub>50</sub> = 4 nM) in the H1975 cell line but only modestly inhibiting EGFR WT autophosphorylation (IC<sub>50</sub> = 0.79 μM) in the A549 cell line. Relative to benchmark compound canertinib in a glutathione conjugation assay, compound <b>10</b> exhibits a 6-fold reduction in intrinsic chemical reactivity with thiol nucleophiles.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0017.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Summary of key in vitro potency and WT selectivity data for <b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Using our crystallography platform,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> we obtained a cocrystal structure of <b>10</b> with monomeric EGFR L858R/T790M (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>a). The 1.5 Å ligand–protein complex shows covalent modification of the target residue Cys797 via the Michael acceptor of the ligand. The enzyme is in a unique conformation for EGFR relative to previous structures with respect to the Asp855-Phe856-Gly857 (DFG) motif and the activation loop conformation. While the Phe856 side chain is oriented out of the hydrophobic core of the protein, partially occupying the ATP binding site, the Asp855 side chain is positioned into the hydrophobic core in a DFG-out conformation. The conformation of the rest of the activation loop is nearly identical to that in the active EGFR kinase domain. There is an approximately 20° rotation of the N-lobe relative to the C-lobe when compared with the apoprotein structure (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>b) requiring unwinding of the first turn of the αC-helix in the ligand-bound structure.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0018.jpeg" id="GRAPHIC-d123e1104-autogenerated" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (a) Monomeric L858R + T790M ligand bound conformation (yellow) vs EGFR WT active (green). A classic DFG-out conformation is observed in the ligand bound T790M structure; however, the activation loop is in a state nearly identical to the active form. The Phe856 side chain is oriented out of the protein core, partially occupying the ATP binding site, and the Asp855 side chain is positioned into the hydrophobic core. (b) Comparison of the monomeric L858R + T790M protein conformations in the apo (blue) and the ligand bound (yellow) states. Rotation of the N-lobe and α-C helix occurs on ligand binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The cocrystal structure suggests that the binding affinity of <b>10</b> is achieved through specific and nonspecific interactions with the protein independent of the covalent bond formation with Cys797 (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). The PP core establishes specific donor–acceptor–donor interactions with the backbone atoms of hinge residues 791–793. The phenoxy linker occupies the ATP-sugar binding site and forms a van der Waals interaction with Phe856 from the DFG motif. The G-loop is well ordered with the Phe723 side chain turned inward toward the ligand binding site to make van der Waals contact with Phe856. The phenyl ring of the phenylpiperazine group is engaged in van der Waals interactions with hinge residues 794–796, while the piperazine ring projects into the solvent region without any visible specific interactions with the protein. Two key water interactions are observed: one between nitrogen of the ligand’s propionamide group, the backbone atom of the Arg841 and the side chain carbonyl of the Asn842, and a second between the carbonyl of the acrylamide and the backbone of Cys797. The side chain of the mutated gatekeeper residue Met790 forms hydrophobic interactions with the pyrrole of the PP core (distance between the β carbon of Met790 and the C2 carbon atom of the pyrrole ring is 3.7 Å). In contrast, when this same ligand is modeled in the WT enzyme, the C2 atom of the pyrrole comes within 2.7 Å of the hydroxyl group of the gatekeeper Thr790 residue (the modeling result is discussed in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">Supporting Information</a>). This unfavorable interaction is the presumed origin of the high selectivity for drug-resistant T790M mutant EGFR over WT.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0019.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>10</b> complex with monomeric L858R + T790M KD (1.5 Å). Two views are shown. Hydrogen bonds to the hinge are shown, with key protein residues highlighted in stick form. Some parts of the protein are omitted for clarity. Clear covalent modification of Cys797 is observed. The ligand phenoxy group interacts with Phe856 through VDW interactions. Two key waters are also highlighted (red spheres).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An edge–face π-interaction exists between the phenyl rings of the anilinopiperazine and the phenoxy linker which may assist in optimally positioning the acrylamide warhead to enable reaction with Cys797.</div><div class="NLM_p">Next, the primary liabilities of <b>10</b> were addressed, specifically poor permeability (RRCK <a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(33, 34)</a> = 2 × 10<sup>–6</sup> cm/s), potent dofetilide binding activity (IC<sub>50</sub> = 1 μM), and high clogP (4.6). The highly basic 4-piperazinylaniline was thought to play a significant role in these liabilities. Replacement of the aniline with an aminopyrazole isostere was envisioned to provide a less lipophilic, metabolically stable surrogate which (unlike the aniline) would be less prone to reactive metabolite formation.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Furthermore, the lower lipophilicity of an aminopyrazole functionality might enable removal of the basic amine found in the piperazinylaniline resulting in a more ligand-efficient lead. To investigate this possibility, the N1-methyl-3-amino- and N1-methyl-4-aminopyrazoles <b>11</b> and <b>12</b> were prepared (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Both compounds demonstrated increased permeability and decreased dofetilide binding activity relative to <b>10</b> while maintaining good EGFR L858R/T790M potency and selectivity over EGFR WT (>100-fold). Ligand efficiency (LE, calculated from <i>K</i><sub>i</sub><sup>est</sup>) for <b>11</b> and <b>12</b> are 0.41 and 0.45, respectively, which are significantly higher than LE of 0.37 for <b>10</b>. The 4-aminopyrazole <b>12</b> better matched the EGFR T790M binding affinity, inactivation rate (<i>k</i><sub>obs</sub>/I), cellular potency, and intrinsic chemical reactivity to GSH of <b>10</b> but showed increased microsomal clearance relative to <b>10</b> and <b>11</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Summary of Early Leads</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0005.gif" alt="" id="fx1" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">log <i>D</i> was measured at pH 7.4.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Human liver microsomal intrinsic clearance.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Permeability measured with low-efflux MDCKII cell.</p></div><div class="footnote" id="t1fn4"><sup>Table d</sup><p class="last">Chemical reactivity of warhead with glutathione relative to canertinib at pH 7.4.</p></div><div class="footnote" id="t1fn5"><sup>Table e</sup><p class="last">Inhibitor concentration at which the <i>k</i><sub>obs</sub>/I is calculated.</p></div></div><div></div></div><div class="NLM_p">The 1.4 Å cocrystal structure of <b>12</b> (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>) is similar to that of <b>10</b>, with the pyrazole making a similar edge–face interaction with the phenyl ether bearing the warhead. The two C–H bonds on the pyrazole ring in <b>12</b> are polarized, and the C–H at the 3-position of the pyrazole forms a weak nonclassical H bond with the backbone carbonyl of Met793 in the hinge. The lower binding affinity of the 3-aminopyrazole <b>11</b> can be explained by the unfavorable interaction between the pyrazole 2-N and the backbone carbonyl of Met793 in an orientation that maintains the edge–face interaction between the pyrazole and phenyl ether.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0020.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>12</b> binding interactions with the monomeric EGFR L858R/T790M binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Having established the <i>N</i>-methyl-4-aminopyrazole as a suitable isostere for the 4-piperazinylaniline, the linker region of the molecule was optimized as a means to reduce metabolic clearance and further minimize the reactivity of the warhead.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Aliphatic Linkers to Minimize Warhead Reactivity</h3><div class="NLM_p">The intrinsic chemical reactivity of a warhead is influenced by the electronic properties of the linker, in this case the aromatic ring from which the warhead is connected. In order to mitigate the potential of forming off-target covalent adducts, the design strategy was to minimize the warhead’s reactivity by avoiding electron deficient linking motifs. It was predicted that utilizing <i>aliphatic</i> linkers would remove the conjugative effects of aromatic systems (e.g., phenoxy linker of <b>12</b>, anilide of canertinib) on the warhead and afford reduced reactivity. A 3-pyrrolidinemethyl ether linker was identified to have the appropriate length, orientation, and conformational constraint<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> to position the warhead for a reaction with Cys797. Compound <b>13</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) was synthesized and tested; however, the <i>K</i><sub>i</sub><sup>est</sup> of 590 nM and negligible irreversible inactivation (<i>k</i><sub>obs</sub>/I of 830 M<sup>–1</sup> s<sup>–1</sup> at 1 μM) indicated that significant optimization was required.</div><div class="NLM_p">To increase binding affinity, a small hydrophobic pocket (identified from the cocrystal structure of <b>12</b>) under the G-loop, created by residues Phe723 and Val726, was targeted. Modeling of <b>13</b> (using the protein structure of <b>12</b> cocrystal structure) suggested that a small lipophilic group at the pyrrolidine 4 position would be suited (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>); thus a CF<sub>3</sub> group was installed (chosen for metabolic stability benefits over methyl or ethyl) resulting in compound <b>14</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). This molecule provided a 17-fold increase in potency (<i>K</i><sub>i</sub><sup>est</sup> = 35 nM) and an increase in irreversible activation (<i>k</i><sub>obs</sub>/I of 5410 M<sup>–1</sup> s<sup>–1</sup> at 1 μM) relative to <b>13</b>. However, introduction of the CF<sub>3</sub> group was concomitant with higher intrinsic reactivity compared to other aliphatic linkers tested with the intrinsic reactivity of <b>14</b> relative to canertinib (9×), similar to that observed with <b>12</b> (7×). In order to improve the potency of the aliphatic linker compounds, alternative opportunities were sought to increase binding affinity using pyrrolidine substituents that do not increase the intrinsic reactivity.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0021.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Comparison of modeled binding mode of <b>13</b> (stick, in blue color) in monomeric L858R/T790M EGFR and bound conformation of <b>14</b> (ball and stick, in green color) in cocrystal structure with the same protein. Cocrystal structure of <b>14</b> with monomeric L858R/T790M EGFR demonstrates that the CF<sub>3</sub> binds in the G loop hydrophobic pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Summary of Initial Aliphatic Linker Designs</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0006.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last">log <i>D</i> was measured at pH 7.4.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Human liver microsomal intrinsic clearance.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Permeability measured with low-efflux MDCKII cell.</p></div><div class="footnote" id="t2fn4"><sup>Table d</sup><p class="last">Chemical reactivity of warhead relative to canertinib (half-life in glutathione buffer at pH 7.4).</p></div><div class="footnote" id="t2fn5"><sup>Table e</sup><p class="last">Inhibitor concentration at which the <i>k</i><sub>obs</sub>/I is calculated.</p></div></div><div></div></div><div class="NLM_p">To help understand the binding mode and ligand conformation of <b>14</b>, its cocrystal structure was determined at 2.2 Å resolution (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>). Although the crystal structure does not reflect the transition state conformation for the covalent bond formation between Cys797 and the warhead acrylamide, it is evident that the conformation of the linker -OCH<sub>2</sub>- is constrained in an orientation <i>syn</i> to the nitrogen of the pyrimidine. The pyrrolidine occupies the space extending from the sugar binding pocket to the triphosphate recognition site of the active site, and the substituents at the 3 and 4 positions of the pyrrolidine ring adopt a trans diaxial conformation. Ligand torsional profile analysis suggests that the minimum energy conformation of <b>14</b> in solution has the linker -OCH<sub>2</sub>- coplanar with the core. In contrast, the bound conformation has the -OCH<sub>2</sub>- rotated out of conjugation to the core, resulting in a strain energy penalty (∼1.4 kcal/mol, calculated with Amber force field) which is compensated for by the binding energy gained from the strong interactions between the CF<sub>3</sub> and the protein.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0022.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Crystal structure of <b>14</b> in complex with monomeric L858R/T790M EGFR (2.2 Å). The CF<sub>3</sub> group fills a small hydrophobic pocket, affording a 17-fold increase in binding affinity. Note interaction between the CF3 group and Phe723 and Phe526.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> 5-Cl Pyrrolopyrimidine Scaffold Significantly Increases Intrinsic Binding Affinity</h3><div class="NLM_p">The cocrystal structure of <b>14</b> also revealed an opportunity to increase binding affinity via targeting an unoccupied hydrophobic pocket near the gatekeeper residue. Placing a halogen at the 5-position of the pyrrolopyrimidine was predicted to fill this pocket. A Cl substitution demonstrated significant increases in both binding affinity <i>and</i> irreversible inactivation (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a><b>)</b>. Relative to <b>13</b> and <b>14</b>, introduction of 5-Cl to afford <b>15</b> and <b>16</b> yielded a 74- and 12-fold increase in <i>K</i><sub>i</sub><sup>est</sup>, respectively. In addition to the enhanced binding affinity, a substantial increase in the inactivation rate was achieved, with <i>k</i><sub>obs</sub>/I values of 19 100 and 51 400 M<sup>–1</sup> s<sup>–1</sup>, respectively. Computational analysis of ligand conformational energy profile predicts that introduction of the halogen at the 5-position will further constrain the linker in an optimal conformation to position the warhead to react with Cys797 (ligand torsional strain energy analysis to support this hypothesis is described in <a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">Supporting Information</a>). This, together with additional hydrophobic interactions with the G loop, yielded consistently potent aliphatic linkers (see pairwise plot, <a class="ref internalNav" href="#fig12" aria-label="Figure 12">Figure 12</a>) and provided the opportunity to optimize the linker in the absence of electron withdrawing groups. The intrinsic reactivity of compound <b>15</b> was more than 19-fold lower than that of canertinib, indicating that high potency, high inactivation rate, and low intrinsic reactivity could all be achieved within the aliphatic linker subseries.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0023.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Pairwise comparison between 5-Cl and 5-H pyrrolopyrimidine analogs. Chlorine substitution of the 5-position of the PP core afforded a 47-fold average increase in binding affinity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Lead Optimization</h3><div class="NLM_p">Compound <b>15</b> had high permeability (RRCK = 13 × 10<sup>–6</sup> cm/s) with significant cellular activity (pEGFR H1975 IC<sub>50</sub> = 45 nM) and high selectivity over EGFR WT (>73×). However, the high metabolic clearance needed to be addressed in order to achieve a desirable human PK profile. The cocrystal structure of <b>14</b> reveals that the CF<sub>3</sub> binds very tightly in the G-loop hydrophobic pocket, with the CF<sub>3</sub> directly interacting with the Phe723 side chain phenyl ring (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>). As half of the CF<sub>3</sub> moiety was exposed to solvent, it presented an opportunity to modulate metabolic stability by replacing the CF<sub>3</sub> with small polar groups. On the basis of the outcome from modeling studies and in silico ADME predictions, -F, -OMe, -OH, -CH<sub>2</sub>OH, and -CH<sub>2</sub>OMe replacements for -CF<sub>3</sub> were explored (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Summary of Lead Optimization</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0007.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0008.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last">log <i>D</i> was measured at pH 7.4. LipE = −[log(H1975 cell IC<sub>50</sub>)] – log <i>D</i>.</p></div><div class="footnote" id="t3fn2"><sup>Table c</sup><p class="last">Human liver microsomal intrinsic clearance.</p></div><div class="footnote" id="t3fn3"><sup>Table d</sup><p class="last">Permeability measured with low-efflux MDCKII cell.</p></div><div class="footnote" id="t3fn4"><sup>Table e</sup><p class="last">Chemical reactivity of warhead relative to canertinib (half-life in glutathione buffer at pH 7.4).</p></div><div class="footnote" id="t3fn5"><sup>Table f</sup><p class="last">Inhibitor concentration at which the <i>k</i><sub>obs</sub>/I is calculated.</p></div></div><div></div></div><div class="NLM_p">Pyrrolidine derivatives <b>1</b> (PF-06459988), <b>17</b>–<b>20</b> demonstrate potent affinity and high inactivation rates with an improvement in metabolic stability relative to compound <b>16</b>. In the cellular assay, <b>1</b>, <b>17</b>, and <b>20</b> were highly potent against L858R/T790M DM and highly selective over WT. Compounds <b>18</b> and <b>19</b>, substituted with an alcohol or hydroxymethyl at the 4-position of the pyrrolidine ring, exhibited low permeability and consequently reduced cellular potency. Compound <b>1</b> emerged as providing the best balance of overall properties including potency, WT selectivity, intrinsic chemical reactivity, ADME properties, and the highest LipE. Its enantiomer (<b>21</b>) exhibited a <i>k</i><sub>obs</sub>/I of 2010 M<sup>–1</sup> s<sup>–1</sup>, indicating modest to no irreversible inhibition, and was less potent in both the enzyme assay (<i>K</i><sub>i</sub><sup>est</sup> = 32 nM) and the cellular assay (H1975 cell IC<sub>50</sub> = 120 nM). This suggests the optimum alignment of the acrylamide warhead with Cys797 is critical for the observed high potency for <b>1</b>.</div><div class="NLM_p">A 1.9 Å cocrystal structure of <b>1</b> in complex with EGFR L858R/T790M DM shows a great deal of similarity to that of <b>14</b> (<a class="ref internalNav" href="#fig13" aria-label="Figure 13">Figure 13</a>). The substituents at the 3- and 4-positions of the pyrrolidine ring adopt a trans-diaxial conformation, which places the polarized methyl of the methoxy group at the 4-position in van der Waals contact with the aromatic side chain of Phe856, which in turn interacts edge to face with the side chain phenyl of Phe723. In addition, the Cl substituent at the 5-position of the PP core interacts with both the Phe856 side chain and the Met790 side chain through hydrophobic interactions. Ligand strain energy analysis using Bachmin V2.0<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> indicates that the bound conformation of compound <b>1</b> possess minimal strain energy (see <a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">Supporting Information</a> for details), which is consistent with the very high binding affinity and cellular potency that it demonstrates against L858R/T790M mutant.</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0024.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Crystal structure of <b>1</b> in complex with monomeric L858R/T790M EGFR (1.9 Å). The diaxial conformation of the pyrroldine places the OMe in van der Waals contact with both the Phe856 of the DFG motif and the Phe723 of the G-loop.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Characterization of Compound <b>1</b></h3><div class="NLM_p">Since compound <b>1</b> emerged as a project lead by having the best overall balance of properties, it was characterized in detail in both biochemical and cellular assays (<a class="ref internalNav" href="#tbl4" aria-label="Tables 4">Tables 4</a>, <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">SI-1, SI-2</a>). Compound <b>1</b> is a potent and efficient inhibitor of EGFR L858R/T790M DM (<i>K</i><sub>i</sub> = 13 nM, <i>k</i><sub>inact</sub> = 0.02 s<sup>–1</sup>, <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> = 1 530 000 M<sup>–1</sup> s<sup>–1</sup>) and shows modest activity toward WT EGFR (<i>K</i><sub>i</sub><sup>est</sup> = 1600 nM, <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub><sup>est</sup> = 4520 M<sup>–1</sup> s<sup>–1</sup>, <a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">Table SI-1</a>). Its cellular biochemical potency was characterized in NSCLC cell lines including H1975 (L858R/T790M), PC9-DRH (Del/T790M), H3255 (L858R), PC9 (Del), HCC827 (Del), and A549 (WT) (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Rociletinib, osimertinib, and erlotinib were also evaluated in the same NSCLC cell lines. Compound <b>1</b>, rociletinib, and osimertinib all demonstrate very high cellular potency against T790M-containing double mutant EGFRs. Rociletinib and osimertinib demonstrate good cellular potency against the oncogenic mutants L858R and Del. In comparison, <b>1</b> also demonstrates good cellular potency against L858R mutant, albeit moderate cellular potency against Del mutant in the PC9 cell line. Erlotinib demonstrates very high cellular potency against both oncogenic mutants and WT EGFR but is inactive against T790M-containing double mutants. Compound <b>1</b> spares WT EGFR and hence demonstrates the highest selectivity between the least potent target and WT EGFR.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Cellular Potency and Selectivity Profile of <b>1</b>, Rociletinib, Osimertinib, and Erlotinib</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center">L858R/T790M</th><th class="colsep0 rowsep0" align="center">Del/T790M</th><th class="colsep0 rowsep0" align="center">L858R</th><th class="colsep0 rowsep0" align="center">Del</th><th class="colsep0 rowsep0" align="center">Del</th><th class="colsep0 rowsep0" align="center">WT</th><th class="colsep0 rowsep0" align="center">WT/DM (L858R/T790M)</th><th class="colsep0 rowsep0" align="center">WT/least potent target</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">H1975 IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">PC9-DRH IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">H3255 IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">PC9 IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">HCC827 IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">A549 IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center">ratio</th><th class="colsep0 rowsep0" align="center">ratio</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">7</td><td class="colsep0 rowsep0" align="left">21</td><td class="colsep0 rowsep0" align="left">140</td><td class="colsep0 rowsep0" align="left">90</td><td class="colsep0 rowsep0" align="left">5100</td><td class="colsep0 rowsep0" align="left">392</td><td class="colsep0 rowsep0" align="left">36</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rociletinib</td><td class="colsep0 rowsep0" align="left">16</td><td class="colsep0 rowsep0" align="left">9</td><td class="colsep0 rowsep0" align="left">46</td><td class="colsep0 rowsep0" align="left">79</td><td class="colsep0 rowsep0" align="left">65</td><td class="colsep0 rowsep0" align="left">1600</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="left">20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">osimertinib</td><td class="colsep0 rowsep0" align="left">15</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="left">36</td><td class="colsep0 rowsep0" align="left">56</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">150</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">erlotinib</td><td class="colsep0 rowsep0" align="left">9000</td><td class="colsep0 rowsep0" align="left">9700</td><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">8</td><td class="colsep0 rowsep0" align="left">11</td><td class="colsep0 rowsep0" align="left">0.0012</td><td class="colsep0 rowsep0" align="left">1</td></tr></tbody></table></div></div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Proteome-Wide Selectivity</h3><div class="NLM_p">Cysteine is the most intrinsically nucleophilic proteinaceous residue, and many protein classes rely on cysteine for function.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Irreversible EGFR inhibitors with high intrinsic reactivity for the warhead have the potential to cross-react, either specifically or nonspecifically, with other proteins, including those outside the kinome, which may lead to unanticipated toxicities. To compare the broad proteome reactivity between <b>1</b> (GSH reactivity ratio of 15) and canertinib (GSH reactivity ratio of 1), clickable probes of these two compounds were designed to enable activity-based protein profiling by installing the alkyne at positions that would neither perturb the intrinsic reactivity of the Michael acceptors nor interfere with the binding to EGFR. Physiochemical and biological properties for the probe for canertinib (<b>22</b>) and the probe for <b>1</b> (<b>23</b>), including cellular IC<sub>50</sub> against wild type and double mutant EGFR, and <i>K</i><sub>obs</sub>/<i>I</i> and GSH reactivities, closely matched the properties for canertinib and <b>1</b>, respectively (<a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Comparison of Properties for <b>1</b> and Canertinib with Their Corresponding Probes</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0009.gif" alt="" id="GRAPHIC-d123e2096-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>Table a</sup><p class="last">log <i>D</i> was measured at pH 7.4.</p></div><div class="footnote" id="t5fn2"><sup>Table b</sup><p class="last">Permeability measured with low-efflux MDCKII cell.</p></div><div class="footnote" id="t5fn3"><sup>Table c</sup><p class="last">Chemical reactivity of warhead with glutathione relative to canertinib at pH 7.4.</p></div><div class="footnote" id="t5fn4"><sup>Table d</sup><p class="last">Inhibitor concentration at which the <i>k</i><sub>obs</sub>/I is calculated.</p></div></div><div></div></div><div class="NLM_p">Initial experiments were performed in the EGFR L858R/T790M mutant H1975 lung cancer cell line. In situ reactivity of the two probes by gel-based analysis was derived from an H1975 in vitro experiment, where cells were treated with 1 μM compound for 15 min to 24 h before the H1975 cells were harvested (<a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>). Fractionated cellular lysates were reacted with azide-rhodamine (N<sub>3</sub>-Rh) under standard copper-catalyzed azide–alkyne cycloaddition (CuACC) conditions.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Covalently probe-modified proteins were revealed by their in-gel fluorescence. Both chemical probes displayed increasing amounts of proteome reactivity in the soluble (<a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>, top) and particulate (<a class="ref internalNav" href="#fig14" aria-label="Figure 14">Figure 14</a>, bottom) proteomes as the length of probe incubation was increased. Compound <b>23</b> (probe to <b>1</b>) displayed a slower, gradual increase in reactivity compared to <b>22</b> (probe to canertinib). The covalently modified proteins included both overlapping and unique targets. The identification of the covalent targets will be revealed in a later manuscript. In agreement with their warhead intrinsic chemical reactivity, considerably more proteome reactivity was observed for <b>22</b> than for <b>23</b>. This was especially apparent at a 1 h time point in H1975 cells (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">Figure SI-1A in Supporting Information</a>) where a more than 50% reduction in total off-target labeling signal was observed (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">Figure SI-1B in Supporting Information</a>). Similarly, more off-target labeling in H3255 cells was observed, where H3255 expresses only the L858R single mutant form of EGFR (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">Figure SI-1C in Supporting Information</a>).</div><div class="NLM_p">Thus, by minimizing the intrinsic chemical reactivity of the electrophilic warhead, <b>1</b> demonstrates significantly increased proteome wide selectivity over canertinib. This is likely one of the reasons that only minimal findings were observed from toxicity studies with <b>1</b>, with duration up to 1 month in mice and dogs at in vivo exposures exceeding antitumor efficacy levels.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0025.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Time-course in situ labeling profiles of 1 μM <b>22</b> (probe to canertinib, left) and <b>23</b> (probe to <b>1</b>, right) in H1975 cells separated into soluble (top) and particulate (bottom) proteomes. H1975 cells were treated for 15 min to 24 h before being harvested. Lysates were analyzed by gel-based florescence, and gels are shown in grayscale. A specific protein with the molecular weight matching that of EGFR is highlighted with a ∗ in the particulate proteome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The kinase selectivity of <b>1</b> was evaluated by multiple biochemical methodologies, and the compound was judged to have moderate kinase selectivity (for details, see <a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">Supporting Information</a>). A variety of in vitro and in vivo safety studies with <b>1</b> were also carried out to understand the potential safety risks due to its moderate kinase selectivity. The potential risks did not translate under more physiologically relevant conditions (i.e., functional in vitro assays and at in vivo exposures exceeding antitumor efficacy levels).</div><div class="NLM_p last">When evaluated in PK/PD and TGI studies in mice implanted with tumor cell lines harboring T790M-containing double mutants L858R/T790M and Del/T790M, <b>1</b> demonstrated robust PK/PD correlation and tumor growth inhibition. A manuscript discussing the results from these in vivo studies including PK/PD and TGI studies will be disclosed in due course.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_06344" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_06344" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The synthesis of compounds <b>10</b>–<b>12</b> began with the incorporation of the trimethylsilylethoxymethyl or SEM-protecting group<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> to 2,4-dichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>24</b> using SEM-Cl and LiHMDS to give <b>25</b> (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>). The phenoxy linker in intermediate <b>26</b> was then introduced using <i>tert</i>-butyl (3-hydroxyphenyl)carbamate and potassium carbonate. Attachment of the key hinge binding heteroaromatic amino side chains was achieved using Buchwald–Hartwig aminations under microwave conditions to yield the amines <b>27</b>–<b>29</b>. Selective deprotection of the Boc group in compounds <b>27</b> and <b>28</b> followed by acryloylation gave the acrylamides <b>30</b> and <b>31</b>. A two-step deprotection of the SEM protecting group was done using trifluoroacetic acid in the first step which led to partial cleavage of the SEM protecting group giving intermediates <b>32</b> and <b>33</b> containing an <i>N</i>-hydroxymethyl moiety. Although these intermediates were not isolated, they were observable by <sup>1</sup>H NMR and showed a characteristic peak at δ 5.38 (see <a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">Supporting Information</a> for the <sup>1</sup>H NMR of intermediate <b>32</b>).<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> The deprotection was completed by treating these intermediates with potassium carbonate to yield the final acrylamides <b>10</b> and <b>11</b>. Alternatively, acrylamide <b>12</b> was obtained by deprotection of the Boc group and partial deprotection of the SEM protecting group in compound <b>29</b> using TFA, acryloylation followed by final deprotection.</div><figure id="sch1" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0026.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) TMSCH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>Cl, LiHMDS, THF, 79%; (b) <i>tert</i>-butyl (3-hydroxyphenyl)carbamate, K<sub>2</sub>CO<sub>3</sub>, MeCN, 90%; (c) ArNH<sub>2</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, Xantphos, 1,4-dioxane, microwave, 43–87%; (d) HCl, 1,4-dioxane; (e) CH<sub>2</sub>═CHCOCl, DCM or THF, 65–70% (steps d and e); (f) TFA, DCM; (g ) K<sub>2</sub>CO<sub>3</sub>, MeOH or EtOH, 46–77% (steps f and g); (h) (i) CH<sub>2</sub>═CHCOCl, DCM, (ii) K<sub>2</sub>CO<sub>3</sub>, EtOH, 47% (steps f and h).</p></p></figure><div class="NLM_p">Compounds <b>13</b> and <b>23</b> were synthesized in a similar fashion starting from pyrrolo[2,3-<i>d</i>]pyrimidine <b>25</b> and reacting it with the alcohols <b>35</b> and <b>36</b> under basic conditions (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). The installation of the aminopyrazole was done using Buchwald–Hartwig amination conditions, and this was followed by the aforementioned two-step deprotection protocol to remove the Boc- and SEM-protecting groups. Acryloylation of the corresponding pyrrolidines to the acrylamides <b>13</b> and <b>23</b> was carried out under carefully monitored conditions using DIPEA and acryloyl chloride to minimize bis-acryloylated side products.</div><figure id="sch2" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) KHMDS, 1,4-dioxane; (b) 1-alkyl-1<i>H</i>-pyrazol-4-amine, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, Xantphos, 1,4-dioxane, microwave; (c) TFA, DCM; (d) K<sub>2</sub>CO<sub>3</sub>, MeOH, H<sub>2</sub>O or NH<sub>4</sub>OH, 1,4-dioxane; (e) CH<sub>2</sub>═CHCOCl, DIPEA, DCM or CH<sub>2</sub>═CHCOCl, THF; <b>13</b>, 0.9% over 5 steps; <b>23</b>, 11% over 5 steps.</p></p></figure><div class="NLM_p">Route optimization efforts were initiated to overcome the harsh conditions required for the Buchwald–Hartwig amination step and to avoid the need for the capricious <i>N</i>-SEM protecting group. To this end, a 196-well screen using two solvents, 1,4-dioxane and toluene, two bases, cesium carbonate and potassium <i>tert</i>-pentoxide, and 48 catalyst–ligand combinations was utilized to review the amination of an unprotected model substrate, 4-(benzyloxy)-2-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine <b>41</b>, with 1-methyl-1<i>H</i>-pyrazol-4-amine (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. 196-Well Amination Screen</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">This screening effort led to the finding that the Buchwald–Hartwig amination can indeed be carried out under milder conditions using an unprotected 2-chloro-pyrrolo[2,3-<i>d</i>]pyrimidine core. The optimized conditions for the amination were <i>tert</i>-BuXPhos palladacycle and potassium <i>tert</i>-pentoxide in 1,4-dioxane at 90 °C. Further refinement of the sequence led to the discovery of an efficient one-pot protocol (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) wherein excess potassium <i>tert</i>-pentoxide (4 equiv) was used as the base to append the alkoxy linker using an appropriate alcohol and 1,4-dioxane as solvent in the first step. After 30 min of aging, <i>tert</i>-BuXPhos palladacycle and the appropriate amine were added to the same pot and the reaction mixture was warmed to 90 °C to complete the incorporation of the heteroaromatic amino side chain. After purification, the Boc-protecting group was cleaved using trifluoroacetic acid to give <b>46</b>. Further optimization of the final acryloylation step indicated that Schotten–Baumann conditions using aqueous sodium bicarbonate and acryloyl chloride in ethyl acetate were most optimal for a robust acryloylation. The synthesis of acrylamide <b>1</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>) illustrates the effectiveness of this atom-economic sequence. This sequence was also used to synthesize the acrylamides <b>14</b>–<b>21</b> using appropriate alcohols to introduce the relevant alkoxy linkers (see <a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">Supporting Information</a> for details).</div><figure id="sch4" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Potassium <i>tert</i>-pentoxide, 1,4-dioxane; (b) 1-methyl-1<i>H</i>-pyrazol-4-amine, <i>tert</i>-BuXPhos palladacycle, 79% over two steps; (c) TFA, DCM, 99%; (d) CH<sub>2</sub>═CHCOCl, aq NaHCO<sub>3</sub>, EtOAc, 77%.</p></p></figure><div class="NLM_p">The synthesis of the chiral alcohol <b>36</b> was achieved as outlined in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. A [3 + 2]-cycloaddition reaction of methyl (<i>E</i>)-3-methoxyacrylate (<b>47</b>) with an azomethine ylide generated in situ from <i>N</i>-benzyl-1-methoxy-<i>N</i>-((trimethylsilyl)methyl)methanamine (<b>48</b>) provided the racemic pyrrolidine ester <b>49</b>. Chiral separation of this racemic ester using chiral supercritical fluid chromatography (SFC) yielded the requisite enantiomer <b>50</b>. The benzyl protecting group in <b>50</b> was then removed under hydrogenolysis conditions and replaced with a Boc protecting group using Boc<sub>2</sub>O. The final step involved the reduction of the ester using lithium borohydride which yielded (3<i>R</i>,4<i>R</i>)-<b>36</b>.</div><figure id="sch5" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) <b>48</b>, TFA, 73%; (b) chiral-SFC (Chiralpak AD-H) 32%; (c) (i) H<sub>2</sub> (1 atm), 10% Pd(OH)<sub>2</sub> (6%), EtOH, (ii) Boc<sub>2</sub>O, 98%; (d) LiBH<sub>4</sub>, THF, 92%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46202" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46202" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Compound <b>1</b> has been discovered as a potent irreversible inhibitor of T790M mutant EGFR, having excellent selectivity against EGFR WT while possessing a minimally reactive electrophile that reduces the propensity of off-target labeling. Critical to the success of the program was the development of an assay capable of separating out the affinity and reactivity components that contribute to the overall potency of each inhibitor. This enables affinity driven SAR. Proteomic evaluation of <b>1</b> in H1975 cells confirmed a reduction of off-target labeling relative to canertinib. Follow-up efforts to optimize kinome selectivity and potency against the oncogenic EGFR Del will be published in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31828" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31828" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> General</h3><div class="NLM_p">Starting materials and other reagents were purchased from commercial suppliers and were used without further purification unless otherwise indicated. All reactions were performed under a positive pressure of nitrogen, argon or with a drying tube at ambient temperature (unless otherwise stated) in anhydrous solvents, unless otherwise indicated. Analytical thin-layer chromatography was performed on glass-backed silica gel 60_F 254 plates (Analtech (0.25 mm)) and eluted with the appropriate solvent ratios (v/v).</div><div class="NLM_p last">The reactions were assayed by high performance liquid chromatography (HPLC) or thin-layer chromatography (TLC) and terminated as judged by the consumption of starting material. The TLC plates were visualized by phosphomolybdic acid stain or iodine stain. Microwave assisted reactions were run in a Biotage initiator. <sup>1</sup>H NMR spectra were recorded on a Bruker instrument operating at 400 MHz unless otherwise indicated. <sup>1</sup>H NMR spectra are obtained as DMSO-<i>d</i><sub>6</sub> or CDCl<sub>3</sub> solutions as indicated (reported in ppm), using chloroform as the reference standard (7.25 ppm) or DMSO-<i>d</i><sub>6</sub> (2.50 ppm). Other NMR solvents were used as needed. When peak multiplicities are reported, the following abbreviations are used: s = singlet, d = doublet, t = triplet, m = multiplet, br = broadened, dd = doublet of doublets, dt = doublet of triplets. Coupling constants, when given, are reported in hertz. The mass spectra were obtained using liquid chromatography–mass spectrometry (LC–MS) on an Agilent instrument using atmospheric pressure chemical ionization (APCI) or electrospray ionization (ESI). High resolution mass measurements were carried out on an Agilent TOF 6200 series with ESI. All test compounds showed >95% purity as determined by combustion analysis or by high-performance liquid chromatography (HPLC). HPLC conditions were as follows: XBridge C18 column at 80 °C, 4.6 mm × 150 mm, 5 μm, 5–95% MeOH/H<sub>2</sub>O buffered with 0.2% formic acid/0.4% ammonium formate, 3 min run, flow rate 1.2 mL/min, UV detection (λ = 254, 224 nm). Combustion analyses were performed by Atlantic Microlab, Inc. (Norcross, GA).</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> 2,4-Dichloro-7-{[2-(trimethylsilyl)ethoxy]methyl}-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>25</b>)</h3><div class="NLM_p last">In a 1000 mL flask, LiHMDS (140 mL, 140 mmol) was diluted in dry THF (100 mL) and cooled to −78 °C. 2,4-Dichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (25.0 g, 133 mmol) was suspended in THF (200 mL) using gentle warming and sonication. This suspension was added dropwise to the LiHMDS solution over 30 min. Additional THF (50 mL) was used to dissolve any residue from the flask, and this suspension was also added dropwise to the LiHMDS solution. After complete addition, the mixture was allowed to stir at −78 °C for 30 min. SEM-Cl (25 mL, 140 mmol) was added dropwise to the mixture, and stirring was continued at −78 °C for 30 min. The ice bath was allowed to slowly warm to room temperature overnight. The reaction was quenched by the addition of cold water (150 mL). EtOAc (200 mL) was added, and the layers were separated. The resulting aqueous layer was extracted with EtOAc (2 × 200 mL). The combined organics were washed with brine (2×) and dried over MgSO<sub>4</sub>, filtered, and concentrated. The orange oil was purified via gravity “plug” chromatography, eluting with 80% heptanes/20% DCM to afford the title compound (33.4 g, 79% yield) as an orange oil which solidified upon standing: LC–MS (APCI) <i>m</i>/<i>z</i> for C<sub>12</sub>H<sub>17</sub>Cl<sub>2</sub>N<sub>3</sub>OSi 318.00/320.05 (M + H)<sup>+</sup> for Cl isotopes; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.38 (d, <i>J</i> = 3.78 Hz, 1 H), 6.67 (d, <i>J</i> = 3.53 Hz, 5 H), 5.61 (s, 2 H), 3.50–3.59 (m, 2 H), 0.85–0.99 (m, 2 H), −0.03 (s, 9 H).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> <i>tert</i>-Butyl {3-[(2-Chloro-7-{[2-(trimethylsilyl)ethoxy]methyl}-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy]phenyl}carbamate (<b>26</b>)</h3><div class="NLM_p last">To a solution of <b>25</b> (1470 mg, 4.62 mmol) in acetonitrile (10 mL) was added <i>tert</i>-butyl (3-hydroxyphenyl)carbamate (966 mg, 4.62 mmol) and K<sub>2</sub>CO<sub>3</sub> (1280 mg, 9.24 mmol), and the mixture heated at 80 °C overnight. The reaction was cooled to room temperature, EtOAc (20 mL) was added, the mixture was washed with water (50 mL), and the aqueous layer was extracted with EtOAc (3 × 20 mL), dried with MgSO<sub>4</sub>, filtered, and concentrated to give a light oil. Upon standing, the light oil solidified to give the title compound (2.05 g, 90% yield) as a tan solid: LC–MS (ESI) <i>m</i>/<i>z</i> for C<sub>23</sub>H<sub>31</sub>ClN<sub>4</sub>O<sub>4</sub>Si 491.20 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.38–9.83 (m, 1 H), 7.73 (d, <i>J</i> = 3.78 Hz, 1 H), 7.41–7.46 (m, 2 H), 7.51 (s, 1 H), 6.97 (dt, <i>J</i> = 5.98, 2.68 Hz, 1 H), 6.58 (d, <i>J</i> = 3.78 Hz, 1 H), 5.64 (s, 2 H), 3.54–3.67 (m, 2 H), 1.54 (s, 9 H), 0.91–0.96 (m, 2 H), 0.00 (s, 9 H).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> General Procedure for the Synthesis of Anilines <b>27</b>–<b>29</b></h3><div class="NLM_p last">To a solution of <b>26</b> (0.61 mmol) in 1,4-dioxane (4 mL) in a microwave vial was added the amine (0.61 mmol) followed by Cs<sub>2</sub>CO<sub>3</sub> (0.915 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (0.009 mmol), and Xantphos (0.009 mmol), and the mixture was heated in the microwave at 140 °C for 45 min. The reaction was cooled to room temperature, brine (20 mL) was added, and the mixture was extracted with EtOAc (3 × 10 mL). The combined extracts were dried over MgSO<sub>4</sub>, filtered, and concentrated to give the anilines.</div></div><div id="sec5_2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> <i>tert</i>-Butyl (3-((2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)carbamate (<b>27</b>)</h3><div class="NLM_p last">Purified over silica gel with gradients from 100% heptane to 90% ethyl acetate–10% ammonia in methanol (7 N) to yield the title product (1.56 g, 81% yield): LC–MS (APCI) <i>m</i>/<i>z</i> 646.3 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.60 (s, 1 H), 9.08 (s, 1 H), 7.59 (d, <i>J</i> = 8.31 Hz, 2 H), 7.46–7.53 (m, 2 H), 7.40–7.46 (m, 1 H), 7.29 (d, <i>J</i> = 3.78 Hz, 1 H), 6.95 (d, <i>J</i> = 8.06 Hz, 1 H), 6.81 (d, <i>J</i> = 8.81 Hz, 2 H), 6.40 (d, <i>J</i> = 3.53 Hz, 1 H), 5.57 (s, 2 H), 3.64 (t, <i>J</i> = 8.06 Hz, 2 H), 3.03–3.18 (m, 4 H), 2.48–2.56 (m, 4 H), 2.31 (s, 3 H), 1.55 (s, 9 H), 0.95 (t, <i>J</i> = 8.06 Hz, 2 H), 0.00 (s, 10 H).</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> <i>tert</i>-Butyl (3-((2-((1-Methyl-1<i>H</i>-pyrazol-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)carbamate (<b>28</b>)</h3><div class="NLM_p last">Purified over silica gel with gradients from 0% to 10% methanol in dichloromethane to yield the title product (1446 mg, 87% yield): LC–MS (APCI) <i>m</i>/<i>z</i> 552.25 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.49 (s, 1 H), 9.29 (s, 1 H)7.28–7.46 (m, 4 H), 7.19 (d, <i>J</i> = 3.53 Hz, 1 H), 6.87 (d, <i>J</i> = 7.55 Hz, 1 H), 6.34 (br s, 1 H), 6.20 (d, <i>J</i> = 3.53 Hz, 1 H), 5.47 (s, 2 H), 3.67 (s, 3 H), 3.50–3.57 (m, 2 H), 1.46 (s, 9 H), 0.77–0.89 (m, 2 H), −0.10 (s, 9 H).</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>tert</i>-Butyl (3-((2-((1-Methyl-1<i>H</i>-pyrazol-4-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)carbamate (<b>29</b>)</h3><div class="NLM_p last">Purified over silica gel with gradients from 0% to 10% ethanol in 50% heptane/50% ethyl acetate to yield the title product (175 mg, 43% yield): LC–MS (APCI) <i>m</i>/<i>z</i> 552.20 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.69–9.35 (m, 1H), 9.23–9.08 (m, 1H), 7.61–7.29 (m, 4H), 7.23–7.12 (m, 1H), 6.94–6.77 (m, 1H), 6.51–6.33 (m, 1H), 5.70–5.23 (m, 2H), 3.77–3.60 (m, 2H), 3.59–3.48 (m, 3H), 1.45 (s, 9H), 0.85 (s, 2H), −0.09 (s, 9H).</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> General Procedure for the Synthesis of Acrylamides <b>30</b>, <b>31</b></h3><div class="NLM_p"><i>Step 1:</i> To a solution of the pyrrolopyrimidine <b>27</b> or <b>28</b> (1 equiv) in DCM (5 mL) was added 4 M HCl in dioxane (5 equiv), and the reaction mixture was stirred at room temperature for 1 h. Evaporation of the solvent provided an intermediate which was taken on to the next step without further purification.</div><div class="NLM_p last"><i>Step 2:</i> To a solution of crude anilines (1 equiv) in THF or DCM was added dropwise prop-2-enoyl chloride (1 equiv), and the mixture was stirred at room temperature for 0.25–1 h. Saturated aqueous NaHCO<sub>3</sub> (10 mL) was added, and the product was extracted using EtOAc (3 × 10 mL), dried with MgSO<sub>4</sub>, filtered, concentrated.</div></div><div id="sec5_3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>N</i>-(3-((2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)acrylamide (<b>30</b>)</h3><div class="NLM_p last">Purified over silica gel with a gradient of 0–10% methanol in ethyl acetate to yield the title product (288 mg, 76% yield, 2 steps): LC–MS (APCI) <i>m</i>/<i>z</i> 600.20 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, MeOH- <i>d</i><sub>4</sub>) δ 7.66–7.76 (m, 2 H), 7.58 (d, <i>J</i> = 9.06 Hz, 2 H), 7.50 (t, <i>J</i> = 8.18 Hz, 1 H), 7.14 (d, <i>J</i> = 3.78 Hz, 1 H), 7.05–7.11 (m, 1 H), 6.91 (d, <i>J</i> = 9.06 Hz, 2 H), 6.40–6.57 (m, 3 H), 5.86 (dd, <i>J</i> = 9.57, 2.27 Hz, 1 H), 5.62 (s, 2 H), 3.62–3.76 (m, 2 H), 3.13–3.28 (m, 4 H), 2.68–2.85 (m, 4 H), 2.47 (s, 3 H), 0.92–1.07 (m, 2 H), 0.00 (s, 9 H).</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>N</i>-(3-((2-((1-Methyl-1<i>H</i>-pyrazol-3-yl)amino)-7-((2-(trimethylsilyl)ethoxy)methyl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)acrylamide (<b>31</b>)</h3><div class="NLM_p last">Purified over silica gel with a gradient of 0–10% methanol in dichloromethane to yield the title product (468 mg, 65% yield, 2 steps): LC–MS (APCI) <i>m</i>/<i>z</i> 506.20 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO- <i>d</i><sub>6</sub>) δ 10.27 (s, 1 H), 9.32 (s, 1 H), 7.63–7.67 (m, 1 H), 7.56 (d, <i>J</i> = 7.81 Hz, 1 H), 7.41 (t, <i>J</i> = 8.06 Hz, 1 H), 7.36 (s, 1 H), 7.21 (d, <i>J</i> = 3.53 Hz, 1 H), 7.00 (dd, <i>J</i> = 8.06, 2.27 Hz, 1 H), 6.38–6.48 (m, 1 H), 6.33 (br s, 1 H), 6.28 (d, <i>J</i> = 2.01 Hz, 1 H), 6.21–6.26 (m, 1 H), 5.70–5.89 (m, 1 H), 5.48 (s, 2 H), 3.67 (s, 3 H), 3.54 (t, <i>J</i> = 8.06 Hz, 2 H), 0.85 (t, <i>J</i> = 8.06 Hz, 2 H), −0.09 (s, 9 H).</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> General Procedure for the Synthesis of Acrylamides <b>10</b> and <b>11</b></h3><div class="NLM_p"><i>Step 1:</i> To a solution of the SEM-protected pyrrolopyrimidine in DCM (5 mL) was added TFA (3 mL), and the reaction mixture was stirred at room temperature for 4 h. Evaporation of solvent provided the <i>N</i>-hydroxymethyl intermediate which was taken to the next step without further purification.</div><div class="NLM_p last"><i>Step 2:</i> To a solution of an <i>N</i>-hydroxymethyl intermediate in MeOH or EtOH (10 mL) was added K<sub>2</sub>CO<sub>3</sub>, and the reaction mixture was stirred at room temperature for 2 h. Water was added, and the product was either extracted using EtOAc (3 × 20 mL), dried with MgSO<sub>4</sub>, filtered, concentrated or precipitated out of solution, filtered, and dried.</div></div><div id="sec5_4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(3-((2-((4-(4-Methylpiperazin-1-yl)phenyl)amino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)acrylamide (<b>10</b>)</h3><div class="NLM_p last">Yield, 174 mg, 77%; LC–MS (APCI) <i>m</i>/<i>z</i> 470.1 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.45 (br s, 1 H), 10.28 (s, 1 H), 8.80 (s, 1 H), 7.56–7.67 (m, 2 H), 7.35–7.49 (m, 3 H), 7.03 (d, <i>J</i> = 3.53 Hz, 1 H), 6.94–7.00 (m, 1 H), 6.70 (d, <i>J</i> = 8.81 Hz, 2 H), 6.37–6.49 (m, 1 H), 6.18–6.32 (m, 2 H), 5.71–5.82 (m, 1 H), 2.91–3.05 (m, 4 H), 2.37–2.46 (m, 5 H), 2.21 (s, 3 H).</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>-(3-((2-((1-Methyl-1<i>H</i>-pyrazol-3-yl)amino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)acrylamide (<b>11</b>)</h3><div class="NLM_p last">Purified over silica gel with a gradient of 0–20% ethanol in ethyl acetate to yield the title product (245 mg, 46% yield): LC–MS (APCI) <i>m</i>/<i>z</i> 376.15 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.48 (br s, 1 H), 10.27 (s, 1 H), 9.13 (br s, 1 H), 7.61–7.67 (m, 1 H), 7.57 (d, <i>J</i> = 8.06 Hz, 1 H), 7.41 (t, <i>J</i> = 8.18 Hz, 1 H), 7.30 (d, <i>J</i> = 2.01 Hz, 1 H), 7.05 (d, <i>J</i> = 3.53 Hz, 1 H), 6.99 (dd, <i>J</i> = 8.06, 1.76 Hz, 1 H), 6.36–6.48 (m, 1 H), 6.22–6.31 (m, 1 H), 6.10–6.21 (m, 2 H), 5.65–5.85 (m, 1 H), 3.66 (s, 3 H).</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-(3-((2-((1-Methyl-1<i>H</i>-pyrazol-4-yl)amino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)phenyl)acrylamide (<b>12</b>)</h3><div class="NLM_p"><i>Step 1:</i> To a solution of the SEM-protected pyrrolopyrimidine <b>29</b> in DCM (5 mL) was added TFA (3 mL), and the reaction mixture was stirred at room temperature for 4 h. Evaporation of solvent provided the <i>N</i>-hydroxymethyl intermediate <b>34</b> which was taken on to the next step without further purification.</div><div class="NLM_p last">To a solution of aniline <b>34</b> (0.2 mmol) in DCM (4 mL) was added prop-2-enoyl chloride (0.2 mmol), and the mixture was stirred at room temperature for 15 min. Ethanol (10 mL) was added to the reaction mixture followed by potassium carbonate (279 mg), and the mixture was stirred for 3 h. The reaction mixture was then filtered, the filtrate was concentrated, and the resultant residue was purified over silica gel with gradients from 0% to 20% ethanol in 50% heptane/50% ethyl acetate to yield the title product (36 mg, 47% yield): LC–MS (APCI) <i>m</i>/<i>z</i> 376.05 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.42 (br s, 1 H), 10.33 (s, 1 H), 8.94 (s, 1 H), 7.58–7.73 (m, 2 H), 7.47 (t, <i>J</i> = 8.06 Hz, 1 H), 7.25 (br s, 1 H), 6.93–7.11 (m, 2 H), 6.37–6.55 (m, 1 H), 6.28 (t, <i>J</i> = 16.24 Hz, 2 H), 5.77 (d, <i>J</i> = 10.07 Hz, 1 H), 3.62 (br s, 3 H)</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> General Procedure for the Synthesis of <b>37</b>, <b>38</b></h3><div class="NLM_p last">Potassium hexamethyldisilazide (1.5 mmol) was added to a mixture of <b>25</b> (1 mmol) and either alcohol <b>35</b> or <b>36</b> (1 mmol) in 1,4-dioxane (4 mL). The reaction mixture was stirred at room temperature for 2–16 h. LC–MS showed the reaction was almost complete, and the alkoxy ether products <b>37</b> and <b>38</b> obtained in this manner were taken on to the next step with no further purification.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> General Procedure for the Synthesis of Amines <b>39</b>, <b>40</b></h3><div class="NLM_p last">To a solution of <b>37</b> or <b>38</b> (1 mmol) in 1,4-dioxane or toluene and 2 drops of NMP in a microwave vial was added the appropriate amine (1.2 mmol) followed by Cs<sub>2</sub>CO<sub>3</sub> (1.0–1.5 mmol), Pd<sub>2</sub>(dba)<sub>3</sub> (0.05–0.1 mmol), and Xantphos (0.05–0.1 mmol), and the mixture was heated in the microwave at 140 °C for 45 min. The reaction was cooled to room temperature, brine (20 mL) was added, and the mixture was extracted with EtOAc (3 × 10 mL). The combined extracts were dried over MgSO<sub>4</sub>, filtered, and concentrated to give the amines <b>39</b> and <b>40</b> which were taken on to the next step with no further purification.</div></div><div id="sec5_7_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Synthesis of Acrylamides <b>13</b>, <b>23</b>. (i) Two-Step General Procedure for Global Deprotection of <b>39</b>, <b>40</b></h3><div class="NLM_p"><i>Step 1:</i> To a solution of the SEM-protected pyrrolopyrimidine in DCM (5–10 mL) was added TFA (3 mL), and the reaction mixture was stirred at room temperature for 1–4 h. Evaporation of solvent provided the <i>N</i>-hydroxymethyl intermediates which were taken on to the next step with no further purification.</div><div class="NLM_p last"><i>Step 2:</i> To a solution of an <i>N</i>-hydroxymethyl intermediate in MeOH (10 mL) and water (2 mL) was added K<sub>2</sub>CO<sub>3</sub>. The reaction mixture was then stirred at room temperature for 2 h. Water was added and the product was extracted using EtOAc (3 × 20 mL), dried with MgSO<sub>4</sub>, filtered, and concentrated to a give the pyrrolidines that were taken to the next step with no further purification. Alternatively, in the case of the <i>N</i>-hydroxymethyl intermediate generated from <b>40</b>, ammonium hydroxide (4 mL) in 1,4-dioxane (8 mL) was utilized, the reaction mixture was stirred for 16 h, and the product was then taken to the next step with no further purification.</div></div><div id="sec5_7_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> (ii) General Procedure for Acrolylation</h3><div class="NLM_p last">To a solution of crude pyrrolidine (1 equiv) in THF (10 mL) was added dropwise a solution of prop-2-enoyl chloride (1 equiv) in THF (1 mL). After addition, the mixture was stirred at room temperature for 1 h and then concentrated. The residue was purified by preparative HPLC to afford the acrylamides <b>13</b> and <b>23</b>.</div></div><div id="sec5_7_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> (<i>R</i>)-1-(3-(((2-((1-Methyl-1<i>H</i>-pyrazol-4-yl)amino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)methyl)pyrrolidin-1-yl)prop-2-en-1-one (<b>13</b>)</h3><div class="NLM_p last">Purified by preparative HPLC by Phenomenex Gemini C18, 4.6 mm × 100 mm, 5 μm column with H<sub>2</sub>O (10% ammonia acetate)/CH<sub>3</sub>CN at 2.5 mL/min to give title compound (3.74 mg, 0.9% yield over 5 steps): LC–MS (APCI) <i>m</i>/<i>z</i> 368.20 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (700 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.86 (br s, 1 H), 7.86–7.88 (m, 1 H), 7.50 (br s, 1 H), 6.91(br. s, 1 H), 6.81–6.87 (m, 1 H), 6.60–6.62(m, 1H), 6.08–6.24 (m, 2 H), 6.02 (d, <i>J</i> = 15.49 Hz, 1 H), 5.71 (d, <i>J</i> = 10.33 Hz, 1 H), 5.50–5.51 (m, 1 H), 5.28(br. s, 1 H), 3.79 (s, 3 H), 3.28–3.38 (m, 1 H), 1.95–2.17 (m, 2 H), 1.51–1.52 (m, 1 H).</div></div><div id="sec5_7_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> 1-((3<i>R</i>,4<i>R</i>)-3-(((2-((1-(But-3-yn-1-yl)-1<i>H</i>-pyrazol-4-yl)amino)-5-chloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)methyl)-4-methoxypyrrolidin-1-yl)prop-2-en-1-one (<b>23</b>)</h3><div class="NLM_p last">Purified via prep-HPLC to give title compound (67 mg, 11% over 5 steps): LC–MS <i>m</i>/<i>z</i> 469.9 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.75–8.55 (d, 1H), 7.88 (s, 1H), 7.77 (s, 1H), 7.59 (s, 1H), 6.72–6.69 (d, 1H), 6.60–6.57 (d, 1H), 6.45–6.41 (m, 2H), 5.72–5.68 (m, 1H), 4.47–4.35 (t, 2H), 4.28–4.20 (m, 2H), 4.10–3.72 (m, 3H), 3.73–3.60 (m, 2H), 3.40 (s, 3H), 2.90–2.70 (m, 3H), 2.05–2.01 (m, 1H);</div></div><div id="sec5_7_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> <i>tert</i>-Butyl (3<i>R</i>,4<i>R</i>)-3-(((5-chloro-2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl)oxy)methyl)-4-methoxypyrrolidine-1-carboxylate (<b>45</b>)</h3><div class="NLM_p last">To a solution 2,4,5-trichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidine (<b>43</b>) (9.28 g, 41.7 mmol) and (3<i>R</i>,4<i>R</i>)-3-hydroxymethyl-4-methoxypyrrolidine-1-carboxylic acid <i>tert</i>-butyl ester (<b>36</b>) (9.65 g, 41.7 mmol) in 1,4-dioxane (100 mL) was added potassium <i>tert</i>-pentoxide (25% w/w in toluene, 80 mL, 167 mmol). The resulting reaction solution was stirred at ambient temperature for 30 min. LC–MS showed a quantitative formation of (3<i>R</i>,4<i>R</i>)-3-(2,5-dichloro-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yloxymethyl)-4-methoxypyrrolidine-1-carboxylic acid <i>tert</i>-butyl ester (<b>44</b>). To the resulting reaction solution were added 1-methyl-1<i>H</i>-pyrazol-4-ylamine (4.86 g, 50.1 mmol) and <i>t</i>-BuXPhos palladacycle (1.1 g, 1.67 mmol). The reaction mixture was stirred and heated at 90 °C in an oil bath for 1 h. The reaction mixture was filtered through Celite and the filtrate was evaporated to remove the volatiles to give a dark gum that was dissolved in ethyl acetate (300 mL) and filtered through a silica gel plug. The filtrate was evaporated and the residue was purified via flash chromatography, eluting with a gradient of 0–100% EtOAc in heptanes to give the title compound (12.4 g, 62% yield): LC–MS (APCI) <i>m</i>/<i>z</i> 378.2 (M + H)<sup>+</sup> for product minus Boc group with Cl isotope pattern; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.51 (br s, 1 H), 9.07 (s, 1 H), 7.86 (s, 1 H), 7.52 (s, 1 H), 7.06 (d, <i>J</i> = 2.20 Hz, 1 H), 4.31–4.54 (m, 2 H), 3.92 (br s, 1 H), 3.80 (s, 3 H), 3.55–3.68 (m, 1 H), 3.44–3.55 (m, 1 H), 3.30 (two singlets, OMe rotamers, 3 H), 2.72 (br s, 1 H), 1.39 (br s, 9 H).</div></div><div id="sec5_7_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> 5-chloro-4-(((3<i>R</i>,4<i>R</i>)-4-methoxypyrrolidin-3-yl)methoxy)-<i>N</i>-(1-methyl-1<i>H</i>-pyrazol-4-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-2-amine 2,2,2-trifluoroacetate (<b>46</b>)</h3><div class="NLM_p last">To a solution of <b>45</b> (12.40 g, 26 mmol) in DCM (60 mL) at 0 °C was added TFA (10.1 mL, 208 mmol), and the resulting solution was stirred at ambient temperature for 2.5 h. The volatiles were removed, and ethyl ether (150 mL) was added. The resulting suspension was stirred for 2 h, then filtered to afford a light pink solid. This solid was washed with ethyl ether (30 mL) and dried to give the title compound (15.7 g, quantitative yield) as a TFA salt: LC–MS (APCI) <i>m</i>/<i>z</i> 378.2 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.56 (br s, 1 H), 9.09 (s, 3 H), 7.85 (s, 1 H), 7.54 (s, 1 H), 7.09 (d, <i>J</i> = 2.32 Hz, 1 H), 4.48 (d, <i>J</i> = 6.48 Hz, 2 H), 4.11 (br s, 1 H), 3.81 (s, 3 H), 3.46–3.60 (m, 1 H), 3.35–3.45 (m, 2 H), 3.32 (s, 3 H), 3.15 (dq, <i>J</i> = 12.01, 6.02 Hz, 1 H), 2.70–2.90 (m, 1 H). Absolute stereochemistry of <b>46</b> was confirmed by small molecule X-ray diffraction of the crystalline HBr salt (see <a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">Supporting Information</a> for synthesis of HBr salt)</div></div><div id="sec5_7_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> 1-{(3<i>R</i>,4<i>R</i>)-3-[({5-chloro-2-[(1-methyl-1<i>H</i>-pyrazol-4-yl)amino]-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (<b>1</b>)</h3><div class="NLM_p last">A mixture of <b>46</b> (15 g, 24.7 mmol), ethyl acetate (200 mL), and saturated aqueous NaHCO<sub>3</sub> (100 mL) was stirred at 0 °C for 10 min. Acryloyl chloride (2.3 mL, 29 mmol) was added dropwise, and the resulting mixture was stirred at ambient temperature for 30 min. Ethyl acetate (150 mL) was added, and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (150 mL) and the combined organic layers were dried over Na<sub>2</sub>SO<sub>4</sub> and evaporated to give a solid that was purified by SFC (ZymorSPHER HAP 5 μm, 21.2 mm × 150 mm column, eluting with 35% EtOH in CO<sub>2</sub> at 120 bar, flow 64 mL/min) to give the title compound as an off white solid (8.3 g, 78% yield): LC–MS (APCI) <i>m</i>/<i>z</i> 431.9 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.51 (s, 1 H), 9.07 (s, 1 H), 7.86 (s, 1 H), 7.52 (s, 1 H), 7.05 (s, 1 H), 6.59 (ddd, <i>J</i> = 16.75, 10.27, 1.34 Hz, 1 H), 6.14 (dd, <i>J</i> = 16.75, 2.32 Hz, 1 H), 5.68 (dt, <i>J</i> = 10.27, 2.32 Hz, 1 H), 4.44 (d, <i>J</i> = 6.24 Hz, 2 H), 3.82–4.09 (m, 2 H), 3.80 (s, 3 H), 3.57–3.76 (m, 2 H), 3.47–3.54 (m, 1 H), 3.31 (d, <i>J</i> = 4.65 Hz, 3 H), 2.67–2.92 (m, 1 H); <sup>13</sup>C NMR (asterisks denote minor rotamer peaks, 101 MHz, DMSO-<i>d</i><sub>6</sub>) δ 163.5, 162.0*, 155.6, 153.2*, 129.8, 129.4, 129.1*, 126.8*, 126.6, 123.7,120.1, 117.3, 101.9*, 101.8, 95.4*, 95.3, 81.4, 79.7*, 65.2, 65.0*, 56.3, 56.2*, 50.3, 49.7*, 46.7*, 46.2, 42.8, 41.0, 38.6.<a class="ref internalNav" href="#extra" aria-label=""></a></div></div><div id="sec5_7_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> (Methyl (3<i>S</i>,4<i>R</i>)-1-benzyl-4-methoxypyrrolidine-3-carboxylate (<b>49</b>)</h3><div class="NLM_p">To a solution of (<i>E</i>)-3-methoxyacrylic acid methyl ester (<b>47</b>) (50 g, 431 mmol) in 2-Me-THF (600 mL) and TFA (6.7 mL) at 0 °C was added <i>N</i>-(methoxymethyl)-<i>N</i>-(trimethylsilylmethyl)benzylamine (<b>48</b>) (204 g, 859 mmol, 2 equiv) dropwise. After addition, reaction was allowed to warm to room temperature and stirred for 2 h. Reaction was transferred to a separatory funnel, washed with saturated aqueous NaHCO<sub>3</sub>, saturated aqueous NaCl, then dried over Na<sub>2</sub>SO<sub>4</sub> and the solvent was removed to leave the crude racemic product as a yellow oil which was purified over silica gel (10% – 35% EtOAc/heptane) to give the racemic trans product (<b>49</b>) as a yellow oil (82.7 g).</div><div class="NLM_p last">Enantiomer separation by chiral-SFC (Chiralpak AD-H 4.6 mm × 250 mm column, 4% MeOH with 0.1% diethylamine, 140 bar, 3.0 mL/min) gave the desired single isomer product (<b>50</b>) (34 g, 32% yield): LC–MS (APCI) <i>m</i>/<i>z</i> 250.0 (M + H)<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.22–7.39 (m, 5 H), 4.07–4.12 (m, 1 H), 3.66 (s, 3 H), 3.51–3.63 (m, 2 H), 3.23 (s, 3 H), 2.90–2.96 (m, 1 H), 2.82–2.88 (m, 1 H), 2.69 (dd, <i>J</i> = 9.95, 6.42 Hz, 1 H), 2.55–2.63 (m, 2 H); [α]<sub>D</sub><sup>27</sup> +23.8° (<i>c</i> 1.3, MeOH).</div></div><div id="sec5_7_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 1-(<i>tert</i>-Butyl) 3-methyl (3<i>S</i>,4<i>R</i>)-4-methoxypyrrolidine-1,3-dicarboxylate (<b>51</b>)</h3><div class="NLM_p last">A solution of (3<i>S</i>,4<i>R</i>)-1-benzyl-4-methoxypyrrolidine-3-carboxylic acid methyl ester (<b>50</b>) (35 g, 140.4 mmol) in ethanol (500 mL) was purged with nitrogen, and then Pd(OH)<sub>2</sub> (2 g, 0.1 equiv) was added and the mixture was stirred overnight under an atmosphere of hydrogen gas at approximately 15 psi (via hydrogen balloon). The reaction was filtered through Celite, and di-<i>tert</i>-butyl dicarbonate (30.9 g, 142 mmol) was added to the resulting filtrate slowly with stirring. After 1 h the reaction mixture was concentrated and the crude material was purified through a short silica gel column, eluting with 10% EtOAc/heptane for 2 volumes, then 1:1 EtOAc/heptane until the product was completely eluted. Product fractions were combined and concentrated to give the title compound as a clear oil (35.81 g, 98% yield): LC–MS (APCI) <i>m</i>/<i>z</i> 160.1 (M + H)<sup>+</sup> for product minus Boc group; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 4.06 (d, <i>J</i> = 4.78 Hz, 1 H), 3.65 (s, 3 H), 3.35–3.53 (m, 3 H), 3.23–3.28 (m, 4 H), 3.17 (br s, 1 H), 1.39 (s, 9 H); [α]<sub>D</sub> −12.5° (<i>c</i> 0.87, MeOH).</div></div><div id="sec5_7_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>tert</i>-Butyl (3<i>R</i>,4<i>R</i>)-3-(hydroxymethyl)-4-methoxypyrrolidine-1-carboxylate (<b>36</b>)</h3><div class="NLM_p last">Lithium borohydride (12.7 g, 583 mmol) was added portionwise to a solution of (3<i>S</i>,4<i>R</i>)-4-methoxypyrrolidine-1,3-dicarboxylic acid 1-<i>tert</i>-butyl ester 3-methyl ester (<b>51</b>) (35.81 g, 138 mmol) in THF (600 mL), then the reaction was heated to 60 °C for 4 h. The reaction was quenched with water at 0 °C and extracted with EtOAc. The organic layer was washed with saturated aqueous NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed and the residue was purified through a plug of silica (3:1 EtOAc/heptane) to yield the title compound as a clear oil (29.35 g, 92% yield): LC–MS (APCI) <i>m</i>/<i>z</i> 132.2 (M + H)<sup>+</sup> for product minus Boc group; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.77–3.83 (m, 1 H), 3.50–3.66 (m, 4H), 3.33 (d, <i>J</i> = 4.03 Hz, 4 H), 3.19 (dd, <i>J</i> = 11.08, 5.29 Hz, 1 H), 2.37–2.47 (m, 1 H), 1.46 (s, 9 H); [α]<sub>D</sub> +9.3° (<i>c</i> 0.86, MeOH).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> Computational Modeling Methods</h3><div class="NLM_p last">All molecules were prepared for docking simulation using LigPrep 2.5 (Schrödinger) to considered proper protonation states and tautomers. The docking simulation was performed with Glide 5.7 (Schrödinger) using protein models based on in-house crystal structures where Cys797 was mutated to alanine to avoid a crash with Michael acceptor on molecules. A pharmacophore-type constraint was applied during docking to locate β-carbon of Michael acceptor in a target space for alkylation. Protein–ligand complexes were minimized using the OPLS2005 force field.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Biochemical Kinase Assays</h3><div class="NLM_p last">EGFR kinase activity assays were reported previously. Methods to estimate reversible binding affinities of covalent inhibitors are discussed in the <a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">Supporting Information</a>.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Intrinsic Chemical Reactivity Assay</h3><div class="NLM_p">The intrinsic chemical reactivity was accessed by evaluating the rate of electrophilic attack of the test compound to a strong nucleophile, glutathione (GSH). This was achieved by monitoring test compound loss during the reaction via LC–MS/MS detection. The experiment was initiated with an aliquot (100 μL) of the test compound to a reaction buffer consisting of 100 μM phosphate buffer, pH 7.4, in the presence or absence of 5 mM GSH. The reaction which did not contain GSH was used as a control for chemical instability. Each compound was tested experimentally in duplicate. The final test compound concentration was 1 μM. The 37 °C reaction temperature was maintained throughout the entire experiment. Aliquots of the reaction volume (100 μL) were taken at 0, 5, 15, 30, 45, 60, 90, and 120 min and quenched 1:1 (v:v) with 40 mM <i>N</i>-ethylmaleimide (NEM) in acetonitrile containing internal standard. CI-1033 served as the positive control in all experiments.</div><div class="NLM_p last">A linear regression analysis using the natural log of the peak area ratio, based on the internal standard, versus time provided the elimination constant (<i>k</i><sub>el</sub>). Half-life was calculated as ln 2/[−(<i>k</i><sub>el</sub>)]. The intrinsic reactivity of each test compound was reported as the ratio of the compound half-life compared to the half-life of canertinib.</div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Cell Lines and Culture Conditions</h3><div class="NLM_p last">H1975 and A549 cancer cell lines were purchased from ATCC and were cultured according to ATCC recommendations. PC9 cells were purchased from RIKEN Cell Bank (Tsukuba, Ibaraki Prefecture, Japan) and were cultured in Gibco RPMI 1640 (Life Technologies, Carlsbad, CA, USA) medium with 10% FBS (Sigma, St. Louis, MO, USA). H3255 cells were from Dr. Bruce E. Johnson at the National Cancer Institute (Bethesda, MD, USA) and were cultured in RPMI 1640, 10% FBS, and ACL-4 supplement (Mediatech Inc., Manassas, VA, USA). PC9-DRH, harboring both the single mutant (Del) and double mutant (Del/T790M) alleles, is a pool of cells derived from PC9 parental line that was selected after treatment with gradually increasing concentrations of dacomitinib up to 2 μM. PC9-DRH EGFR alleles consist of 70% Del/T790M and 30% Del. PC9-DRH cells were cultured in Gibco RPMI 1640 medium with 10% FBS and maintained in dacomitinib (2 μM).</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> EGFR Cellular Autophosphorylation ELISA</h3><div class="NLM_p last">Cells were plated (25 000–50 000 cells/well) in a final volume of 100 μL of complete media in 96-well microtiter plates and cultured overnight (37 °C, 5% CO<sub>2</sub>). Inhibitors were solubilized in DMSO and tested in duplicate utilizing 11-point serial dilutions with the highest concentration at 1 or 10 μM (0.3% v/v final DMSO). Inhibitors were incubated with cells for 2 h at 37 °C, 5% CO<sub>2</sub>. For EGFR wild type assays, cells were plated in full-serum (10%) media for 24 h prior to compound treatment; cells were treated in full serum media as described and then stimulated for 10 min with EGF (Life Technologies) in serum-free media (50 ng/mL for A549). For all cells after inhibitor treatment (± EGF), media were removed and 100 μL of ice-cold lysis buffer was added: 1× cell lysis buffer (Cell Signaling Technology, Danvers, MA, USA), 1 mM phenylmethanesulfonyl fluoride (Calbiochem/EMD Chemicals, Billerica, MA, USA), 1 mM sodium orthovanadate (New England Biolabs Inc., Ipswich, MA, USA), complete Mini EDTA-free protease inhibitor cocktail tablets (Roche Applied Science, Indianapolis, IN, USA), and PhosSTOP (Roche Applied Science). Plates were shaken (20–30 min, 4 °C) to lyse the cells, and 100 μL lysate was added to an ELISA plate. PathScan Phospho-EGF receptor (Try1068) sandwich ELISA (Cell Signaling Technology) was used to quantify EGFR autophosphorylation per the manufacturer’s protocol. IC<sub>50</sub> values were determined by nonlinear regression analysis with a four-parameter fit by utilizing a Microsoft Excel based macro.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01633">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15305" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15305" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01633" class="ext-link">10.1021/acs.jmedchem.5b01633</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Methods to estimate reversible binding affinities of covalent inhibitors, experimental procedures, and spectral data for compounds <b>14</b>–<b>22</b> and relevant intermediates, additional data on proteome wide selectivity for compound <b>1</b>, kinase selectivity data for compound <b>1</b>, ligand torsional strain energy analysis for <b>15</b> and <b>16</b>, ligand strain energy analysis for bound conformation of compound <b>1</b> in EGFR DM, and modeling of compound <b>10</b> in EGFR WT protein (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings for <b>1</b>, <b>10</b>–<b>23</b>, canertinib (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Molecular formula strings for <b>1</b>, rociletinib, osimertinib, erlotinib (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_003.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf">jm5b01633_si_001.pdf (1.22 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_002.csv">jm5b01633_si_002.csv (1.54 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_003.csv">jm5b01633_si_003.csv (0.63 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG7">5HG7</a> for compound <b>1</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG5">5HG5</a> for compound <b>10</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG8">5HG8</a> for compound <b>12</b>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG9">5HG9</a> for compound <b>14</b>.</p><div class="testing" data-doi="10.1021/acs.jmedchem.5b01633" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85364" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85364" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hengmiao Cheng</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1f777a716d66317c777a71785f6f7976657a6d317c7072"><span class="__cf_email__" data-cfemail="1e767b706c67307d767b70795e6e7877647b6c307d7173">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sajiv K. Nair</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ee9d8f848798c085c0808f879cae9e8887948b9cc08d8183"><span class="__cf_email__" data-cfemail="0a796b60637c246124646b63784a7a6c63706f7824696567">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brion W. Murray</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#f89a8a919796d6958d8a8a9981b8889e91829d8ad69b9795"><span class="__cf_email__" data-cfemail="7614041f1918581b030404170f3606101f0c13045815191b">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chau Almaden</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Bailey</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sangita Baxi</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Doug Behenna</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sujin Cho-Schultz</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Deepak Dalvie</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dac M. Dinh</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin P. Edwards</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jun Li Feng</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rose Ann Ferre</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ketan S. Gajiwala</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle D. Hemkens</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amy Jackson-Fisher</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mehran Jalaie</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ted O. Johnson</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert S. Kania</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan Kephart</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jennifer Lafontaine</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Beth Lunney</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin K.-C. Liu</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Zhengyu Liu</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean Matthews</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Asako Nagata</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sherry Niessen</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martha A. Ornelas</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Suvi T. M. Orr</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mason Pairish</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Simon Planken</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shijian Ren</span> - <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao
Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Richter</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin Ryan</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neal Sach</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Shen</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tod Smeal</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jim Solowiej</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Sutton</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Khanh Tran</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elaine Tseng</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William Vernier</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marlena Walls</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuiwang Wang</span> - <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao
Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott L. Weinrich</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuibo Xin</span> - <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao
Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haiwei Xu</span> - <span class="hlFld-Affiliation affiliation">Wuxi AppTec, 288 Fute
Zhong Road, Waigaoqiao
Free Trade Zone, Shanghai 200131, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Min-Jean Yin</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Zientek</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ru Zhou</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John C. Kath</span> - <span class="hlFld-Affiliation affiliation">La
Jolla Laboratories, Pfizer Worldwide Research
and Development, 10770
Science Center Drive, San Diego, California 92121, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d123e4094-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i52">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62010" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62010" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We are grateful to Klaus Dress for data management and visualization and to Jeff Elleraas, Loanne Chung, and Phuong Tran for purification work.</p></div><div class="postAsapNotesSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="postAsapNotesSection">Note Added After ASAP Publication</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83738" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83738" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="first last">After this paper was published ASAP January 28, 2016, a correction was made to Figure 1. The corrected version was reposted February 25, 2016.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i53" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i53"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i54" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i54"> Abbreviations Used</h2><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild-type</p></td></tr><tr><td class="NLM_term">DM</td><td class="NLM_def"><p class="first last">double mutant (L858R/T790M, or Del/T790M)</p></td></tr><tr><td class="NLM_term">TM</td><td class="NLM_def"><p class="first last">triple mutant (L858R/T790M/V948R)</p></td></tr><tr><td class="NLM_term">KD</td><td class="NLM_def"><p class="first last">kinase domain</p></td></tr><tr><td class="NLM_term">Del</td><td class="NLM_def"><p class="first last">exon 19 E746-A750 deletion oncogenic mutation</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung cancer</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">DOF</td><td class="NLM_def"><p class="first last">dofetilide</p></td></tr><tr><td class="NLM_term">sol</td><td class="NLM_def"><p class="first last">solubility</p></td></tr><tr><td class="NLM_term">PSA</td><td class="NLM_def"><p class="first last">polar surface area</p></td></tr><tr><td class="NLM_term">RRCK</td><td class="NLM_def"><p class="first last">permeability measured with low-efflux MDCKII cell</p></td></tr></table></div></div><div class="NLM_fn" id="extra"> <p class="last">Compound <b>1</b> (PF-06459988) is commercially available via Sigma-Aldrich (catalog no. PZ0296).</p></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63368" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63368" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 40 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D. M.; Forman, D.; Bray, F.</span> <span class="citation_source-book">GLOBOCAN 2012</span>, version <span class="NLM_edition">1.1</span>; <span> </span><span class="NLM_article-title">Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]</span>; <span class="NLM_publisher-name">International Agency for Research on Cancer</span>: <span class="NLM_publisher-loc">Lyon, France</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>. Available from <a href="http://globocan.iarc.fr" class="extLink">http://globocan.iarc.fr</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+Ferlay&author=I.+Soerjomataram&author=M.+Ervik&author=R.+Dikshit&author=S.+Eser&author=C.+Mathers&author=M.+Rebelo&author=D.+M.+Parkin&author=D.+Forman&author=F.+Bray&title=GLOBOCAN+2012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DFerlay%26aufirst%3DJ.%26btitle%3DGLOBOCAN%25202012%26atitle%3DCancer%2520Incidence%2520and%2520Mortality%2520Worldwide%253A%2520IARC%2520CancerBase%2520No.%252011%2520%255BInternet%255D%26pub%3DInternational%2520Agency%2520for%2520Research%2520on%2520Cancer%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruvka, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1080</span><span class="refDoi"> DOI: 10.1200/JCO.2012.43.3912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1200%2FJCO.2012.43.3912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=23401451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltl2mtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1070-1080&issue=8&author=K.+Ohashiauthor=Y.+E.+Maruvkaauthor=F.+Michorauthor=W.+Pao&title=Epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor-resistant+disease&doi=10.1200%2FJCO.2012.43.3912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease</span></div><div class="casAuthors">Ohashi, Kadoaki; Maruvka, Yosef E.; Michor, Franziska; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1070-1080</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose EGFR-mutant lung cancer was first described as a new clin. entity in 2004.  Here, we present an update on new controversies and conclusions regarding the disease.  Methods This article reviews the clin. implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance.  Results The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC).  Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer.  Conclusion The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC.  Efforts should now conc. on making EGFR-mutant lung cancer a chronic rather than fatal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3FJbVyt6ydLVg90H21EOLACvtfcHk0lio3EvSFGiHXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltl2mtb0%253D&md5=dfda1563a90ce24bc51e55ebbf47d981</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.3912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.3912%26sid%3Dliteratum%253Aachs%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DMaruvka%26aufirst%3DY.%2BE.%26aulast%3DMichor%26aufirst%3DF.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor-resistant%2520disease%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3D8%26spage%3D1070%26epage%3D1080%26doi%3D10.1200%2FJCO.2012.43.3912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00344-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&issue=14&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28iressa%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer&doi=10.1016%2FS0960-894X%2801%2900344-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0lio3EvSFGiHXw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528iressa%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26issue%3D14%26spage%3D1911%26epage%3D1914%26doi%3D10.1016%2FS0960-894X%2801%2900344-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Shepherd, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuleanu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maoleekoonpiroj, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smylie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kooten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dediu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findlay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezjk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santabarbara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, L.</span><span> </span><span class="NLM_article-title">Erlotinib in previously treated non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1056/NEJMoa050753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1056%2FNEJMoa050753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=16014882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=123-132&issue=2&author=F.+A.+Shepherdauthor=J.+R.+Pereiraauthor=T.+Ciuleanuauthor=E.+H.+Tanauthor=V.+Hirshauthor=S.+Thongprasertauthor=D.+Camposauthor=S.+Maoleekoonpirojauthor=M.+Smylieauthor=R.+Martinsauthor=M.+van+Kootenauthor=M.+Dediuauthor=B.+Findlayauthor=D.+Tuauthor=D.+Johnstonauthor=A.+Bezjkauthor=G.+Clarkauthor=P.+Santabarbaraauthor=L.+Seymour&title=Erlotinib+in+previously+treated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa050753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Shepherd, Frances A.; Pereira, Jose Rodrigues; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjk, Andrea; Clark, Gary; Santabarbara, Pedro; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a randomized, placebo-controlled, double-blind trial to det. whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy.  Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens.  The patients were stratified according to center, performance status, response to prior chemotherapy, no. of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo.  The median age of the 731 patients who underwent randomization was 61.4 yeas; 49 % had received two prior chemotherapy regimens, and 93 % had received platinum-based chemotherapy.  The response rate was 8.9 % in the erlotinib group and less than 1 % in the placebo group (P < 0.001); the median duration of the response wa 7.9 mo and 3.7 mo, resp.  Progression-free survival was 2.2 mo and 1.8 mo, resp. (hazard ratio, 0.61, adjusted for stratification categories; P < 0.001).  Overall survival was 6.7 mo and 4.7 mo, resp. (hazard ratio, 0.70; P < 0.001), in favor of erlotinib.  Five percent of patients discontinued erlotinib because of toxic effects.  Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr8tjSBsYtbVg90H21EOLACvtfcHk0ljmZEMNMNls9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D&md5=1633999cf09b8387ad88f40f75a5bb93</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050753%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DPereira%26aufirst%3DJ.%2BR.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DD.%26aulast%3DMaoleekoonpiroj%26aufirst%3DS.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3Dvan%2BKooten%26aufirst%3DM.%26aulast%3DDediu%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DD.%26aulast%3DBezjk%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DErlotinib%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26issue%3D2%26spage%3D123%26epage%3D132%26doi%3D10.1056%2FNEJMoa050753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Lichtenberger, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holcmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhren, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amberg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolle, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrumpf, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boelke, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollenberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kislat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roeck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harder, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibilia, M.</span><span> </span><span class="NLM_article-title">Epidermal EGFR controls cutaneous host defense and prevents inflammation</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">199</span><span class="NLM_x">) </span> <span class="NLM_fpage">199ra111</span><div class="note"><p class="first last">(14 pp).</p></div><span class="refDoi"> DOI: 10.1126/scitranslmed.3005886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1126%2Fscitranslmed.3005886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=23966300" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=199ra111&issue=199&author=B.+M.+Lichtenbergerauthor=P.+A.+Gerberauthor=M.+Holcmannauthor=B.+A.+Buhrenauthor=N.+Ambergauthor=V.+Smolleauthor=H.+Schrumpfauthor=E.+Boelkeauthor=P.+Ansariauthor=C.+MacKenzieauthor=A.+Wollenbergauthor=A.+Kislatauthor=J.+W.+Fischerauthor=K.+Roeckauthor=J.+Harderauthor=J.+M.+Schroederauthor=B.+Homeyauthor=M.+Sibilia&title=Epidermal+EGFR+controls+cutaneous+host+defense+and+prevents+inflammation&doi=10.1126%2Fscitranslmed.3005886"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3005886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3005886%26sid%3Dliteratum%253Aachs%26aulast%3DLichtenberger%26aufirst%3DB.%2BM.%26aulast%3DGerber%26aufirst%3DP.%2BA.%26aulast%3DHolcmann%26aufirst%3DM.%26aulast%3DBuhren%26aufirst%3DB.%2BA.%26aulast%3DAmberg%26aufirst%3DN.%26aulast%3DSmolle%26aufirst%3DV.%26aulast%3DSchrumpf%26aufirst%3DH.%26aulast%3DBoelke%26aufirst%3DE.%26aulast%3DAnsari%26aufirst%3DP.%26aulast%3DMacKenzie%26aufirst%3DC.%26aulast%3DWollenberg%26aufirst%3DA.%26aulast%3DKislat%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DJ.%2BW.%26aulast%3DRoeck%26aufirst%3DK.%26aulast%3DHarder%26aufirst%3DJ.%26aulast%3DSchroeder%26aufirst%3DJ.%2BM.%26aulast%3DHomey%26aufirst%3DB.%26aulast%3DSibilia%26aufirst%3DM.%26atitle%3DEpidermal%2520EGFR%2520controls%2520cutaneous%2520host%2520defense%2520and%2520prevents%2520inflammation%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26issue%3D199%26spage%3D199ra111%26doi%3D10.1126%2Fscitranslmed.3005886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Mascia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garber, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuspa, S. H.</span><span> </span><span class="NLM_article-title">Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">199</span><span class="NLM_x">) </span> <span class="NLM_fpage">199ra110</span><div class="note"><p class="first last">(13 pp).</p></div><span class="refDoi"> DOI: 10.1126/scitranslmed.3005773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1126%2Fscitranslmed.3005773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=23966299" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=199ra110&issue=199&author=F.+Masciaauthor=G.+Lamauthor=C.+Keithauthor=C.+Garberauthor=S.+M.+Steinbergauthor=E.+Kohnauthor=S.+H.+Yuspa&title=Genetic+ablation+of+epidermal+EGFR+reveals+the+dynamic+origin+of+adverse+effects+of+anti-EGFR+therapy&doi=10.1126%2Fscitranslmed.3005773"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3005773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3005773%26sid%3Dliteratum%253Aachs%26aulast%3DMascia%26aufirst%3DF.%26aulast%3DLam%26aufirst%3DG.%26aulast%3DKeith%26aufirst%3DC.%26aulast%3DGarber%26aufirst%3DC.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DKohn%26aufirst%3DE.%26aulast%3DYuspa%26aufirst%3DS.%2BH.%26atitle%3DGenetic%2520ablation%2520of%2520epidermal%2520EGFR%2520reveals%2520the%2520dynamic%2520origin%2520of%2520adverse%2520effects%2520of%2520anti-EGFR%2520therapy%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26issue%3D199%26spage%3D199ra110%26doi%3D10.1126%2Fscitranslmed.3005773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">2240</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&issue=8&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+Tumor+Specimens+at+the+Time+of+Acquired+Resistance+to+EGFR-TKI+Therapy+in+155+Patients+with+EGFR-Mutant+Lung+Cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0ljmZEMNMNls9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520Tumor%2520Specimens%2520at%2520the%2520Time%2520of%2520Acquired%2520Resistance%2520to%2520EGFR-TKI%2520Therapy%2520in%2520155%2520Patients%2520with%2520EGFR-Mutant%2520Lung%2520Cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D8%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Eyck, L. F.</span><span> </span><span class="NLM_article-title">A helix scaffold for the assembly of active protein kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">38</span><span class="NLM_x">) </span> <span class="NLM_fpage">14377</span><span class="NLM_x">–</span> <span class="NLM_lpage">14382</span><span class="refDoi"> DOI: 10.1073/pnas.0807988105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1073%2Fpnas.0807988105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=18787129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1SgtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=14377-14382&issue=38&author=A.+P.+Kornevauthor=S.+S.+Taylorauthor=L.+F.+Ten+Eyck&title=A+helix+scaffold+for+the+assembly+of+active+protein+kinases&doi=10.1073%2Fpnas.0807988105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A helix scaffold for the assembly of active protein kinases</span></div><div class="casAuthors">Kornev, Alexandr P.; Taylor, Susan S.; Ten Eyck, Lynn F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">14377-14382,S14377/1-S14377/12</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Structures of set of serine-threonine and tyrosine kinases were investigated by the recently developed bioinformatics tool Local Spatial Patterns (LSP) alignment.  We report a set of conserved motifs comprised mostly of hydrophobic residues.  These residues are scattered throughout the protein sequence and thus were not previously detected by traditional methods.  These motifs traverse the conserved protein kinase core and play integrating and regulatory roles.  They are anchored to the F-helix, which acts as an organizing "hub" providing precise positioning of the key catalytic and regulatory elements.  Consideration of these discovered structures helps to explain previously inexplicable results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU7MdhKf3Ul7Vg90H21EOLACvtfcHk0ljX9N8Xq8zGGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1SgtrnJ&md5=238b0ae88119a68784849994e2f21a78</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0807988105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0807988105%26sid%3Dliteratum%253Aachs%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DTen%2BEyck%26aufirst%3DL.%2BF.%26atitle%3DA%2520helix%2520scaffold%2520for%2520the%2520assembly%2520of%2520active%2520protein%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D38%26spage%3D14377%26epage%3D14382%26doi%3D10.1073%2Fpnas.0807988105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span> </span><span class="NLM_article-title">Defining the conserved internal architecture of a protein kinase</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1804</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">440</span><span class="NLM_x">–</span> <span class="NLM_lpage">444</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2009.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2Fj.bbapap.2009.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=19879387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ynu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1804&publication_year=2010&pages=440-444&issue=3&author=A.+P.+Kornevauthor=S.+S.+Taylor&title=Defining+the+conserved+internal+architecture+of+a+protein+kinase&doi=10.1016%2Fj.bbapap.2009.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Defining the conserved internal architecture of a protein kinase</span></div><div class="casAuthors">Kornev, Alexandr P.; Taylor, Susan S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1804</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">440-444</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Protein kinases constitute a large protein family of important regulators in all eukaryotic cells.  All of the protein kinases have a similar bilobal fold, and their key structural features have been well studied.  However, the recent discovery of non-contiguous hydrophobic ensembles inside the protein kinase core shed new light on the internal organization of these mols.  Two hydrophobic "spines" traverse both lobes of the protein kinase mol., providing a firm but flexible connection between its key elements.  The spine model introduces a useful framework for anal. of intramol. communications, mol. dynamics, and drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1YnTs23RLkrVg90H21EOLACvtfcHk0ljX9N8Xq8zGGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ynu74%253D&md5=275cf28f3883575b737639edfc2f454b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2009.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2009.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26atitle%3DDefining%2520the%2520conserved%2520internal%2520architecture%2520of%2520a%2520protein%2520kinase%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2010%26volume%3D1804%26issue%3D3%26spage%3D440%26epage%3D444%26doi%3D10.1016%2Fj.bbapap.2009.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornev, A. P.</span><span> </span><span class="NLM_article-title">Integration of signaling in the kinome: Architecture and regulation of the αC Helix</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1854</span><span class="NLM_x">, </span> <span class="NLM_fpage">1567</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2015.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2Fj.bbapap.2015.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=25891902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmvVyrtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1854&publication_year=2015&pages=1567&author=S.+S.+Taylorauthor=A.+S.+Shawauthor=N.+Kannanauthor=A.+P.+Kornev&title=Integration+of+signaling+in+the+kinome%3A+Architecture+and+regulation+of+the+%CE%B1C+Helix&doi=10.1016%2Fj.bbapap.2015.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of signaling in the kinome: Architecture and regulation of the αC Helix</span></div><div class="casAuthors">Taylor, Susan S.; Shaw, Andrey S.; Kannan, Natarajan; Kornev, Alexandr P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1854</span>
        (<span class="NLM_cas:issue">10_Part_B</span>),
    <span class="NLM_cas:pages">1567-1574</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Eukaryotic protein kinases have evolved to be highly regulated and dynamic mol. switches that are typically kept in an inactive state and then activated in response to extracellular signals.  The hallmark signature of an active kinase is a hydrophobic spine called the regulatory (R) spine, which consists of four residues, two in the N-lobe and two in the C-lobe.  RS1 is in the catalytic loop, RS2 is the Phe in the DFG motif, RS3 is at the C-terminus of the αC-Helix, and RS4 is at the beginning of β4.  Assembly of the R-spine is typically facilitated by phosphorylation of the Activation Loop.  The assembled R-spine brings together all of the functional motifs that are essential for transferring the phosphate from ATP to a tethered protein substrate.  This includes the G-Loop, which anchors the ATP, the catalytic loop, the DFG motif fused to the Activation Loop, and the αC-Helix.  We focus here on the properties of the αC-Helix showing (1) how residues communicate with different parts of the mol., (2) how it is recruited to the active site as a consequence of assembling of the R-spine, and (3) how it is regulated by linkers/motifs/proteins that lie outside the conserved kinase core.  This article is part of a Special Issue entitled: Inhibitors of Protein Kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfWj2cGcicALVg90H21EOLACvtfcHk0ljX9N8Xq8zGGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmvVyrtb8%253D&md5=524f8bd4ac5cc60d04cd4758bfe737f2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2015.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2015.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BS.%26aulast%3DKannan%26aufirst%3DN.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26atitle%3DIntegration%2520of%2520signaling%2520in%2520the%2520kinome%253A%2520Architecture%2520and%2520regulation%2520of%2520the%2520%25CE%25B1C%2520Helix%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2015%26volume%3D1854%26spage%3D1567%26doi%3D10.1016%2Fj.bbapap.2015.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">6243</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span><span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&issue=14&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+Protein+Kinase+Inhibitors%3A+Balancing+the+Benefits+and+Risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lifD8TGV9i2nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520Protein%2520Kinase%2520Inhibitors%253A%2520Balancing%2520the%2520Benefits%2520and%2520Risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D14%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabnis, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span> <span class="citation_source-journal">Chem. Biol. (Oxford, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&issue=2&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+Irreversible+Inhibitors+of+the+Protein+Kinase+Cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0lifD8TGV9i2nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520Irreversible%2520Inhibitors%2520of%2520the%2520Protein%2520Kinase%2520Cysteinome%26jtitle%3DChem.%2520Biol.%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2013%26volume%3D20%26issue%3D2%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramite, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulabaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahal, U. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuff, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uccello, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanmugasundaram, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span> </span><span class="NLM_article-title">Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">10072</span><span class="NLM_x">–</span> <span class="NLM_lpage">10079</span><span class="refDoi"> DOI: 10.1021/jm501412a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501412a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10072-10079&issue=23&author=M.+E.+Flanaganauthor=J.+A.+Abramiteauthor=D.+P.+Andersonauthor=A.+Aulabaughauthor=U.+P.+Dahalauthor=A.+M.+Gilbertauthor=C.+Liauthor=J.+Montgomeryauthor=S.+R.+Oppenheimerauthor=T.+Ryderauthor=B.+P.+Schuffauthor=D.+P.+Uccelloauthor=G.+S.+Walkerauthor=Y.+Wuauthor=M.+F.+Brownauthor=J.+M.+Chenauthor=M.+M.+Haywardauthor=M.+C.+Noeauthor=R.+S.+Obachauthor=L.+Philippeauthor=V.+Shanmugasundaramauthor=M.+J.+Shapiroauthor=J.+Starrauthor=J.+Strohauthor=Y.+Che&title=Chemical+and+Computational+Methods+for+the+Characterization+of+Covalent+Reactive+Groups+for+the+Prospective+Design+of+Irreversible+Inhibitors&doi=10.1021%2Fjm501412a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors</span></div><div class="casAuthors">Flanagan, Mark E.; Abramite, Joseph A.; Anderson, Dennis P.; Aulabaugh, Ann; Dahal, Upendra P.; Gilbert, Adam M.; Li, Chao; Montgomery, Justin; Oppenheimer, Stacey R.; Ryder, Tim; Schuff, Brandon P.; Uccello, Daniel P.; Walker, Gregory S.; Wu, Yan; Brown, Matthew F.; Chen, Jinshan M.; Hayward, Matthew M.; Noe, Mark C.; Obach, R. Scott; Philippe, Laurence; Shanmugasundaram, Veerabahu; Shapiro, Michael J.; Starr, Jeremy; Stroh, Justin; Che, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10072-10079</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Interest in drugs that covalently modify their target is driven by the desire for enhanced efficacy that can result from the silencing of enzymic activity until protein resynthesis can occur, along with the potential for increased selectivity by targeting uniquely positioned nucleophilic residues in the protein.  However, covalent approaches carry addnl. risk for toxicities or hypersensitivity reactions that can result from covalent modification of unintended targets.  Here we describe methods for measuring the reactivity of covalent reactive groups (CRGs) with a biol. relevant nucleophile, glutathione (GSH), along with kinetic data for a broad array of electrophiles.  We also describe a computational method for predicting electrophilic reactivity, which taken together can be applied to the prospective design of thiol-reactive covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAzTSCv_Nj6bVg90H21EOLACvtfcHk0lifD8TGV9i2nQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLbM&md5=3ccf59ab7a494655185e5eb5becf8c48</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm501412a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501412a%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DAbramite%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DD.%2BP.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DDahal%26aufirst%3DU.%2BP.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DOppenheimer%26aufirst%3DS.%2BR.%26aulast%3DRyder%26aufirst%3DT.%26aulast%3DSchuff%26aufirst%3DB.%2BP.%26aulast%3DUccello%26aufirst%3DD.%2BP.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DJ.%2BM.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DPhilippe%26aufirst%3DL.%26aulast%3DShanmugasundaram%26aufirst%3DV.%26aulast%3DShapiro%26aufirst%3DM.%2BJ.%26aulast%3DStarr%26aufirst%3DJ.%26aulast%3DStroh%26aufirst%3DJ.%26aulast%3DChe%26aufirst%3DY.%26atitle%3DChemical%2520and%2520Computational%2520Methods%2520for%2520the%2520Characterization%2520of%2520Covalent%2520Reactive%2520Groups%2520for%2520the%2520Prospective%2520Design%2520of%2520Irreversible%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D10072%26epage%3D10079%26doi%3D10.1021%2Fjm501412a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Allen, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span> </span><span class="NLM_article-title">CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">5, Suppl. 16</span><span class="NLM_x">) </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span><span class="refDoi"> DOI: 10.1053/j.seminoncol.2003.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1053%2Fj.seminoncol.2003.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=14613028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2003&pages=65-78&issue=5%2C+Suppl.+16&author=L.+F.+Allenauthor=I.+A.+Eisemanauthor=D.+W.+Fryauthor=P.+F.+Lenehan&title=CI-1033%2C+an+irreversible+pan-erbB+receptor+inhibitor+and+its+potential+application+for+the+treatment+of+breast+cancer&doi=10.1053%2Fj.seminoncol.2003.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer</span></div><div class="casAuthors">Allen, Lee F.; Eiseman, Irene A.; Fry, David W.; Lenehan, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  The erbB family of cell surface receptor proteins consists of four members, all of which play a role in the development and growth of the normal breast.  The activity of this signaling pathway is normally tightly controlled, and dysregulation has been shown to play a significant role in the pathogenesis and progression of breast and other cancers.  The potent transforming potential of these receptors is further enhanced by the coexpression of multiple members of this receptor family, which worsens prognosis.  Therapeutic blockade of erbB-2 receptor signaling has to date been shown to be effective in only a subset of chemotherapy-resistant breast cancer patients.  CI-1033 is a highly potent and selective pan-erbB inhibitor that efficiently blocks signal transduction through all four members of the erbB receptor family.  In addn., it covalently binds to these receptors, irreversibility inhibiting them, and thereby provides for prolonged suppression of erbB receptor-mediated signaling.  Clin., it has been shown to have an acceptable side effect profile at potentially therapeutic doses and schedules.  Biomarker studies have shown target inhibition in patients, and evidence of antitumor activity has also been obsd. in phase I studies.  Given the broad expression pattern of the erbB family of receptors in solid tumors, and the important proliferative effect of co-expression of multiple erbB receptors, CI-1033, as an irreversible, pan-erbB inhibitor, has the potential to have an important role in the future treatment of breast and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnHJoa4ri9ObVg90H21EOLACvtfcHk0lgVwXEtIOg2Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrF&md5=13e9d00d8a20f3c79b4f7fe1032f07b5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2003.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2003.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DL.%2BF.%26aulast%3DEiseman%26aufirst%3DI.%2BA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26atitle%3DCI-1033%252C%2520an%2520irreversible%2520pan-erbB%2520receptor%2520inhibitor%2520and%2520its%2520potential%2520application%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2003%26volume%3D30%26issue%3D5%252C%2520Suppl.%252016%26spage%3D65%26epage%3D78%26doi%3D10.1053%2Fj.seminoncol.2003.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaenne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1158%2F0008-5472.CAN-07-1885" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&issue=24&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+Jaenne&title=PF00299804%2C+an+Irreversible+Pan-ERBB+Inhibitor%2C+Is+Effective+in+Lung+Cancer+Models+with+EGFR+and+ERBB2+Mutations+that+Are+Resistant+to+Gefitinib&doi=10.1158%2F0008-5472.CAN-07-1885"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1885%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJaenne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520Irreversible%2520Pan-ERBB%2520Inhibitor%252C%2520Is%2520Effective%2520in%2520Lung%2520Cancer%2520Models%2520with%2520EGFR%2520and%2520ERBB2%2520Mutations%2520that%2520Are%2520Resistant%2520to%2520Gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D24%26spage%3D11924%26epage%3D11932%26doi%3D10.1158%2F0008-5472.CAN-07-1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadranel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.-H.</span><span> </span><span class="NLM_article-title">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">528</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span><span class="refDoi"> DOI: 10.1016/S1470-2045(12)70087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&issue=5&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.-M.+Chenauthor=K.+Parkauthor=S.-W.+Kimauthor=C.+Zhouauthor=W.-C.+Suauthor=M.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.-H.+Tanauthor=T.-Y.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.-H.+Yang&title=Afatinib+versus+placebo+for+patients+with+advanced%2C+metastatic+non-small-cell+lung+cancer+after+failure+of+erlotinib%2C+gefitinib%2C+or+both%2C+and+one+or+two+lines+of+chemotherapy+%28LUX-Lung+1%29%3A+a+phase+2b%2F3+randomised+trial&doi=10.1016%2FS1470-2045%2812%2970087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0lgVwXEtIOg2Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.-M.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.-H.%26aulast%3DChao%26aufirst%3DT.-Y.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26atitle%3DAfatinib%2520versus%2520placebo%2520for%2520patients%2520with%2520advanced%252C%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520after%2520failure%2520of%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%252C%2520and%2520one%2520or%2520two%2520lines%2520of%2520chemotherapy%2520%2528LUX-Lung%25201%2529%253A%2520a%2520phase%25202b%252F3%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26issue%3D5%26spage%3D528%26epage%3D538%26doi%3D10.1016%2FS1470-2045%2812%2970087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x"> (</span><span class="NLM_issue">7276</span><span class="NLM_x">) </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&issue=7276&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lhh0oMEFneSQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2009%26volume%3D462%26issue%3D7276%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&issue=12&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St.+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+Mutant-Selective+Covalent+Inhibitor+of+EGFR+that+Overcomes+T790M-Mediated+Resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lhh0oMEFneSQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt.%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520Mutant-Selective%2520Covalent%2520Inhibitor%2520of%2520EGFR%2520that%2520Overcomes%2520T790M-Mediated%2520Resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26issue%3D12%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&issue=9&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lhh0oMEFneSQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D9%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemmitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrigley, G. L.</span><span> </span><span class="NLM_article-title">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">8249</span><span class="NLM_x">–</span> <span class="NLM_lpage">8267</span><span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&issue=20&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+Potent+and+Selective+EGFR+Inhibitor+%28AZD9291%29+of+Both+Sensitizing+and+T790M+Resistance+Mutations+That+Spares+the+Wild+Type+Form+of+the+Receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lhDjEf_dXptYg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520EGFR%2520Inhibitor%2520%2528AZD9291%2529%2520of%2520Both%2520Sensitizing%2520and%2520T790M%2520Resistance%2520Mutations%2520That%2520Spares%2520the%2520Wild%2520Type%2520Form%2520of%2520the%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D20%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuaqui, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span> </span><span class="NLM_article-title">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">7025</span><span class="NLM_x">–</span> <span class="NLM_lpage">7048</span><span class="refDoi"> DOI: 10.1021/jm400822z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&issue=17&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+E.+Crossauthor=L.+A.+Dakinauthor=J.+E.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+V.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+M.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+Reactivity-Based+Development+of+Covalent+Inhibitors+of+the+Activating+and+Gatekeeper+Mutant+Forms+of+the+Epidermal+Growth+Factor+Receptor+%28EGFR%29&doi=10.1021%2Fjm400822z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%2BM.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520Reactivity-Based%2520Development%2520of%2520Covalent%2520Inhibitors%2520of%2520the%2520Activating%2520and%2520Gatekeeper%2520Mutant%2520Forms%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D17%26spage%3D7025%26epage%3D7048%26doi%3D10.1021%2Fjm400822z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span><span class="refDoi"> DOI: 10.1021/jm201591k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&issue=6&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Novel+Conformationally+Constrained+Inhibitors+Targeting+Epidermal+Growth+Factor+Receptor+Threonine790+%E2%86%92+Methionine790+Mutant&doi=10.1021%2Fjm201591k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Conformationally%2520Constrained%2520Inhibitors%2520Targeting%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Threonine790%2520%25E2%2586%2592%2520Methionine790%2520Mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D6%26spage%3D2711%26epage%3D2723%26doi%3D10.1021%2Fjm201591k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5 d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">8803</span><span class="NLM_x">–</span> <span class="NLM_lpage">8813</span><span class="refDoi"> DOI: 10.1021/jm4012388</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4012388" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8803-8813&issue=21&author=S.+Xuauthor=T.+Xuauthor=L.+Zhangauthor=Z.+Zhangauthor=J.+Luoauthor=Y.+Liuauthor=X.+Luauthor=Z.+Tuauthor=X.+Renauthor=K.+Ding&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+2-Oxo-3%2C4-dihydropyrimido%5B4%2C5+d%5Dpyrimidinyl+Derivatives+as+New+Irreversible+Epidermal+Growth+Factor+Receptor+Inhibitors+with+Improved+Pharmacokinetic+Properties&doi=10.1021%2Fjm4012388"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm4012388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4012388%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%25202-Oxo-3%252C4-dihydropyrimido%255B4%252C5%2520d%255Dpyrimidinyl%2520Derivatives%2520as%2520New%2520Irreversible%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Inhibitors%2520with%2520Improved%2520Pharmacokinetic%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D21%26spage%3D8803%26epage%3D8813%26doi%3D10.1021%2Fjm4012388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span> </span><span class="NLM_article-title">Discovery of Pteridin-7(8H)one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">7821</span><span class="NLM_x">–</span> <span class="NLM_lpage">7837</span><span class="refDoi"> DOI: 10.1021/jm401045n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401045n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7821-7837&issue=20&author=W.+Zhouauthor=X.+Liuauthor=Z.+Tuauthor=L.+Zhangauthor=X.+Kuauthor=F.+Baiauthor=Z.+Zhaoauthor=Y.+Xuauthor=K.+Dingauthor=H.+Li&title=Discovery+of+Pteridin-7%288H%29one-Based+Irreversible+Inhibitors+Targeting+the+Epidermal+Growth+Factor+Receptor+%28EGFR%29+Kinase+T790M%2FL858R+Mutant&doi=10.1021%2Fjm401045n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm401045n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401045n%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DKu%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520Pteridin-7%25288H%2529one-Based%2520Irreversible%2520Inhibitors%2520Targeting%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%2520Kinase%2520T790M%252FL858R%2520Mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D20%26spage%3D7821%26epage%3D7837%26doi%3D10.1021%2Fjm401045n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span> </span><span class="NLM_article-title">A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">9889</span><span class="NLM_x">–</span> <span class="NLM_lpage">9900</span><span class="refDoi"> DOI: 10.1021/jm5014659</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5014659" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9889-9900&issue=23&author=G.+Xiaauthor=W.+Chenauthor=J.+Zhangauthor=J.+Shaoauthor=Y.+Zhangauthor=W.+Huangauthor=L.+Zhangauthor=W.+Qiauthor=X.+Sunauthor=B.+Liauthor=Z.+Xiangauthor=C.+Maauthor=J.+Xuauthor=H.+Dengauthor=Y.+Liauthor=P.+Liauthor=H.+Miaoauthor=J.+Hanauthor=Y.+Liuauthor=J.+Shenauthor=Y.+Yu&title=A+Chemical+Tuned+Strategy+to+Develop+Novel+Irreversible+EGFR-TK+Inhibitors+with+Improved+Safety+and+Pharmacokinetic+Profiles&doi=10.1021%2Fjm5014659"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm5014659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5014659%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DMiao%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26atitle%3DA%2520Chemical%2520Tuned%2520Strategy%2520to%2520Develop%2520Novel%2520Irreversible%2520EGFR-TK%2520Inhibitors%2520with%2520Improved%2520Safety%2520and%2520Pharmacokinetic%2520Profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D9889%26epage%3D9900%26doi%3D10.1021%2Fjm5014659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Termathe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Wrangowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruetter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlenbrock, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaumann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eppmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kibies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffgaard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menninger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Cuaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinnefeld, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahedi, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kast, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">6844</span><span class="NLM_x">–</span> <span class="NLM_lpage">6863</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6844-6863&issue=17&author=J.+Engelauthor=A.+Richtersauthor=M.+Getlikauthor=S.+Tomassiauthor=M.+Keulauthor=M.+Termatheauthor=J.+Lategahnauthor=C.+Beckerauthor=S.+Mayer-Wrangowskiauthor=C.+Gruetterauthor=N.+Uhlenbrockauthor=J.+Kruellauthor=N.+Schaumannauthor=S.+Eppmannauthor=P.+Kibiesauthor=F.+Hoffgaardauthor=J.+Heilauthor=S.+Menningerauthor=S.+Ortiz-Cuaranauthor=J.+M.+Heuckmannauthor=V.+Tinnefeldauthor=R.+P.+Zahediauthor=M.+L.+Sosauthor=C.+Schultz-Fademrechtauthor=R.+K.+Thomasauthor=S.+M.+Kastauthor=D.+Rauh&title=Targeting+Drug+Resistance+in+EGFR+with+Covalent+Inhibitors%3A+A+Structure-Based+Design+Approach&doi=10.1021%2Facs.jmedchem.5b01082"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01082%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTermathe%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DGruetter%26aufirst%3DC.%26aulast%3DUhlenbrock%26aufirst%3DN.%26aulast%3DKruell%26aufirst%3DJ.%26aulast%3DSchaumann%26aufirst%3DN.%26aulast%3DEppmann%26aufirst%3DS.%26aulast%3DKibies%26aufirst%3DP.%26aulast%3DHoffgaard%26aufirst%3DF.%26aulast%3DHeil%26aufirst%3DJ.%26aulast%3DMenninger%26aufirst%3DS.%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DTinnefeld%26aufirst%3DV.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DKast%26aufirst%3DS.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DTargeting%2520Drug%2520Resistance%2520in%2520EGFR%2520with%2520Covalent%2520Inhibitors%253A%2520A%2520Structure-Based%2520Design%2520Approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D17%26spage%3D6844%26epage%3D6863%26doi%3D10.1021%2Facs.jmedchem.5b01082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Cheng, H.; Johnson, T. O.,  Jr.; Kath, J. C.; Liu, K. K.-C.; Lunney, E. A.; Nagata, A.; Nair, S. K.; Planken, S. P.; Sutton, S. C.</span><span> </span><span class="NLM_article-title">Preparation of pyrrolopyrimidine and purine derivatives for the treatment of abnormal cell growth</span>. WO2013042006,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=H.+Cheng&author=T.+O.+Johnson&author=J.+C.+Kath&author=K.+K.-C.+Liu&author=E.+A.+Lunney&author=A.+Nagata&author=S.+K.+Nair&author=S.+P.+Planken&author=S.+C.+Sutton&title=Preparation+of+pyrrolopyrimidine+and+purine+derivatives+for+the+treatment+of+abnormal+cell+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26atitle%3DPreparation%2520of%2520pyrrolopyrimidine%2520and%2520purine%2520derivatives%2520for%2520the%2520treatment%2520of%2520abnormal%2520cell%2520growth%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Planken, S.; Nair, S. K.; Kath, J. C.; Lafontaine, J.; Weinrich, S.; Cheng, H.; Sutton, S. C.; Johnson, T. O.; Zientek, M.; Nagata, A.; Gajiwala, K.; Solowiej, J.; Murray, B. W.; Yin, M.-J.; Hemkens, M.</span><span> </span><span class="NLM_article-title">Discovery and development of a series of irreversible EGFR_T790M 7H-pyrrolo[2,3-d]pyrimidine inhibitors with high selectivity over EGFR wild type</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 249th National Meeting and Exposition of the American Chemical Society, Denver, CO, U.S., March 22–26, 2015; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>MEDI-320.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+Planken&author=S.+K.+Nair&author=J.+C.+Kath&author=J.+Lafontaine&author=S.+Weinrich&author=H.+Cheng&author=S.+C.+Sutton&author=T.+O.+Johnson&author=M.+Zientek&author=A.+Nagata&author=K.+Gajiwala&author=J.+Solowiej&author=B.+W.+Murray&author=M.-J.+Yin&author=M.+Hemkens&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPlanken%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520a%2520series%2520of%2520irreversible%2520EGFR_T790M%25207H-pyrrolo%255B2%252C3-d%255Dpyrimidine%2520inhibitors%2520with%2520high%2520selectivity%2520over%2520EGFR%2520wild%2520type%26btitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Schwartz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmic, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1073/pnas.1313733111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&issue=1&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+W.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance&doi=10.1073%2Fpnas.1313733111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact ≤ 2.1 × 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0lgOtPM8b-KSaQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26issue%3D1%26spage%3D173%26epage%3D178%26doi%3D10.1073%2Fpnas.1313733111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Kuzmic, P.</span><span> </span><span class="NLM_article-title">Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">237</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1006/abio.1996.0238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1006%2Fabio.1996.0238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=8660575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADyaK28XjtlOktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=1996&pages=260-273&issue=2&author=P.+Kuzmic&title=Program+DYNAFIT+for+the+analysis+of+enzyme+kinetic+data%3A+application+to+HIV+proteinase&doi=10.1006%2Fabio.1996.0238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase</span></div><div class="casAuthors">Kuzmic, Petr</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">260-273</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A computer program with the code name DYNAFIT was developed for fitting either the initial velocities or the time course of enzyme reactions to an arbitrary mol. mechanism represented symbolically by a set of chem. equations.  Seven numerical tests and five graphical tests are applied to judge the goodness of fit.  Exptl. data on the inhibition of the dissociative dimeric proteinase from HIV were used in four test examples.  A set of initial velocities was analyzed to see if a tight-binding inhibitor could bind to the HIV proteinase monomer.  Three different sets of progress curves were analyzed (i) to det. the kinetic properties of an irreversible inhibitor, (ii) to investigate the dissocn. and denaturation mechanism for the protease dimer, and (iii) to investigate the inhibition mechanism for a transient inhibitor.  The program is available by anonymous ftp via uwmml.pharmacy.wisc.edu and on the World Wide Web via http://uwmml.pharmacy.wisc. edu.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGa_hR-OebWLVg90H21EOLACvtfcHk0ljwDbtfE_BUMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtlOktL4%253D&md5=71b4b01a4d81d3e38490b1124fe836b4</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1006%2Fabio.1996.0238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1996.0238%26sid%3Dliteratum%253Aachs%26aulast%3DKuzmic%26aufirst%3DP.%26atitle%3DProgram%2520DYNAFIT%2520for%2520the%2520analysis%2520of%2520enzyme%2520kinetic%2520data%253A%2520application%2520to%2520HIV%2520proteinase%26jtitle%3DAnal.%2520Biochem.%26date%3D1996%26volume%3D237%26issue%3D2%26spage%3D260%26epage%3D273%26doi%3D10.1006%2Fabio.1996.0238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Kuzmic, P.</span><span> </span><span class="NLM_article-title">DynaFit—a software package for enzymology</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1016/S0076-6879(09)67010-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2FS0076-6879%2809%2967010-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2009&pages=247-280&author=P.+Kuzmic&title=DynaFit%E2%80%94a+software+package+for+enzymology&doi=10.1016%2FS0076-6879%2809%2967010-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2809%2967010-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252809%252967010-5%26sid%3Dliteratum%253Aachs%26aulast%3DKuzmic%26aufirst%3DP.%26atitle%3DDynaFit%25E2%2580%2594a%2520software%2520package%2520for%2520enzymology%26jtitle%3DMethods%2520Enzymol.%26date%3D2009%26volume%3D467%26spage%3D247%26epage%3D280%26doi%3D10.1016%2FS0076-6879%2809%2967010-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span> </span><span class="NLM_article-title">Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition</span> <span class="citation_source-journal">Structure (Oxford, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1016/j.str.2012.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2Fj.str.2012.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFeq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=209-219&issue=2&author=K.+S.+Gajiwalaauthor=J.+Fengauthor=R.+Ferreauthor=K.+Ryanauthor=O.+Brodskyauthor=S.+Weinrichauthor=J.+C.+Kathauthor=A.+Stewart&title=Insights+into+the+Aberrant+Activity+of+Mutant+EGFR+Kinase+Domain+and+Drug+Recognition&doi=10.1016%2Fj.str.2012.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition</span></div><div class="casAuthors">Gajiwala, Ketan S.; Feng, Junli; Ferre, RoseAnn; Ryan, Kevin; Brodsky, Oleg; Weinrich, Scott; Kath, John C.; Stewart, Al</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-219</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The oncogenicity of the L858R mutant form of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer is thought to be due to the constitutive activation of its kinase domain.  The selectivity of the marketed drugs gefitinib and erlotinib for L858R mutant is attributed to their specific recognition of the active kinase and to weaker ATP binding by L858R EGFR.  We present crystal structures showing that neither L858R nor the drug-resistant L858R+T790M EGFR kinase domain is in the constitutively active conformation.  Addnl. co-crystal structures show that gefitinib and dacomitinib, an irreversible anilinoquinazoline deriv. currently in clin. development, may not be conformation specific for the active state of the enzyme.  Structural data further reveal the potential mode of recognition of one of the autophosphorylation sites in the C-terminal tail, Tyr-1016, by the kinase domain.  Biochem. and biophys. evidence suggest that the oncogenic mutations impact the conformational dynamics of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi6kAQLM6h7LVg90H21EOLACvtfcHk0ljwDbtfE_BUMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFeq&md5=439bfda2e4e33786a15742e53cc271bc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DWeinrich%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DStewart%26aufirst%3DA.%26atitle%3DInsights%2520into%2520the%2520Aberrant%2520Activity%2520of%2520Mutant%2520EGFR%2520Kinase%2520Domain%2520and%2520Drug%2520Recognition%26jtitle%3DStructure%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2013%26volume%3D21%26issue%3D2%26spage%3D209%26epage%3D219%26doi%3D10.1016%2Fj.str.2012.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney-Pickett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umland, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebhard, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-kattan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span> </span><span class="NLM_article-title">Development of a new permeability assay using low-efflux MDCKII cells</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4974</span><span class="NLM_x">–</span> <span class="NLM_lpage">4985</span><span class="refDoi"> DOI: 10.1002/jps.22674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&issue=11&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+new+permeability+assay+using+low-efflux+MDCKII+cells&doi=10.1002%2Fjps.22674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0ljwDbtfE_BUMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520new%2520permeability%2520assay%2520using%2520low-efflux%2520MDCKII%2520cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26issue%3D11%26spage%3D4974%26epage%3D4985%26doi%3D10.1002%2Fjps.22674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nkansah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney-Pickett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span> </span><span class="NLM_article-title">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1199</span><span class="NLM_x">–</span> <span class="NLM_lpage">1212</span><span class="refDoi"> DOI: 10.1021/mp2004912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2004912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1199-1212&issue=5&author=M.+V.+Varmaauthor=I.+Gardnerauthor=S.+J.+Steynauthor=P.+Nkansahauthor=C.+J.+Rotterauthor=C.+Whitney-Pickettauthor=H.+Zhangauthor=L.+Diauthor=M.+Cramauthor=K.+S.+Fennerauthor=A.+F.+El-Kattan&title=pH-Dependent+solubility+and+permeability+criteria+for+provisional+biopharmaceutics+classification+%28BCS+and+BDDCS%29+in+early+drug+discovery&doi=10.1021%2Fmp2004912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span></div><div class="casAuthors">Varma, Manthena V.; Gardner, Iain; Steyn, Stefanus J.; Nkansah, Paul; Rotter, Charles J.; Whitney-Pickett, Carrie; Zhang, Hui; Di, Li; Cram, Michael; Fenner, Katherine S.; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1212</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is a scientific framework that provides a basis for predicting the oral absorption of drugs.  These concepts have been extended in the Biopharmaceutics Drug Disposition Classification System (BDDCS) to explain the potential mechanism of drug clearance and understand the effects of uptake and efflux transporters on absorption, distribution, metab., and elimination.  The objective of present work is to establish criteria for provisional biopharmaceutics classification using pH-dependent passive permeability and aq. soly. data generated from high throughput screening methodologies in drug discovery settings.  The apparent permeability across monolayers of clonal cell line of Madin-Darby canine kidney cells, selected for low endogenous efflux transporter expression, was measured for a set of 105 drugs, with known BCS and BDDCS class.  The permeability at apical pH 6.5 for acidic drugs and at pH 7.4 for nonacidic drugs showed a good correlation with the fraction absorbed in human (Fa).  Receiver operating characteristic (ROC) curve anal. was utilized to define the permeability class boundary.  At permeability ≥5 × 10-6 cm/s, the accuracy of predicting Fa of ≥0.90 was 87%.  Also, this cutoff showed more than 80% sensitivity and specificity in predicting the literature permeability classes (BCS), and the metab. classes (BDDCS).  The equil. soly. of a subset of 49 drugs was measured in pH 1.2 medium, pH 6.5 phosphate buffer, and in FaSSIF medium (pH 6.5).  Although dose was not considered, good concordance of the measured soly. with BCS and BDDCS soly. class was achieved, when soly. at pH 1.2 was used for acidic compds. and FaSSIF soly. was used for basic, neutral, and zwitterionic compds.  Using a cutoff of 200 μg/mL, the data set suggested a 93% sensitivity and 86% specificity in predicting both the BCS and BDDCS soly. classes.  In conclusion, this study identified pH-dependent permeability and soly. criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process.  Addnl., such a classification system will enable discovery scientists to assess the potential limiting factors to oral absorption, as well as help predict the drug disposition mechanisms and potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84irw4TD15rVg90H21EOLACvtfcHk0lhRD9qoRy355g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D&md5=2bcb29ea512d2e0665973292e4a4a0a3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fmp2004912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2004912%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DNkansah%26aufirst%3DP.%26aulast%3DRotter%26aufirst%3DC.%2BJ.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCram%26aufirst%3DM.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DpH-Dependent%2520solubility%2520and%2520permeability%2520criteria%2520for%2520provisional%2520biopharmaceutics%2520classification%2520%2528BCS%2520and%2520BDDCS%2529%2520in%2520early%2520drug%2520discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26issue%3D5%26spage%3D1199%26epage%3D1212%26doi%3D10.1021%2Fmp2004912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalaie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koenig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vojkovsky, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span> </span><span class="NLM_article-title">Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">8091</span><span class="NLM_x">–</span> <span class="NLM_lpage">8109</span><span class="refDoi"> DOI: 10.1021/jm300967g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300967g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8091-8109&issue=18&author=J.+J.+Cuiauthor=M.+McTigueauthor=M.+Nambuauthor=M.+Tran-Dubeauthor=M.+Pairishauthor=H.+Shenauthor=L.+Jiaauthor=H.+Chengauthor=J.+Hoffmanauthor=P.+Leauthor=M.+Jalaieauthor=G.+H.+Goetzauthor=M.+Koenigauthor=T.+Vojkovskyauthor=F.-J.+Zhangauthor=S.+Doauthor=I.+Botrousauthor=K.+Ryanauthor=N.+Grodskyauthor=Y.-l.+Dengauthor=M.+Parkerauthor=S.+Timofeevskiauthor=B.+W.+Murrayauthor=S.+Yamazakiauthor=S.+Aguirreauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensen&title=Discovery+of+a+Novel+Class+of+Exquisitely+Selective+Mesenchymal-Epithelial+Transition+Factor+%28c-MET%29+Protein+Kinase+Inhibitors+and+Identification+of+the+Clinical+Candidate+2-%284-%281-%28Quinolin-6-ylmethyl%29-1H-%5B1%2C2%2C3%5Dtriazolo%5B4%2C5-b%5Dpyrazin-6-yl%29-1H-pyrazol-1-yl%29ethanol+%28PF-04217903%29+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm300967g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm300967g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300967g%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DGoetz%26aufirst%3DG.%2BH.%26aulast%3DKoenig%26aufirst%3DM.%26aulast%3DVojkovsky%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DF.-J.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DY.-l.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAguirre%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Class%2520of%2520Exquisitely%2520Selective%2520Mesenchymal-Epithelial%2520Transition%2520Factor%2520%2528c-MET%2529%2520Protein%2520Kinase%2520Inhibitors%2520and%2520Identification%2520of%2520the%2520Clinical%2520Candidate%25202-%25284-%25281-%2528Quinolin-6-ylmethyl%2529-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-b%255Dpyrazin-6-yl%2529-1H-pyrazol-1-yl%2529ethanol%2520%2528PF-04217903%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D18%26spage%3D8091%26epage%3D8109%26doi%3D10.1021%2Fjm300967g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Chein, R.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corey, E. J.</span><span> </span><span class="NLM_article-title">Strong Conformational Preferences of Heteroaromatic Ethers and Electron Pair Repulsion</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">135</span><span class="refDoi"> DOI: 10.1021/ol9025364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol9025364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSnurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=132-135&issue=1&author=R.-J.+Cheinauthor=E.+J.+Corey&title=Strong+Conformational+Preferences+of+Heteroaromatic+Ethers+and+Electron+Pair+Repulsion&doi=10.1021%2Fol9025364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Strong Conformational Preferences of Heteroaromatic Ethers and Electron Pair Repulsion</span></div><div class="casAuthors">Chein, Rong-Jie; Corey, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">132-135</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Electron-pair repulsion in 2-methoxyheteroarenes is important for N, but not for O or S heteroatoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgArLQp_Bpl7Vg90H21EOLACvtfcHk0lhRD9qoRy355g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSnurnJ&md5=f558c5f754f1610e85bab3a0f556b0db</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fol9025364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol9025364%26sid%3Dliteratum%253Aachs%26aulast%3DChein%26aufirst%3DR.-J.%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26atitle%3DStrong%2520Conformational%2520Preferences%2520of%2520Heteroaromatic%2520Ethers%2520and%2520Electron%2520Pair%2520Repulsion%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26issue%3D1%26spage%3D132%26epage%3D135%26doi%3D10.1021%2Fol9025364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Perola, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charifson, P. S.</span><span> </span><span class="NLM_article-title">Conformational Analysis of Drug-Like Molecules Bound to Proteins: An Extensive Study of Ligand Reorganization upon Binding</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">2499</span><span class="NLM_x">–</span> <span class="NLM_lpage">2510</span><span class="refDoi"> DOI: 10.1021/jm030563w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030563w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2499-2510&issue=10&author=E.+Perolaauthor=P.+S.+Charifson&title=Conformational+Analysis+of+Drug-Like+Molecules+Bound+to+Proteins%3A+An+Extensive+Study+of+Ligand+Reorganization+upon+Binding&doi=10.1021%2Fjm030563w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Analysis of Drug-Like Molecules Bound to Proteins: An Extensive Study of Ligand Reorganization upon Binding</span></div><div class="casAuthors">Perola, Emanuele; Charifson, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2499-2510</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describes a large-scale study on the nature and the energetics of the conformational changes drug-like mols. experience upon binding.  Ligand strain energies and conformational reorganization were analyzed with different computational methods on 150 crystal structures of pharmaceutically relevant protein-ligand complexes.  The common knowledge that ligands rarely bind in their lowest calcd. energy conformation was confirmed.  Addnl., the authors found that over 60% of the ligands do not bind in a local min. conformation.  While approx. 60% of the ligands were calcd. to bind with strain energies lower than 5 kcal/mol, strain energies over 9 kcal/mol were calcd. in at least 10% of the cases regardless of the method used.  A clear correlation was found between acceptable strain energy and ligand flexibility, while there was no correlation between strain energy and binding affinity, thus indicating that expensive conformational rearrangements can be tolerated in some cases without overly penalizing the tightness of binding.  On the basis of the trends obsd., thresholds for the acceptable strain energies of bioactive conformations were defined with consideration of the impact of ligand flexibility.  An anal. of the degree of folding of the bound ligands confirmed the general tendency of small mols. to bind in an extended conformation.  The results suggest that the unfolding of hydrophobic ligands during binding, which exposes hydrophobic surfaces to contact with protein residues, could be one of the factors accounting for high reorganization energies.  Finally, different methods for conformational anal. were evaluated, and guidelines were defined to maximize the prevalence of bioactive conformations in computationally generated ensembles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMrN0dFKglcbVg90H21EOLACvtfcHk0lgJcWoT5NPGcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVans78%253D&md5=8f54a8285ef1ffc5e1a19f748f4674bf</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm030563w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030563w%26sid%3Dliteratum%253Aachs%26aulast%3DPerola%26aufirst%3DE.%26aulast%3DCharifson%26aufirst%3DP.%2BS.%26atitle%3DConformational%2520Analysis%2520of%2520Drug-Like%2520Molecules%2520Bound%2520to%2520Proteins%253A%2520An%2520Extensive%2520Study%2520of%2520Ligand%2520Reorganization%2520upon%2520Binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D10%26spage%3D2499%26epage%3D2510%26doi%3D10.1021%2Fjm030563w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Lanning, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitby, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dix, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hett, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joslyn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niessen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulce, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteley, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">767</span><span class="refDoi"> DOI: 10.1038/nchembio.1582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1038%2Fnchembio.1582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=25038787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=760-767&issue=9&author=B.+R.+Lanningauthor=L.+R.+Whitbyauthor=M.+M.+Dixauthor=J.+Douhanauthor=A.+M.+Gilbertauthor=E.+C.+Hettauthor=T.+O.+Johnsonauthor=C.+Joslynauthor=J.+C.+Kathauthor=S.+Niessenauthor=L.+R.+Robertsauthor=M.+E.+Schnuteauthor=C.+Wangauthor=J.+J.+Hulceauthor=B.+Weiauthor=L.+O.+Whiteleyauthor=M.+M.+Haywardauthor=B.+F.+Cravatt&title=A+road+map+to+evaluate+the+proteome-wide+selectivity+of+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span></div><div class="casAuthors">Lanning, Bryan R.; Whitby, Landon R.; Dix, Melissa M.; Douhan, John; Gilbert, Adam M.; Hett, Erik C.; Johnson, Theodore O.; Joslyn, Chris; Kath, John C.; Niessen, Sherry; Roberts, Lee R.; Schnute, Mark E.; Wang, Chu; Hulce, Jonathan J.; Wei, Baoxian; Whiteley, Laurence O.; Hayward, Matthew M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">760-767</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinases are principal components of signal transduction pathways and the focus of intense basic and drug discovery research.  Irreversible inhibitors that covalently modify non-catalytic cysteines in kinase active sites have emerged as valuable probes and approved drugs.  Many protein classes, however, have functional cysteines, and therefore understanding the proteome-wide selectivity of covalent kinase inhibitors is imperative.  Here, we accomplish this objective using activity-based protein profiling coupled with quant. MS to globally map the targets, both specific and nonspecific, of covalent kinase inhibitors in human cells.  Many of the specific off-targets represent nonkinase proteins that, notably, have conserved active site cysteines.  We define windows of selectivity for covalent kinase inhibitors and show that, when these windows are exceeded, rampant proteome-wide reactivity and kinase target-independent cell death conjointly occur.  Our findings, taken together, provide an exptl. road map to illuminate opportunities and surmount challenges for the development of covalent kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAiUlEg9R5rVg90H21EOLACvtfcHk0lgJcWoT5NPGcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO&md5=6f17b0d1b00e088f37c511eea577d290</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1582%26sid%3Dliteratum%253Aachs%26aulast%3DLanning%26aufirst%3DB.%2BR.%26aulast%3DWhitby%26aufirst%3DL.%2BR.%26aulast%3DDix%26aufirst%3DM.%2BM.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DHett%26aufirst%3DE.%2BC.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DJoslyn%26aufirst%3DC.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHulce%26aufirst%3DJ.%2BJ.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWhiteley%26aufirst%3DL.%2BO.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520road%2520map%2520to%2520evaluate%2520the%2520proteome-wide%2520selectivity%2520of%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26issue%3D9%26spage%3D760%26epage%3D767%26doi%3D10.1038%2Fnchembio.1582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Rostovtsev, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fokin, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpless, K. B.</span><span> </span><span class="NLM_article-title">A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">2596</span><span class="NLM_x">–</span> <span class="NLM_lpage">2599</span><span class="refDoi"> DOI: 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=2596-2599&issue=14&author=V.+V.+Rostovtsevauthor=L.+G.+Greenauthor=V.+V.+Fokinauthor=K.+B.+Sharpless&title=A+stepwise+Huisgen+cycloaddition+process%3A+copper%28I%29-catalyzed+regioselective+%22ligation%22+of+azides+and+terminal+alkynes&doi=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3773%252820020715%252941%253A14%253C2596%253A%253AAID-ANIE2596%253E3.0.CO%253B2-4%26sid%3Dliteratum%253Aachs%26aulast%3DRostovtsev%26aufirst%3DV.%2BV.%26aulast%3DGreen%26aufirst%3DL.%2BG.%26aulast%3DFokin%26aufirst%3DV.%2BV.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DA%2520stepwise%2520Huisgen%2520cycloaddition%2520process%253A%2520copper%2528I%2529-catalyzed%2520regioselective%2520%2522ligation%2522%2520of%2520azides%2520and%2520terminal%2520alkynes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2002%26volume%3D41%26issue%3D14%26spage%3D2596%26epage%3D2599%26doi%3D10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Muchowski, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solas, D. R.</span><span> </span><span class="NLM_article-title">Protecting groups for the pyrrole and indole nitrogen atom. The [2-(trimethylsilyl)ethoxy]methyl moiety. Lithiation of 1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrole</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span><span class="refDoi"> DOI: 10.1021/jo00175a053</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00175a053" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1984&pages=203-5&issue=1&author=J.+M.+Muchowskiauthor=D.+R.+Solas&title=Protecting+groups+for+the+pyrrole+and+indole+nitrogen+atom.+The+%5B2-%28trimethylsilyl%29ethoxy%5Dmethyl+moiety.+Lithiation+of+1-%5B%5B2-%28trimethylsilyl%29ethoxy%5Dmethyl%5Dpyrrole&doi=10.1021%2Fjo00175a053"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjo00175a053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00175a053%26sid%3Dliteratum%253Aachs%26aulast%3DMuchowski%26aufirst%3DJ.%2BM.%26aulast%3DSolas%26aufirst%3DD.%2BR.%26atitle%3DProtecting%2520groups%2520for%2520the%2520pyrrole%2520and%2520indole%2520nitrogen%2520atom.%2520The%2520%255B2-%2528trimethylsilyl%2529ethoxy%255Dmethyl%2520moiety.%2520Lithiation%2520of%25201-%255B%255B2-%2528trimethylsilyl%2529ethoxy%255Dmethyl%255Dpyrrole%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1984%26volume%3D49%26issue%3D1%26spage%3D203%26epage%3D5%26doi%3D10.1021%2Fjo00175a053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 57 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Aaron F. Baldwin, Michaella A. Caporello, Guoyong Chen, Adam E. Goetz, Weifeng Hu, Chengfeng Jin, Kevin M. Knopf, Zhifeng Li, Cuong V. Lu, Sebastien Monfette, Angela L. A. Puchlopek-Dermenci, <span class="NLM_string-name hlFld-ContribAuthor">Feng Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Kilogram-Scale Preparation of an Aminopyrazole Building Block via Copper-Catalyzed Aryl Amidation. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2021,</strong> <em>25 </em>
                                    (4)
                                     , 1065-1073. <a href="https://doi.org/10.1021/acs.oprd.1c00066" title="DOI URL">https://doi.org/10.1021/acs.oprd.1c00066</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.1c00066&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.1c00066%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DKilogram-Scale%252BPreparation%252Bof%252Ban%252BAminopyrazole%252BBuilding%252BBlock%252Bvia%252BCopper-Catalyzed%252BAryl%252BAmidation%26aulast%3DBaldwin%26aufirst%3DAaron%2BF.%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D22022021%26date%3D06042021%26volume%3D25%26issue%3D4%26spage%3D1065%26epage%3D1073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yonggang Meng, Bin Yu, He Huang, Youmei Peng, Ertong Li, Yongfang Yao, Chuanjun Song, Wenquan Yu, Kaikai Zhu, Kai Wang, Dongxu Yi, Jinfa Du, <span class="NLM_string-name hlFld-ContribAuthor">Junbiao Chang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Dosimertinib, a Highly Potent, Selective, and Orally Efficacious Deuterated EGFR Targeting Clinical Candidate for the Treatment of Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (2)
                                     , 925-937. <a href="https://doi.org/10.1021/acs.jmedchem.0c02005" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02005%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BDosimertinib%25252C%252Ba%252BHighly%252BPotent%25252C%252BSelective%25252C%252Band%252BOrally%252BEfficacious%252BDeuterated%252BEGFR%252BTargeting%252BClinical%252BCandidate%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DMeng%26aufirst%3DYonggang%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D19112020%26date%3D18012021%26volume%3D64%26issue%3D2%26spage%3D925%26epage%3D937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Adi Lahiani, Dikla Haham-Geula, David Lankri, Susan Cornell-Kennon, Erik M. Schaefer, Dmitry Tsvelikhovsky, <span class="NLM_string-name hlFld-ContribAuthor">Philip Lazarovici</span>. </span><span class="cited-content_cbyCitation_article-title">Neurotropic activity and safety of methylene-cycloalkylacetate (MCA) derivative 3-(3-allyl-2-methylenecyclohexyl) propanoic acid. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Neuroscience</span><span> <strong>2020,</strong> <em>11 </em>
                                    (17)
                                     , 2577-2589. <a href="https://doi.org/10.1021/acschemneuro.0c00255" title="DOI URL">https://doi.org/10.1021/acschemneuro.0c00255</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschemneuro.0c00255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschemneuro.0c00255%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Neuroscience%26atitle%3DNeurotropic%252Bactivity%252Band%252Bsafety%252Bof%252Bmethylene-cycloalkylacetate%252B%252528MCA%252529%252Bderivative%252B3-%2525283-allyl-2-methylenecyclohexyl%252529%252Bpropanoic%252Bacid%26aulast%3DLahiani%26aufirst%3DAdi%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D15072020%26date%3D03082020%26date%3D15072020%26volume%3D11%26issue%3D17%26spage%3D2577%26epage%3D2589" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Philipp S. Schmalhorst, <span class="NLM_string-name hlFld-ContribAuthor">Andreas Bergner</span>. </span><span class="cited-content_cbyCitation_article-title">A Grid Map Based Approach to Identify Nonobvious Ligand Design Opportunities in 3D Protein Structure Ensembles. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (4)
                                     , 2178-2188. <a href="https://doi.org/10.1021/acs.jcim.0c00051" title="DOI URL">https://doi.org/10.1021/acs.jcim.0c00051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.0c00051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.0c00051%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DA%252BGrid%252BMap%252BBased%252BApproach%252Bto%252BIdentify%252BNonobvious%252BLigand%252BDesign%252BOpportunities%252Bin%252B3D%252BProtein%252BStructure%252BEnsembles%26aulast%3DSchmalhorst%26aufirst%3DPhilipp%2BS.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D17012020%26date%3D17032020%26date%3D05032020%26volume%3D60%26issue%3D4%26spage%3D2178%26epage%3D2188" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Adolfo Cuesta, Xiaobo Wan, Alma L. Burlingame, <span class="NLM_string-name hlFld-ContribAuthor">Jack Taunton</span>. </span><span class="cited-content_cbyCitation_article-title">Ligand Conformational Bias Drives Enantioselective Modification of a Surface-Exposed Lysine on Hsp90. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2020,</strong> <em>142 </em>
                                    (7)
                                     , 3392-3400. <a href="https://doi.org/10.1021/jacs.9b09684" title="DOI URL">https://doi.org/10.1021/jacs.9b09684</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.9b09684&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.9b09684%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DLigand%252BConformational%252BBias%252BDrives%252BEnantioselective%252BModification%252Bof%252Ba%252BSurface-Exposed%252BLysine%252Bon%252BHsp90%26aulast%3DCuesta%26aufirst%3DAdolfo%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D07092019%26date%3D03022020%26volume%3D142%26issue%3D7%26spage%3D3392%26epage%3D3400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Farideh Badichi Akher, Abdolkarim Farrokhzadeh, Neil Ravenscroft, <span class="NLM_string-name hlFld-ContribAuthor">Michelle M. Kuttel</span>. </span><span class="cited-content_cbyCitation_article-title">A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (41)
                                     , 4246-4259. <a href="https://doi.org/10.1021/acs.biochem.9b00710" title="DOI URL">https://doi.org/10.1021/acs.biochem.9b00710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.9b00710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.9b00710%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DA%252BMechanistic%252BStudy%252Bof%252Ba%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitor%252Bagainst%252Bthe%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13082019%26date%3D23092019%26date%3D07102019%26volume%3D58%26issue%3D41%26spage%3D4246%26epage%3D4259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Bryan Li, Ruizhi Li, Peter Dorff, J. Christopher McWilliams, Robert M. Guinn, Steven M. Guinness, Lu Han, Ke Wang, <span class="NLM_string-name hlFld-ContribAuthor">Shu Yu</span>. </span><span class="cited-content_cbyCitation_article-title">Deprotection of N-Boc Groups under Continuous-Flow High-Temperature Conditions. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2019,</strong> <em>84 </em>
                                    (8)
                                     , 4846-4855. <a href="https://doi.org/10.1021/acs.joc.8b02909" title="DOI URL">https://doi.org/10.1021/acs.joc.8b02909</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b02909&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b02909%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDeprotection%252Bof%252BN-Boc%252BGroups%252Bunder%252BContinuous-Flow%252BHigh-Temperature%252BConditions%26aulast%3DLi%26aufirst%3DBryan%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D10122018%26date%3D18012019%26date%3D08012019%26volume%3D84%26issue%3D8%26spage%3D4846%26epage%3D4855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yong Tao, Nandell F. Keene, Kristin E. Wiglesworth, Barbara Sitter, <span class="NLM_string-name hlFld-ContribAuthor">J. Christopher McWilliams</span>. </span><span class="cited-content_cbyCitation_article-title">Early Process Development of an Irreversible Epidermal Growth Factor Receptor (EGFR) T790 M Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2019,</strong> <em>23 </em>
                                    (3)
                                     , 382-388. <a href="https://doi.org/10.1021/acs.oprd.8b00437" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00437</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00437%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DEarly%252BProcess%252BDevelopment%252Bof%252Ban%252BIrreversible%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BT790%252BM%252BInhibitor%26aulast%3DTao%26aufirst%3DYong%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D13122018%26date%3D14022019%26date%3D31012019%26volume%3D23%26issue%3D3%26spage%3D382%26epage%3D388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Liyang Shi, Zhenpeng Zhong, Xitao Li, Yiqing Zhou, <span class="NLM_string-name hlFld-ContribAuthor">Zhengying Pan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (2)
                                     , 1054-1066. <a href="https://doi.org/10.1021/acs.jmedchem.8b01823" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01823</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b01823%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ban%252BOrally%252BAvailable%252BJanus%252BKinase%252B3%252BSelective%252BCovalent%252BInhibitor%26aulast%3DShi%26aufirst%3DLiyang%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21112018%26date%3D07012019%26volume%3D62%26issue%3D2%26spage%3D1054%26epage%3D1066" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yuming Wang, Lijun Li, Jun Fan, Yang Dai, Alan Jiang, Meiyu Geng, Jing Ai, <span class="NLM_string-name hlFld-ContribAuthor">Wenhu Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (20)
                                     , 9085-9104. <a href="https://doi.org/10.1021/acs.jmedchem.7b01843" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01843</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01843&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01843%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252BIrreversible%252BPan-Fibroblast%252BGrowth%252BFactor%252BReceptor%252B%252528FGFR%252529%252BInhibitors%26aulast%3DWang%26aufirst%3DYuming%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D14122017%26date%3D16032018%26date%3D09032018%26volume%3D61%26issue%3D20%26spage%3D9085%26epage%3D9104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ted W. Johnson, Rebecca A. Gallego, <span class="NLM_string-name hlFld-ContribAuthor">Martin P. Edwards</span>. </span><span class="cited-content_cbyCitation_article-title">Lipophilic Efficiency as an Important Metric in Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6401-6420. <a href="https://doi.org/10.1021/acs.jmedchem.8b00077" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00077</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00077&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00077%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DLipophilic%252BEfficiency%252Bas%252Ban%252BImportant%252BMetric%252Bin%252BDrug%252BDesign%26aulast%3DJohnson%26aufirst%3DTed%2BW.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D16012018%26date%3D17042018%26date%3D28032018%26volume%3D61%26issue%3D15%26spage%3D6401%26epage%3D6420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ken A.  Brameld</span>, <span class="hlFld-ContribAuthor ">Timothy D.  Owens</span>, <span class="hlFld-ContribAuthor ">Erik  Verner</span>, <span class="hlFld-ContribAuthor ">Eleni  Venetsanakos</span>, <span class="hlFld-ContribAuthor ">J. Michael  Bradshaw</span>, <span class="hlFld-ContribAuthor ">Vernon T.  Phan</span>, <span class="hlFld-ContribAuthor ">Danny  Tam</span>, <span class="hlFld-ContribAuthor ">Kwan  Leung</span>, <span class="hlFld-ContribAuthor ">Jin  Shu</span>, <span class="hlFld-ContribAuthor ">Jacob  LaStant</span>, <span class="hlFld-ContribAuthor ">David G.  Loughhead</span>, <span class="hlFld-ContribAuthor ">Tony  Ton</span>, <span class="hlFld-ContribAuthor ">Dane E.  Karr</span>, <span class="hlFld-ContribAuthor ">Mary E.  Gerritsen</span>, <span class="hlFld-ContribAuthor ">David M.  Goldstein</span>, and <span class="hlFld-ContribAuthor ">Jens Oliver  Funk</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (15)
                                     , 6516-6527. <a href="https://doi.org/10.1021/acs.jmedchem.7b00360" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00360</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00360%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthe%252BIrreversible%252BCovalent%252BFGFR%252BInhibitor%252B8-%2525283-%2525284-Acryloylpiperazin-1-yl%252529propyl%252529-6-%2525282%25252C6-dichloro-3%25252C5-dimethoxyphenyl%252529-2-%252528methylamino%252529pyrido%25255B2%25252C3-d%25255Dpyrimidin-7%2525288H%252529-one%252B%252528PRN1371%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BSolid%252BTumors%26aulast%3DBrameld%26aufirst%3DKen%2BA.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D07032017%26date%3D25072017%26date%3D10082017%26date%3D30062017%26volume%3D60%26issue%3D15%26spage%3D6516%26epage%3D6527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Douglas C.  Behenna</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Theodore O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">T. Eric  Ballard</span>, <span class="hlFld-ContribAuthor ">Louise  Bernier</span>, <span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Judith G.  Deal</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle  Hemkens</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">John C.  Kath</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Neal W.  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Manli  Shi</span>, <span class="hlFld-ContribAuthor ">James  Solowiej</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">Paolo  Vicini</span>, <span class="hlFld-ContribAuthor ">Yuli  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Longqing  Liu</span>, <span class="hlFld-ContribAuthor ">Yiqin  Luo</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Chengyi  Zhang</span>, and <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (7)
                                     , 3002-3019. <a href="https://doi.org/10.1021/acs.jmedchem.6b01894" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01894</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01894&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01894%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN-%252528%2525283R%25252C4R%252529-4-Fluoro-1-%2525286-%252528%2525283-methoxy-1-methyl-1H-pyrazol-4-yl%252529amino%252529-9-methyl-9H-purin-2-yl%252529pyrrolidine-3-yl%252529acrylamide%252B%252528PF-06747775%252529%252Bthrough%252BStructure-Based%252BDrug%252BDesign%25253A%252BA%252BHigh%252BAffinity%252BIrreversible%252BInhibitor%252BTargeting%252BOncogenic%252BEGFR%252BMutants%252Bwith%252BSelectivity%252Bover%252BWild-Type%252BEGFR%26aulast%3DPlanken%26aufirst%3DSimon%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D11012017%26date%3D29032017%26date%3D13042017%26date%3D13032017%26volume%3D60%26issue%3D7%26spage%3D3002%26epage%3D3019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinping  Gan</span>, <span class="hlFld-ContribAuthor ">Haiying  Zhang</span>, and <span class="hlFld-ContribAuthor ">W. Griffith  Humphreys</span>  . </span><span class="cited-content_cbyCitation_article-title">Drug–Protein Adducts: Chemistry, Mechanisms of Toxicity, and Methods of Characterization. </span><span class="cited-content_cbyCitation_journal-name">Chemical Research in Toxicology</span><span> <strong>2016,</strong> <em>29 </em>
                                    (12)
                                     , 2040-2057. <a href="https://doi.org/10.1021/acs.chemrestox.6b00274" title="DOI URL">https://doi.org/10.1021/acs.chemrestox.6b00274</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrestox.6b00274&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrestox.6b00274%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Research%2520in%2520Toxicology%26atitle%3DDrug%2525E2%252580%252593Protein%252BAdducts%25253A%252BChemistry%25252C%252BMechanisms%252Bof%252BToxicity%25252C%252Band%252BMethods%252Bof%252BCharacterization%26aulast%3DGan%26aufirst%3DJinping%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D15082016%26date%3D05122016%26date%3D19122016%26date%3D29112016%26volume%3D29%26issue%3D12%26spage%3D2040%26epage%3D2057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edward J.  Hennessy</span>, <span class="hlFld-ContribAuthor ">Claudio  Chuaqui</span>, <span class="hlFld-ContribAuthor ">Susan  Ashton</span>, <span class="hlFld-ContribAuthor ">Nicola  Colclough</span>, <span class="hlFld-ContribAuthor ">Darren A. E.  Cross</span>, <span class="hlFld-ContribAuthor ">Judit É.  Debreczeni</span>, <span class="hlFld-ContribAuthor ">Cath  Eberlein</span>, <span class="hlFld-ContribAuthor ">Lakshmaiah  Gingipalli</span>, <span class="hlFld-ContribAuthor ">Teresa C. M.  Klinowska</span>, <span class="hlFld-ContribAuthor ">Jonathan P.  Orme</span>, <span class="hlFld-ContribAuthor ">Li  Sha</span>, and <span class="hlFld-ContribAuthor ">Xiaoyun  Wu</span>  . </span><span class="cited-content_cbyCitation_article-title">Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (5)
                                     , 514-519. <a href="https://doi.org/10.1021/acsmedchemlett.6b00058" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00058%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DUtilization%252Bof%252BStructure-Based%252BDesign%252Bto%252BIdentify%252BNovel%25252C%252BIrreversible%252BInhibitors%252Bof%252BEGFR%252BHarboring%252Bthe%252BT790M%252BMutation%26aulast%3DHennessy%26aufirst%3DEdward%2BJ.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D09022016%26date%3D21032016%26date%3D24032016%26date%3D12052016%26date%3D21032016%26volume%3D7%26issue%3D5%26spage%3D514%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhenqiang  Xia</span>, <span class="hlFld-ContribAuthor ">Ridong  Huang</span>, <span class="hlFld-ContribAuthor ">Xinglong  Zhou</span>, <span class="hlFld-ContribAuthor ">Yingying  Chai</span>, <span class="hlFld-ContribAuthor ">Hai  Chen</span>, <span class="hlFld-ContribAuthor ">Lingling  Ma</span>, <span class="hlFld-ContribAuthor ">Quanwei  Yu</span>, <span class="hlFld-ContribAuthor ">Ying  Li</span>, <span class="hlFld-ContribAuthor ">Weimin  Li</span>, <span class="hlFld-ContribAuthor ">Yang  He</span>. </span><span class="cited-content_cbyCitation_article-title">The synthesis and bioactivity of pyrrolo[2,3-d]pyrimidine derivatives as tyrosine kinase inhibitors for NSCLC cells with EGFR mutations. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113711. <a href="https://doi.org/10.1016/j.ejmech.2021.113711" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113711</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113711&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113711%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DThe%252Bsynthesis%252Band%252Bbioactivity%252Bof%252Bpyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252Btyrosine%252Bkinase%252Binhibitors%252Bfor%252BNSCLC%252Bcells%252Bwith%252BEGFR%252Bmutations%26aulast%3DXia%26aufirst%3DZhenqiang%26date%3D2021%26volume%3D224%26spage%3D113711" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Mahsa  Toolabi</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrimidine-based EGFR TK inhibitors in targeted cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>221 </em>, 113523. <a href="https://doi.org/10.1016/j.ejmech.2021.113523" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113523</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113523&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113523%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DPyrimidine-based%252BEGFR%252BTK%252Binhibitors%252Bin%252Btargeted%252Bcancer%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2021%26volume%3D221%26spage%3D113523" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.-Mohsen M.E.  Omar</span>, <span class="hlFld-ContribAuthor ">Omaima M.  AboulWafa</span>, <span class="hlFld-ContribAuthor ">Mai E.  Amr</span>, <span class="hlFld-ContribAuthor ">Mai S.  El-Shoukrofy</span>. </span><span class="cited-content_cbyCitation_article-title">Antiproliferative activity, enzymatic inhibition and apoptosis-promoting effects of benzoxazole-based hybrids on human breast cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>109 </em>, 104752. <a href="https://doi.org/10.1016/j.bioorg.2021.104752" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104752</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104752%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DAntiproliferative%252Bactivity%25252C%252Benzymatic%252Binhibition%252Band%252Bapoptosis-promoting%252Beffects%252Bof%252Bbenzoxazole-based%252Bhybrids%252Bon%252Bhuman%252Bbreast%252Bcancer%252Bcells%26aulast%3DOmar%26aufirst%3DA.-Mohsen%2BM.E.%26date%3D2021%26volume%3D109%26spage%3D104752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amit  Shraga</span>, <span class="hlFld-ContribAuthor ">Efrat  Resnick</span>, <span class="hlFld-ContribAuthor ">Ronen  Gabizon</span>, <span class="hlFld-ContribAuthor ">Nir  London</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent fragment screening. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 243-265. <a href="https://doi.org/10.1016/bs.armc.2021.04.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2021.04.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2021.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2021.04.001%26sid%3Dliteratum%253Aachs%26atitle%3DCovalent%252Bfragment%252Bscreening%26aulast%3DShraga%26aufirst%3DAmit%26date%3D2021%26spage%3D243%26epage%3D265%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">R.  Padmini</span>, <span class="hlFld-ContribAuthor ">V.  Uma Maheshwari</span>, <span class="hlFld-ContribAuthor ">P.  Saravanan</span>, <span class="hlFld-ContribAuthor ">Keun  Woo Lee</span>, <span class="hlFld-ContribAuthor ">M.  Razia</span>, <span class="hlFld-ContribAuthor ">Mona S.  Alwahibi</span>, <span class="hlFld-ContribAuthor ">B.  Ravindran</span>, <span class="hlFld-ContribAuthor ">Mohamed  Soliman Elshikh</span>, <span class="hlFld-ContribAuthor ">Young  Ock Kim</span>, <span class="hlFld-ContribAuthor ">Hyungsuk  Kim</span>, <span class="hlFld-ContribAuthor ">Hak-Jae  Kim</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of novel bioactive molecules from garlic bulbs: A special effort to determine the anticancer potential against lung cancer with targeted drugs. </span><span class="cited-content_cbyCitation_journal-name">Saudi Journal of Biological Sciences</span><span> <strong>2020,</strong> <em>27 </em>
                                    (12)
                                     , 3274-3289. <a href="https://doi.org/10.1016/j.sjbs.2020.09.041" title="DOI URL">https://doi.org/10.1016/j.sjbs.2020.09.041</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.sjbs.2020.09.041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.sjbs.2020.09.041%26sid%3Dliteratum%253Aachs%26jtitle%3DSaudi%2520Journal%2520of%2520Biological%2520Sciences%26atitle%3DIdentification%252Bof%252Bnovel%252Bbioactive%252Bmolecules%252Bfrom%252Bgarlic%252Bbulbs%25253A%252BA%252Bspecial%252Beffort%252Bto%252Bdetermine%252Bthe%252Banticancer%252Bpotential%252Bagainst%252Blung%252Bcancer%252Bwith%252Btargeted%252Bdrugs%26aulast%3DPadmini%26aufirst%3DR.%26date%3D2020%26volume%3D27%26issue%3D12%26spage%3D3274%26epage%3D3289" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhen  Xiao</span>, <span class="hlFld-ContribAuthor ">Cilong  Chu</span>, <span class="hlFld-ContribAuthor ">Lingjia  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Feiyi  Yang</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of thiapyran-pyrimidine derivatives as potential EGFR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (19)
                                     , 115669. <a href="https://doi.org/10.1016/j.bmc.2020.115669" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115669</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115669%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthiapyran-pyrimidine%252Bderivatives%252Bas%252Bpotential%252BEGFR%252Binhibitors%26aulast%3DXiao%26aufirst%3DZhen%26date%3D2020%26volume%3D28%26issue%3D19%26spage%3D115669" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhen  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Cilong  Chu</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Lingjia  Zhou</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Xin  Li</span>, <span class="hlFld-ContribAuthor ">Liying  Yu</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112511. <a href="https://doi.org/10.1016/j.ejmech.2020.112511" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112511%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bactivity%252Bof%252Bnovel%252Bthiophene-pyrimidine%252Bderivatives%252Bas%252BEGFR%252Binhibitors%252Bovercoming%252BT790M%252Band%252BL858R%25252FT790M%252Bmutations%26aulast%3DXiao%26aufirst%3DZhen%26date%3D2020%26volume%3D203%26spage%3D112511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaodong  Dou</span>, <span class="hlFld-ContribAuthor ">Huixia  Huang</span>, <span class="hlFld-ContribAuthor ">Lan  Jiang</span>, <span class="hlFld-ContribAuthor ">Guiwang  Zhu</span>, <span class="hlFld-ContribAuthor ">Hongwei  Jin</span>, <span class="hlFld-ContribAuthor ">Ning  Jiao</span>, <span class="hlFld-ContribAuthor ">Liangren  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhenming  Liu</span>, <span class="hlFld-ContribAuthor ">Lihe  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Rational modification, synthesis and biological evaluation of 3,4-dihydroquinoxalin-2(1H)-one derivatives as potent and selective c-Jun N-terminal kinase 3 (JNK3) inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>201 </em>, 112445. <a href="https://doi.org/10.1016/j.ejmech.2020.112445" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112445%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRational%252Bmodification%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252B3%25252C4-dihydroquinoxalin-2%2525281H%252529-one%252Bderivatives%252Bas%252Bpotent%252Band%252Bselective%252Bc-Jun%252BN-terminal%252Bkinase%252B3%252B%252528JNK3%252529%252Binhibitors%26aulast%3DDou%26aufirst%3DXiaodong%26date%3D2020%26volume%3D201%26spage%3D112445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohammad Rizki Fadhil  Pratama</span>, <span class="hlFld-ContribAuthor ">Hadi  Poerwono</span>, <span class="hlFld-ContribAuthor ">Siswandono  Siswodihardjo</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular docking of novel 5-O-benzoylpinostrobin derivatives as wild type and L858R/T790M/V948R mutant EGFR inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Basic and Clinical Physiology and Pharmacology</span><span> <strong>2019,</strong> <em>30 </em>
                                    (6)
                                     <a href="https://doi.org/10.1515/jbcpp-2019-0301" title="DOI URL">https://doi.org/10.1515/jbcpp-2019-0301</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1515/jbcpp-2019-0301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1515%2Fjbcpp-2019-0301%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Basic%2520and%2520Clinical%2520Physiology%2520and%2520Pharmacology%26atitle%3DMolecular%252Bdocking%252Bof%252Bnovel%252B5-O-benzoylpinostrobin%252Bderivatives%252Bas%252Bwild%252Btype%252Band%252BL858R%25252FT790M%25252FV948R%252Bmutant%252BEGFR%252Binhibitor%26aulast%3DPratama%26aufirst%3DMohammad%2BRizki%2BFadhil%26date%3D2019%26volume%3D30%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenshuai  Dai</span>, <span class="hlFld-ContribAuthor ">Zhe  Zhang</span>, <span class="hlFld-ContribAuthor ">Yikui  Du</span>. </span><span class="cited-content_cbyCitation_article-title">Modulation of Conformational Preferences of Heteroaromatic Ethers and Amides through Protonation and Ionization: Charge Effect. </span><span class="cited-content_cbyCitation_journal-name">ChemistryOpen</span><span> <strong>2019,</strong> <em>8 </em>
                                    (7)
                                     , 840-851. <a href="https://doi.org/10.1002/open.201900103" title="DOI URL">https://doi.org/10.1002/open.201900103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/open.201900103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fopen.201900103%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistryOpen%26atitle%3DModulation%252Bof%252BConformational%252BPreferences%252Bof%252BHeteroaromatic%252BEthers%252Band%252BAmides%252Bthrough%252BProtonation%252Band%252BIonization%25253A%252BCharge%252BEffect%26aulast%3DDai%26aufirst%3DWenshuai%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D7%26spage%3D840%26epage%3D851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ann Christin  Reiersølmoen</span>, <span class="hlFld-ContribAuthor ">Thomas Ihle  Aarhus</span>, <span class="hlFld-ContribAuthor ">Sarah  Eckelt</span>, <span class="hlFld-ContribAuthor ">Kristin Gabestad  Nørsett</span>, <span class="hlFld-ContribAuthor ">Eirik  Sundby</span>, <span class="hlFld-ContribAuthor ">Bård Helge  Hoff</span>. </span><span class="cited-content_cbyCitation_article-title">Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>88 </em>, 102918. <a href="https://doi.org/10.1016/j.bioorg.2019.102918" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.102918</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.102918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.102918%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPotent%252Band%252Bselective%252BEGFR%252Binhibitors%252Bbased%252Bon%252B5-aryl-7H-pyrrolopyrimidin-4-amines%26aulast%3DReiers%25C3%25B8lmoen%26aufirst%3DAnn%2BChristin%26date%3D2019%26volume%3D88%26spage%3D102918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guanghui  Tang</span>, <span class="hlFld-ContribAuthor ">Lihong  Liu</span>, <span class="hlFld-ContribAuthor ">Xueying  Wang</span>, <span class="hlFld-ContribAuthor ">Zhengying  Pan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk). </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>173 </em>, 167-183. <a href="https://doi.org/10.1016/j.ejmech.2019.03.055" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.03.055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.03.055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.03.055%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bselective%252Bcovalent%252Birreversible%252Binhibitors%252Bof%252Binterleukin-2-inducible%252BT-cell%252Bkinase%252B%252528Itk%252529%26aulast%3DTang%26aufirst%3DGuanghui%26date%3D2019%26volume%3D173%26spage%3D167%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Moira  Rachman</span>, <span class="hlFld-ContribAuthor ">Andrea  Scarpino</span>, <span class="hlFld-ContribAuthor ">Dávid  Bajusz</span>, <span class="hlFld-ContribAuthor ">Gyula  Pálfy</span>, <span class="hlFld-ContribAuthor ">István  Vida</span>, <span class="hlFld-ContribAuthor ">András  Perczel</span>, <span class="hlFld-ContribAuthor ">Xavier  Barril</span>, <span class="hlFld-ContribAuthor ">György M.  Keserű</span>. </span><span class="cited-content_cbyCitation_article-title">DUckCov: a Dynamic Undocking‐Based Virtual Screening Protocol for Covalent Binders. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (10)
                                     , 1011-1021. <a href="https://doi.org/10.1002/cmdc.201900078" title="DOI URL">https://doi.org/10.1002/cmdc.201900078</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900078&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900078%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DDUckCov%25253A%252Ba%252BDynamic%252BUndocking%2525E2%252580%252590Based%252BVirtual%252BScreening%252BProtocol%252Bfor%252BCovalent%252BBinders%26aulast%3DRachman%26aufirst%3DMoira%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D10%26spage%3D1011%26epage%3D1021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Avick Kumar  Ghosh</span>, <span class="hlFld-ContribAuthor ">Indranil  Samanta</span>, <span class="hlFld-ContribAuthor ">Anushree  Mondal</span>, <span class="hlFld-ContribAuthor ">Wenshe Ray  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Inhibition in Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2019,</strong> <em>14 </em>
                                    (9)
                                     , 889-906. <a href="https://doi.org/10.1002/cmdc.201900107" title="DOI URL">https://doi.org/10.1002/cmdc.201900107</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201900107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201900107%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DCovalent%252BInhibition%252Bin%252BDrug%252BDiscovery%26aulast%3DGhosh%26aufirst%3DAvick%2BKumar%26date%3D2019%26date%3D2019%26volume%3D14%26issue%3D9%26spage%3D889%26epage%3D906" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches in the Development of Covalent Irreversible EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 45-128. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00003-2" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00003-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00003-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00003-2%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BApproaches%252Bin%252Bthe%252BDevelopment%252Bof%252BCovalent%252BIrreversible%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D45%26epage%3D128%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher M.  Harris</span>, <span class="hlFld-ContribAuthor ">Sage E.  Foley</span>, <span class="hlFld-ContribAuthor ">Eric R.  Goedken</span>, <span class="hlFld-ContribAuthor ">Mark  Michalak</span>, <span class="hlFld-ContribAuthor ">Sara  Murdock</span>, <span class="hlFld-ContribAuthor ">Noel S.  Wilson</span>. </span><span class="cited-content_cbyCitation_article-title">Merits and Pitfalls in the Characterization of Covalent Inhibitors of Bruton’s Tyrosine Kinase. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2018,</strong> <em>23 </em>
                                    (10)
                                     , 1040-1050. <a href="https://doi.org/10.1177/2472555218787445" title="DOI URL">https://doi.org/10.1177/2472555218787445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/2472555218787445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F2472555218787445%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DMerits%252Band%252BPitfalls%252Bin%252Bthe%252BCharacterization%252Bof%252BCovalent%252BInhibitors%252Bof%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%26aulast%3DHarris%26aufirst%3DChristopher%2BM.%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D10%26spage%3D1040%26epage%3D1050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">German P.  Barletta</span>, <span class="hlFld-ContribAuthor ">Marcia Anahi  Hasenahuer</span>, <span class="hlFld-ContribAuthor ">Maria Silvina  Fornasari</span>, <span class="hlFld-ContribAuthor ">Gustavo  Parisi</span>, <span class="hlFld-ContribAuthor ">Sebastian  Fernandez-Alberti</span>. </span><span class="cited-content_cbyCitation_article-title">Dynamics fingerprints of active conformers of epidermal growth factor receptor kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Computational Chemistry</span><span> <strong>2018,</strong> <em>39 </em>
                                    (29)
                                     , 2472-2480. <a href="https://doi.org/10.1002/jcc.25590" title="DOI URL">https://doi.org/10.1002/jcc.25590</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcc.25590&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcc.25590%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Computational%2520Chemistry%26atitle%3DDynamics%252Bfingerprints%252Bof%252Bactive%252Bconformers%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Bkinase%26aulast%3DBarletta%26aufirst%3DGerman%2BP.%26date%3D2018%26date%3D2018%26volume%3D39%26issue%3D29%26spage%3D2472%26epage%3D2480" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EGFR
              L858R/T790M
              and EGFR
              L858R/T790M/C797S
              resistance mutations in NSCLC: Current developments in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5)
                                     , 1550-1581. <a href="https://doi.org/10.1002/med.21488" title="DOI URL">https://doi.org/10.1002/med.21488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21488%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252BEGFR%252BL858R%25252FT790M%252Band%252BEGFR%252BL858R%25252FT790M%25252FC797S%252Bresistance%252Bmutations%252Bin%252BNSCLC%25253A%252BCurrent%252Bdevelopments%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1550%26epage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shailima  Rampogu</span>, <span class="hlFld-ContribAuthor ">Minky  Son</span>, <span class="hlFld-ContribAuthor ">Ayoung  Baek</span>, <span class="hlFld-ContribAuthor ">Chanin  Park</span>, <span class="hlFld-ContribAuthor ">Rabia Mukthar  Rana</span>, <span class="hlFld-ContribAuthor ">Amir  Zeb</span>, <span class="hlFld-ContribAuthor ">Saravanan  Parameswaran</span>, <span class="hlFld-ContribAuthor ">Keun Woo  Lee</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting natural compounds against HER2 kinase domain as potential anticancer drugs applying pharmacophore based molecular modelling approaches. </span><span class="cited-content_cbyCitation_journal-name">Computational Biology and Chemistry</span><span> <strong>2018,</strong> <em>74 </em>, 327-338. <a href="https://doi.org/10.1016/j.compbiolchem.2018.04.002" title="DOI URL">https://doi.org/10.1016/j.compbiolchem.2018.04.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.compbiolchem.2018.04.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.compbiolchem.2018.04.002%26sid%3Dliteratum%253Aachs%26jtitle%3DComputational%2520Biology%2520and%2520Chemistry%26atitle%3DTargeting%252Bnatural%252Bcompounds%252Bagainst%252BHER2%252Bkinase%252Bdomain%252Bas%252Bpotential%252Banticancer%252Bdrugs%252Bapplying%252Bpharmacophore%252Bbased%252Bmolecular%252Bmodelling%252Bapproaches%26aulast%3DRampogu%26aufirst%3DShailima%26date%3D2018%26volume%3D74%26spage%3D327%26epage%3D338" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jinxing  Hu</span>, <span class="hlFld-ContribAuthor ">Yufei  Han</span>, <span class="hlFld-ContribAuthor ">Jingtao  Wang</span>, <span class="hlFld-ContribAuthor ">Yue  Liu</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>, <span class="hlFld-ContribAuthor ">Yajing  Liu</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of selective EGFR modulator to inhibit L858R/T790M double mutants bearing a N-9-Diphenyl-9H-purin-2-amine scaffold. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (8)
                                     , 1810-1822. <a href="https://doi.org/10.1016/j.bmc.2018.02.029" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.02.029</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.02.029&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.02.029%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bselective%252BEGFR%252Bmodulator%252Bto%252Binhibit%252BL858R%25252FT790M%252Bdouble%252Bmutants%252Bbearing%252Ba%252BN-9-Diphenyl-9H-purin-2-amine%252Bscaffold%26aulast%3DHu%26aufirst%3DJinxing%26date%3D2018%26volume%3D26%26issue%3D8%26spage%3D1810%26epage%3D1822" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahaveer  Singh</span>, <span class="hlFld-ContribAuthor ">Hemant R.  Jadhav</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting non-small cell lung cancer with small-molecule EGFR tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2018,</strong> <em>23 </em>
                                    (3)
                                     , 745-753. <a href="https://doi.org/10.1016/j.drudis.2017.10.004" title="DOI URL">https://doi.org/10.1016/j.drudis.2017.10.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2017.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2017.10.004%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DTargeting%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bwith%252Bsmall-molecule%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DSingh%26aufirst%3DMahaveer%26date%3D2018%26volume%3D23%26issue%3D3%26spage%3D745%26epage%3D753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Zhao</span>, <span class="hlFld-ContribAuthor ">Philip E.  Bourne</span>. </span><span class="cited-content_cbyCitation_article-title">Progress with covalent small-molecule kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2018,</strong> <em>23 </em>
                                    (3)
                                     , 727-735. <a href="https://doi.org/10.1016/j.drudis.2018.01.035" title="DOI URL">https://doi.org/10.1016/j.drudis.2018.01.035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2018.01.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2018.01.035%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DProgress%252Bwith%252Bcovalent%252Bsmall-molecule%252Bkinase%252Binhibitors%26aulast%3DZhao%26aufirst%3DZheng%26date%3D2018%26volume%3D23%26issue%3D3%26spage%3D727%26epage%3D735" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Zhang</span>, <span class="hlFld-ContribAuthor ">Jin  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Shen</span>, <span class="hlFld-ContribAuthor ">Hui-Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Wei-Ming  Duan</span>, <span class="hlFld-ContribAuthor ">Hong-Yi  Zhao</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hei</span>, <span class="hlFld-ContribAuthor ">Minhang  Xin</span>, <span class="hlFld-ContribAuthor ">Yong-Xiao  Cao</span>, <span class="hlFld-ContribAuthor ">San-Qi  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of 2,4,6-trisubstitued pyrido[3,4-d]pyrimidine derivatives as new EGFR-TKIs. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>148 </em>, 221-237. <a href="https://doi.org/10.1016/j.ejmech.2018.02.051" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.02.051</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.02.051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.02.051%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B2%25252C4%25252C6-trisubstitued%252Bpyrido%25255B3%25252C4-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bnew%252BEGFR-TKIs%26aulast%3DZhang%26aufirst%3DHao%26date%3D2018%26volume%3D148%26spage%3D221%26epage%3D237" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Deheng  Chen</span>, <span class="hlFld-ContribAuthor ">Dexiang  Guo</span>, <span class="hlFld-ContribAuthor ">Ziqin  Yan</span>, <span class="hlFld-ContribAuthor ">Yujun  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Allenamide as a bioisostere of acrylamide in the design and synthesis of targeted covalent inhibitors. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (2)
                                     , 244-253. <a href="https://doi.org/10.1039/C7MD00571G" title="DOI URL">https://doi.org/10.1039/C7MD00571G</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7MD00571G&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7MD00571G%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DAllenamide%252Bas%252Ba%252Bbioisostere%252Bof%252Bacrylamide%252Bin%252Bthe%252Bdesign%252Band%252Bsynthesis%252Bof%252Btargeted%252Bcovalent%252Binhibitors%26aulast%3DChen%26aufirst%3DDeheng%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D2%26spage%3D244%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sonali  Kurup</span>, <span class="hlFld-ContribAuthor ">Bradley  McAllister</span>, <span class="hlFld-ContribAuthor ">Pavlina  Liskova</span>, <span class="hlFld-ContribAuthor ">Trusha  Mistry</span>, <span class="hlFld-ContribAuthor ">Anthony  Fanizza</span>, <span class="hlFld-ContribAuthor ">Dan  Stanford</span>, <span class="hlFld-ContribAuthor ">Jolanta  Slawska</span>, <span class="hlFld-ContribAuthor ">Ulrich  Keller</span>, <span class="hlFld-ContribAuthor ">Alexander  Hoellein</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological activity of
              N
              4
              -phenylsubstituted-7
              H
              -pyrrolo[2,3-
              d
              ]pyrimidin-4-amines as dual inhibitors of aurora kinase A and epidermal growth factor receptor kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2018,</strong> <em>33 </em>
                                    (1)
                                     , 74-84. <a href="https://doi.org/10.1080/14756366.2017.1376666" title="DOI URL">https://doi.org/10.1080/14756366.2017.1376666</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2017.1376666&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2017.1376666%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bactivity%252Bof%252BN%252B4%252B-phenylsubstituted-7%252BH%252B-pyrrolo%25255B2%25252C3-%252Bd%252B%25255Dpyrimidin-4-amines%252Bas%252Bdual%252Binhibitors%252Bof%252Baurora%252Bkinase%252BA%252Band%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Bkinase%26aulast%3DKurup%26aufirst%3DSonali%26date%3D2018%26date%3D2017%26volume%3D33%26issue%3D1%26spage%3D74%26epage%3D84" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marcia Anahi  Hasenahuer</span>, <span class="hlFld-ContribAuthor ">German Patricio  Barletta</span>, <span class="hlFld-ContribAuthor ">Sebastián  Fernandez-Alberti</span>, <span class="hlFld-ContribAuthor ">Gustavo  Parisi</span>, <span class="hlFld-ContribAuthor ">María Silvina  Fornasari</span>, . </span><span class="cited-content_cbyCitation_article-title">Pockets as structural descriptors of EGFR kinase conformations. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2017,</strong> <em>12 </em>
                                    (12)
                                     , e0189147. <a href="https://doi.org/10.1371/journal.pone.0189147" title="DOI URL">https://doi.org/10.1371/journal.pone.0189147</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0189147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0189147%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DPockets%252Bas%252Bstructural%252Bdescriptors%252Bof%252BEGFR%252Bkinase%252Bconformations%26aulast%3DHasenahuer%26aufirst%3DMarcia%2BAnahi%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D12%26spage%3De0189147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luhong  Wang</span>, <span class="hlFld-ContribAuthor ">Jingyuan  Zhao</span>, <span class="hlFld-ContribAuthor ">Yao  Yao</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Xiuli  Sun</span>, <span class="hlFld-ContribAuthor ">Yanxia  Li</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Hong  Yuan</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent binding design strategy: A prospective method for discovery of potent targeted anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 493-505. <a href="https://doi.org/10.1016/j.ejmech.2017.09.024" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.09.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.09.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.09.024%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCovalent%252Bbinding%252Bdesign%252Bstrategy%25253A%252BA%252Bprospective%252Bmethod%252Bfor%252Bdiscovery%252Bof%252Bpotent%252Btargeted%252Banticancer%252Bagents%26aulast%3DWang%26aufirst%3DLuhong%26date%3D2017%26volume%3D142%26spage%3D493%26epage%3D505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Melissa M.  Dix</span>, <span class="hlFld-ContribAuthor ">Sabrina  Barbas</span>, <span class="hlFld-ContribAuthor ">Zachary E.  Potter</span>, <span class="hlFld-ContribAuthor ">Shuyan  Lu</span>, <span class="hlFld-ContribAuthor ">Oleg  Brodsky</span>, <span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Douglas  Behenna</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Kevin  Ryan</span>, <span class="hlFld-ContribAuthor ">RoseAnn  Ferre</span>, <span class="hlFld-ContribAuthor ">Michael R.  Lazear</span>, <span class="hlFld-ContribAuthor ">Matthew M.  Hayward</span>, <span class="hlFld-ContribAuthor ">John C.  Kath</span>, <span class="hlFld-ContribAuthor ">Benjamin F.  Cravatt</span>. </span><span class="cited-content_cbyCitation_article-title">Proteome-wide Map of Targets of T790M-EGFR-Directed Covalent Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2017,</strong> <em>24 </em>
                                    (11)
                                     , 1388-1400.e7. <a href="https://doi.org/10.1016/j.chembiol.2017.08.017" title="DOI URL">https://doi.org/10.1016/j.chembiol.2017.08.017</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2017.08.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2017.08.017%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DProteome-wide%252BMap%252Bof%252BTargets%252Bof%252BT790M-EGFR-Directed%252BCovalent%252BInhibitors%26aulast%3DNiessen%26aufirst%3DSherry%26date%3D2017%26volume%3D24%26issue%3D11%26spage%3D1388%26epage%3D1400.e7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingfeng  Chen</span>, <span class="hlFld-ContribAuthor ">Weitao  Fu</span>, <span class="hlFld-ContribAuthor ">Chen  Feng</span>, <span class="hlFld-ContribAuthor ">Rong  Qu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Lulu  Zheng</span>, <span class="hlFld-ContribAuthor ">Bo  Fang</span>, <span class="hlFld-ContribAuthor ">Yinda  Qiu</span>, <span class="hlFld-ContribAuthor ">Jie  Hu</span>, <span class="hlFld-ContribAuthor ">Yuepiao  Cai</span>, <span class="hlFld-ContribAuthor ">Jianpeng  Feng</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Liu</span>, <span class="hlFld-ContribAuthor ">Guang  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>140 </em>, 510-527. <a href="https://doi.org/10.1016/j.ejmech.2017.08.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%252Band%252Bsynthesis%252Bof%252B2%25252C4-diaminopyrimidines%252Bas%252BEGFR%252BL858R%25252FT790M%252Bselective%252Binhibitors%252Bfor%252BNSCLC%26aulast%3DChen%26aufirst%3DLingfeng%26date%3D2017%26volume%3D140%26spage%3D510%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Weiwei  Han</span>, <span class="hlFld-ContribAuthor ">Yongli  Du</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemistry & Biodiversity</span><span> <strong>2017,</strong> <em>14 </em>
                                    (7)
                                     , e1600372. <a href="https://doi.org/10.1002/cbdv.201600372" title="DOI URL">https://doi.org/10.1002/cbdv.201600372</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbdv.201600372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbdv.201600372%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%2526%2520Biodiversity%26atitle%3DRecent%252BDevelopment%252Bof%252Bthe%252BSecond%252Band%252BThird%252BGeneration%252BIrreversible%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitors%26aulast%3DHan%26aufirst%3DWeiwei%26date%3D2017%26date%3D2017%26volume%3D14%26issue%3D7%26spage%3De1600372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haoyang  Zhang</span>, <span class="hlFld-ContribAuthor ">Wenkui  Wu</span>, <span class="hlFld-ContribAuthor ">Chao  Feng</span>, <span class="hlFld-ContribAuthor ">Zhaogang  Liu</span>, <span class="hlFld-ContribAuthor ">Enhe  Bai</span>, <span class="hlFld-ContribAuthor ">Xueyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Meng  Lei</span>, <span class="hlFld-ContribAuthor ">Hao  Cheng</span>, <span class="hlFld-ContribAuthor ">Huayun  Feng</span>, <span class="hlFld-ContribAuthor ">Jingmiao  Shi</span>, <span class="hlFld-ContribAuthor ">Jia  Wang</span>, <span class="hlFld-ContribAuthor ">Zhao  Zhang</span>, <span class="hlFld-ContribAuthor ">Tao  Jin</span>, <span class="hlFld-ContribAuthor ">Shanshan  Chen</span>, <span class="hlFld-ContribAuthor ">Shihe  Hu</span>, <span class="hlFld-ContribAuthor ">Yongqiang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, SAR discussion, in vitro and in vivo evaluation of novel selective EGFR modulator to inhibit L858R/T790M double mutants. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>135 </em>, 12-23. <a href="https://doi.org/10.1016/j.ejmech.2017.04.036" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.04.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.04.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.04.036%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252BSAR%252Bdiscussion%25252C%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bevaluation%252Bof%252Bnovel%252Bselective%252BEGFR%252Bmodulator%252Bto%252Binhibit%252BL858R%25252FT790M%252Bdouble%252Bmutants%26aulast%3DZhang%26aufirst%3DHaoyang%26date%3D2017%26volume%3D135%26spage%3D12%26epage%3D23" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lenka  Munoz</span>. </span><span class="cited-content_cbyCitation_article-title">Non-kinase targets of protein kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2017,</strong> <em>16 </em>
                                    (6)
                                     , 424-440. <a href="https://doi.org/10.1038/nrd.2016.266" title="DOI URL">https://doi.org/10.1038/nrd.2016.266</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd.2016.266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd.2016.266%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DNon-kinase%252Btargets%252Bof%252Bprotein%252Bkinase%252Binhibitors%26aulast%3DMunoz%26aufirst%3DLenka%26date%3D2017%26date%3D2017%26volume%3D16%26issue%3D6%26spage%3D424%26epage%3D440" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pauline  Rullière</span>. </span><span class="cited-content_cbyCitation_article-title">Methyl 3-Methoxyacrylate. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 1-3. <a href="https://doi.org/10.1002/047084289X.rn02030" title="DOI URL">https://doi.org/10.1002/047084289X.rn02030</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/047084289X.rn02030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F047084289X.rn02030%26sid%3Dliteratum%253Aachs%26atitle%3DMethyl%252B3-Methoxyacrylate%26aulast%3DRulli%25C3%25A8re%26aufirst%3DPauline%26date%3D2017%26date%3D2017%26spage%3D1%26epage%3D3%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Ltd%26atitle%3DEncyclopedia%252Bof%252BReagents%252Bfor%252BOrganic%252BSynthesis%26date%3D2001%26date%3D2001%26volume%3D97" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">D.M.  Wilson</span>, <span class="hlFld-ContribAuthor ">J.G.  Kettle</span>, <span class="hlFld-ContribAuthor ">F.W.  Goldberg</span>, <span class="hlFld-ContribAuthor ">K.M.  Foote</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 39-75. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12391-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12391-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12391-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12391-1%26sid%3Dliteratum%253Aachs%26atitle%3DSelective%252BKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.A.%26date%3D2017%26spage%3D39%26epage%3D75%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">N.A.  Meanwell</span>. </span><span class="cited-content_cbyCitation_article-title">A Synopsis of the Properties and Applications of Heteroaromatic Rings in Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 245-361. <a href="https://doi.org/10.1016/bs.aihch.2016.11.002" title="DOI URL">https://doi.org/10.1016/bs.aihch.2016.11.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2016.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2016.11.002%26sid%3Dliteratum%253Aachs%26atitle%3DA%252BSynopsis%252Bof%252Bthe%252BProperties%252Band%252BApplications%252Bof%252BHeteroaromatic%252BRings%252Bin%252BMedicinal%252BChemistry%26aulast%3DMeanwell%26aufirst%3DN.A.%26date%3D2017%26spage%3D245%26epage%3D361%26pub%3DElsevier%26date%3D2017%26volume%3D123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Minhao  Huang</span>, <span class="hlFld-ContribAuthor ">Tianfeng  Xu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Xiao-e  Yan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Yong  Xu</span>, <span class="hlFld-ContribAuthor ">Caihong  Yun</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790M mutant with improved pharmacokinetic properties. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>126 </em>, 1107-1117. <a href="https://doi.org/10.1016/j.ejmech.2016.12.006" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.12.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.12.006%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bstructure-guided%252Boptimization%252Bof%252Bpyrido%25255B2%25252C3-d%25255Dpyrimidin-7-ones%252Bas%252Bselective%252Binhibitors%252Bof%252BEGFRL858R%25252FT790M%252Bmutant%252Bwith%252Bimproved%252Bpharmacokinetic%252Bproperties%26aulast%3DYu%26aufirst%3DLei%26date%3D2017%26volume%3D126%26spage%3D1107%26epage%3D1117" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ke  Yan</span>, <span class="hlFld-ContribAuthor ">Bing  Wang</span>, <span class="hlFld-ContribAuthor ">Holun  Cheng</span>, <span class="hlFld-ContribAuthor ">Zhiwei  Ji</span>, <span class="hlFld-ContribAuthor ">Jing  Huang</span>, <span class="hlFld-ContribAuthor ">Zhigang  Gao</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Skin Surface-Based Transformation Visualization between Biological Macromolecules. </span><span class="cited-content_cbyCitation_journal-name">Journal of Healthcare Engineering</span><span> <strong>2017,</strong> <em>2017 </em>, 1-12. <a href="https://doi.org/10.1155/2017/4818604" title="DOI URL">https://doi.org/10.1155/2017/4818604</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2017/4818604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2017%2F4818604%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Healthcare%2520Engineering%26atitle%3DMolecular%252BSkin%252BSurface-Based%252BTransformation%252BVisualization%252Bbetween%252BBiological%252BMacromolecules%26aulast%3DYan%26aufirst%3DKe%26date%3D2017%26volume%3D2017%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">John M.  Strelow</span>. </span><span class="cited-content_cbyCitation_article-title">A Perspective on the Kinetics of Covalent and Irreversible Inhibition. </span><span class="cited-content_cbyCitation_journal-name">SLAS DISCOVERY: Advancing the Science of Drug Discovery</span><span> <strong>2017,</strong> <em>22 </em>
                                    (1)
                                     , 3-20. <a href="https://doi.org/10.1177/1087057116671509" title="DOI URL">https://doi.org/10.1177/1087057116671509</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1087057116671509&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1087057116671509%26sid%3Dliteratum%253Aachs%26jtitle%3DSLAS%2520DISCOVERY%253A%2520Advancing%2520the%2520Science%2520of%2520Drug%2520Discovery%26atitle%3DA%252BPerspective%252Bon%252Bthe%252BKinetics%252Bof%252BCovalent%252Band%252BIrreversible%252BInhibition%26aulast%3DStrelow%26aufirst%3DJohn%2BM.%26date%3D2017%26date%3D2016%26volume%3D22%26issue%3D1%26spage%3D3%26epage%3D20" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin-Chi  Liao</span>, <span class="hlFld-ContribAuthor ">Chia-Chi  Lin</span>, <span class="hlFld-ContribAuthor ">Jih-Hsiang  Lee</span>, <span class="hlFld-ContribAuthor ">James Chih-Hsin  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomedical Science</span><span> <strong>2016,</strong> <em>23 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12929-016-0305-9" title="DOI URL">https://doi.org/10.1186/s12929-016-0305-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12929-016-0305-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12929-016-0305-9%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomedical%2520Science%26atitle%3DUpdate%252Bon%252Brecent%252Bpreclinical%252Band%252Bclinical%252Bstudies%252Bof%252BT790M%252Bmutant-specific%252Birreversible%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DLiao%26aufirst%3DBin-Chi%26date%3D2016%26date%3D2016%26volume%3D23%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Joel D.  Federspiel</span>, <span class="hlFld-ContribAuthor ">Simona G.  Codreanu</span>, <span class="hlFld-ContribAuthor ">Sandeep  Goyal</span>, <span class="hlFld-ContribAuthor ">Matthew E.  Albertolle</span>, <span class="hlFld-ContribAuthor ">Eric  Lowe</span>, <span class="hlFld-ContribAuthor ">Juli  Teague</span>, <span class="hlFld-ContribAuthor ">Hansen  Wong</span>, <span class="hlFld-ContribAuthor ">F. Peter  Guengerich</span>, <span class="hlFld-ContribAuthor ">Daniel C.  Liebler</span>. </span><span class="cited-content_cbyCitation_article-title">Specificity of Protein Covalent Modification by the Electrophilic Proteasome Inhibitor Carfilzomib in Human Cells. </span><span class="cited-content_cbyCitation_journal-name">Molecular & Cellular Proteomics</span><span> <strong>2016,</strong> <em>15 </em>
                                    (10)
                                     , 3233-3242. <a href="https://doi.org/10.1074/mcp.M116.059709" title="DOI URL">https://doi.org/10.1074/mcp.M116.059709</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1074/mcp.M116.059709&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1074%2Fmcp.M116.059709%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520%2526%2520Cellular%2520Proteomics%26atitle%3DSpecificity%252Bof%252BProtein%252BCovalent%252BModification%252Bby%252Bthe%252BElectrophilic%252BProteasome%252BInhibitor%252BCarfilzomib%252Bin%252BHuman%252BCells%26aulast%3DFederspiel%26aufirst%3DJoel%2BD.%26date%3D2016%26volume%3D15%26issue%3D10%26spage%3D3233%26epage%3D3242" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monia  Hossam</span>, <span class="hlFld-ContribAuthor ">Deena S.  Lasheen</span>, <span class="hlFld-ContribAuthor ">Khaled A. M.  Abouzid</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles. </span><span class="cited-content_cbyCitation_journal-name">Archiv der Pharmazie</span><span> <strong>2016,</strong> <em>349 </em>
                                    (8)
                                     , 573-593. <a href="https://doi.org/10.1002/ardp.201600063" title="DOI URL">https://doi.org/10.1002/ardp.201600063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ardp.201600063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fardp.201600063%26sid%3Dliteratum%253Aachs%26jtitle%3DArchiv%2520der%2520Pharmazie%26atitle%3DCovalent%252BEGFR%252BInhibitors%25253A%252BBinding%252BMechanisms%25252C%252BSynthetic%252BApproaches%25252C%252Band%252BClinical%252BProfiles%26aulast%3DHossam%26aufirst%3DMonia%26date%3D2016%26date%3D2016%26volume%3D349%26issue%3D8%26spage%3D573%26epage%3D593" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0010.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0012.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Summary of first generation and second generation EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0013.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Summary of third generation EGFR inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0014.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Kinetic mechanism for two-step covalent inhibition of EGFR.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0015.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Correlation between absolute and estimated <i>K</i><sub>i</sub> values, <i>R</i><sup>2</sup> = 0.68.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0016.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Modeled interactions of PP core with Met790 and hinge residue of monomeric L858R/T790M EGFR. Hydrophobic surface of the binding site is near the hinge, and T790M is shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0017.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Summary of key in vitro potency and WT selectivity data for <b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0018.jpeg" id="rightTab-GRAPHIC-d123e1104-autogenerated" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. (a) Monomeric L858R + T790M ligand bound conformation (yellow) vs EGFR WT active (green). A classic DFG-out conformation is observed in the ligand bound T790M structure; however, the activation loop is in a state nearly identical to the active form. The Phe856 side chain is oriented out of the protein core, partially occupying the ATP binding site, and the Asp855 side chain is positioned into the hydrophobic core. (b) Comparison of the monomeric L858R + T790M protein conformations in the apo (blue) and the ligand bound (yellow) states. Rotation of the N-lobe and α-C helix occurs on ligand binding.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0019.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Compound <b>10</b> complex with monomeric L858R + T790M KD (1.5 Å). Two views are shown. Hydrogen bonds to the hinge are shown, with key protein residues highlighted in stick form. Some parts of the protein are omitted for clarity. Clear covalent modification of Cys797 is observed. The ligand phenoxy group interacts with Phe856 through VDW interactions. Two key waters are also highlighted (red spheres).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0020.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound <b>12</b> binding interactions with the monomeric EGFR L858R/T790M binding site.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0021.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Comparison of modeled binding mode of <b>13</b> (stick, in blue color) in monomeric L858R/T790M EGFR and bound conformation of <b>14</b> (ball and stick, in green color) in cocrystal structure with the same protein. Cocrystal structure of <b>14</b> with monomeric L858R/T790M EGFR demonstrates that the CF<sub>3</sub> binds in the G loop hydrophobic pocket.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0022.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Crystal structure of <b>14</b> in complex with monomeric L858R/T790M EGFR (2.2 Å). The CF<sub>3</sub> group fills a small hydrophobic pocket, affording a 17-fold increase in binding affinity. Note interaction between the CF3 group and Phe723 and Phe526.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0023.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Pairwise comparison between 5-Cl and 5-H pyrrolopyrimidine analogs. Chlorine substitution of the 5-position of the PP core afforded a 47-fold average increase in binding affinity.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0024.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Crystal structure of <b>1</b> in complex with monomeric L858R/T790M EGFR (1.9 Å). The diaxial conformation of the pyrroldine places the OMe in van der Waals contact with both the Phe856 of the DFG motif and the Phe723 of the G-loop.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0025.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Time-course in situ labeling profiles of 1 μM <b>22</b> (probe to canertinib, left) and <b>23</b> (probe to <b>1</b>, right) in H1975 cells separated into soluble (top) and particulate (bottom) proteomes. H1975 cells were treated for 15 min to 24 h before being harvested. Lysates were analyzed by gel-based florescence, and gels are shown in grayscale. A specific protein with the molecular weight matching that of EGFR is highlighted with a ∗ in the particulate proteome.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0026.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 1. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) TMSCH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>Cl, LiHMDS, THF, 79%; (b) <i>tert</i>-butyl (3-hydroxyphenyl)carbamate, K<sub>2</sub>CO<sub>3</sub>, MeCN, 90%; (c) ArNH<sub>2</sub>, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, Xantphos, 1,4-dioxane, microwave, 43–87%; (d) HCl, 1,4-dioxane; (e) CH<sub>2</sub>═CHCOCl, DCM or THF, 65–70% (steps d and e); (f) TFA, DCM; (g ) K<sub>2</sub>CO<sub>3</sub>, MeOH or EtOH, 46–77% (steps f and g); (h) (i) CH<sub>2</sub>═CHCOCl, DCM, (ii) K<sub>2</sub>CO<sub>3</sub>, EtOH, 47% (steps f and h).</p></p></figure><figure data-id="sch2" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 2. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) KHMDS, 1,4-dioxane; (b) 1-alkyl-1<i>H</i>-pyrazol-4-amine, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, Xantphos, 1,4-dioxane, microwave; (c) TFA, DCM; (d) K<sub>2</sub>CO<sub>3</sub>, MeOH, H<sub>2</sub>O or NH<sub>4</sub>OH, 1,4-dioxane; (e) CH<sub>2</sub>═CHCOCl, DIPEA, DCM or CH<sub>2</sub>═CHCOCl, THF; <b>13</b>, 0.9% over 5 steps; <b>23</b>, 11% over 5 steps.</p></p></figure><figure data-id="sch3" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. 196-Well Amination Screen</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 4. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) Potassium <i>tert</i>-pentoxide, 1,4-dioxane; (b) 1-methyl-1<i>H</i>-pyrazol-4-amine, <i>tert</i>-BuXPhos palladacycle, 79% over two steps; (c) TFA, DCM, 99%; (d) CH<sub>2</sub>═CHCOCl, aq NaHCO<sub>3</sub>, EtOAc, 77%.</p></p></figure><figure data-id="sch5" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/medium/jm-2015-01633b_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Scheme 5. <sup>a</sup></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-5/acs.jmedchem.5b01633/20160310/images/large/jm-2015-01633b_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01633&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>(a) <b>48</b>, TFA, 73%; (b) chiral-SFC (Chiralpak AD-H) 32%; (c) (i) H<sub>2</sub> (1 atm), 10% Pd(OH)<sub>2</sub> (6%), EtOH, (ii) Boc<sub>2</sub>O, 98%; (d) LiBH<sub>4</sub>, THF, 92%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i55">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04018" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04018" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 40 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Ferlay, J.; Soerjomataram, I.; Ervik, M.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D. M.; Forman, D.; Bray, F.</span> <span class="citation_source-book">GLOBOCAN 2012</span>, version <span class="NLM_edition">1.1</span>; <span> </span><span class="NLM_article-title">Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]</span>; <span class="NLM_publisher-name">International Agency for Research on Cancer</span>: <span class="NLM_publisher-loc">Lyon, France</span>,<span class="NLM_x"> </span><span class="NLM_year">2013</span>. Available from <a href="http://globocan.iarc.fr" class="extLink">http://globocan.iarc.fr</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=J.+Ferlay&author=I.+Soerjomataram&author=M.+Ervik&author=R.+Dikshit&author=S.+Eser&author=C.+Mathers&author=M.+Rebelo&author=D.+M.+Parkin&author=D.+Forman&author=F.+Bray&title=GLOBOCAN+2012"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DFerlay%26aufirst%3DJ.%26btitle%3DGLOBOCAN%25202012%26atitle%3DCancer%2520Incidence%2520and%2520Mortality%2520Worldwide%253A%2520IARC%2520CancerBase%2520No.%252011%2520%255BInternet%255D%26pub%3DInternational%2520Agency%2520for%2520Research%2520on%2520Cancer%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruvka, Y. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michor, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1080</span><span class="refDoi"> DOI: 10.1200/JCO.2012.43.3912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1200%2FJCO.2012.43.3912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=23401451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXltl2mtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=1070-1080&issue=8&author=K.+Ohashiauthor=Y.+E.+Maruvkaauthor=F.+Michorauthor=W.+Pao&title=Epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor-resistant+disease&doi=10.1200%2FJCO.2012.43.3912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease</span></div><div class="casAuthors">Ohashi, Kadoaki; Maruvka, Yosef E.; Michor, Franziska; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1070-1080</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Purpose EGFR-mutant lung cancer was first described as a new clin. entity in 2004.  Here, we present an update on new controversies and conclusions regarding the disease.  Methods This article reviews the clin. implications of EGFR mutations in lung cancer with a focus on epidermal growth factor receptor tyrosine kinase inhibitor resistance.  Results The discovery of EGFR mutations has altered the ways in which we consider and treat non-small-cell lung cancer (NSCLC).  Patients whose metastatic tumors harbor EGFR mutations are expected to live longer than 2 years, more than double the previous survival rates for lung cancer.  Conclusion The information presented in this review can guide practitioners and help them inform their patients about EGFR mutations and their impact on the treatment of NSCLC.  Efforts should now conc. on making EGFR-mutant lung cancer a chronic rather than fatal disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3FJbVyt6ydLVg90H21EOLACvtfcHk0lhn3DUv8IuMtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXltl2mtb0%253D&md5=dfda1563a90ce24bc51e55ebbf47d981</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.43.3912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.43.3912%26sid%3Dliteratum%253Aachs%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DMaruvka%26aufirst%3DY.%2BE.%26aulast%3DMichor%26aufirst%3DF.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor-resistant%2520disease%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26issue%3D8%26spage%3D1070%26epage%3D1080%26doi%3D10.1200%2FJCO.2012.43.3912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Barker, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibson, K. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundy, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Godfrey, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barlow, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Healy, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodburn, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Curry, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scarlett, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henthorn, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, L.</span><span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">1911</span><span class="NLM_x">–</span> <span class="NLM_lpage">1914</span><span class="refDoi"> DOI: 10.1016/S0960-894X(01)00344-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&issue=14&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28iressa%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer&doi=10.1016%2FS0960-894X%2801%2900344-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0lhn3DUv8IuMtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528iressa%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26issue%3D14%26spage%3D1911%26epage%3D1914%26doi%3D10.1016%2FS0960-894X%2801%2900344-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Shepherd, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuleanu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maoleekoonpiroj, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smylie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kooten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dediu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findlay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezjk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santabarbara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, L.</span><span> </span><span class="NLM_article-title">Erlotinib in previously treated non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1056/NEJMoa050753</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1056%2FNEJMoa050753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=16014882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=123-132&issue=2&author=F.+A.+Shepherdauthor=J.+R.+Pereiraauthor=T.+Ciuleanuauthor=E.+H.+Tanauthor=V.+Hirshauthor=S.+Thongprasertauthor=D.+Camposauthor=S.+Maoleekoonpirojauthor=M.+Smylieauthor=R.+Martinsauthor=M.+van+Kootenauthor=M.+Dediuauthor=B.+Findlayauthor=D.+Tuauthor=D.+Johnstonauthor=A.+Bezjkauthor=G.+Clarkauthor=P.+Santabarbaraauthor=L.+Seymour&title=Erlotinib+in+previously+treated+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa050753"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Shepherd, Frances A.; Pereira, Jose Rodrigues; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjk, Andrea; Clark, Gary; Santabarbara, Pedro; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a randomized, placebo-controlled, double-blind trial to det. whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy.  Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens.  The patients were stratified according to center, performance status, response to prior chemotherapy, no. of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo.  The median age of the 731 patients who underwent randomization was 61.4 yeas; 49 % had received two prior chemotherapy regimens, and 93 % had received platinum-based chemotherapy.  The response rate was 8.9 % in the erlotinib group and less than 1 % in the placebo group (P < 0.001); the median duration of the response wa 7.9 mo and 3.7 mo, resp.  Progression-free survival was 2.2 mo and 1.8 mo, resp. (hazard ratio, 0.61, adjusted for stratification categories; P < 0.001).  Overall survival was 6.7 mo and 4.7 mo, resp. (hazard ratio, 0.70; P < 0.001), in favor of erlotinib.  Five percent of patients discontinued erlotinib because of toxic effects.  Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr8tjSBsYtbVg90H21EOLACvtfcHk0lhn3DUv8IuMtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D&md5=1633999cf09b8387ad88f40f75a5bb93</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050753%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DPereira%26aufirst%3DJ.%2BR.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DD.%26aulast%3DMaoleekoonpiroj%26aufirst%3DS.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3Dvan%2BKooten%26aufirst%3DM.%26aulast%3DDediu%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DD.%26aulast%3DBezjk%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DErlotinib%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26issue%3D2%26spage%3D123%26epage%3D132%26doi%3D10.1056%2FNEJMoa050753" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Lichtenberger, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holcmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhren, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amberg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smolle, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrumpf, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boelke, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ansari, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacKenzie, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wollenberg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kislat, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fischer, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roeck, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harder, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Homey, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibilia, M.</span><span> </span><span class="NLM_article-title">Epidermal EGFR controls cutaneous host defense and prevents inflammation</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">199</span><span class="NLM_x">) </span> <span class="NLM_fpage">199ra111</span><div class="note"><p class="first last">(14 pp).</p></div><span class="refDoi"> DOI: 10.1126/scitranslmed.3005886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1126%2Fscitranslmed.3005886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=23966300" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=199ra111&issue=199&author=B.+M.+Lichtenbergerauthor=P.+A.+Gerberauthor=M.+Holcmannauthor=B.+A.+Buhrenauthor=N.+Ambergauthor=V.+Smolleauthor=H.+Schrumpfauthor=E.+Boelkeauthor=P.+Ansariauthor=C.+MacKenzieauthor=A.+Wollenbergauthor=A.+Kislatauthor=J.+W.+Fischerauthor=K.+Roeckauthor=J.+Harderauthor=J.+M.+Schroederauthor=B.+Homeyauthor=M.+Sibilia&title=Epidermal+EGFR+controls+cutaneous+host+defense+and+prevents+inflammation&doi=10.1126%2Fscitranslmed.3005886"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3005886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3005886%26sid%3Dliteratum%253Aachs%26aulast%3DLichtenberger%26aufirst%3DB.%2BM.%26aulast%3DGerber%26aufirst%3DP.%2BA.%26aulast%3DHolcmann%26aufirst%3DM.%26aulast%3DBuhren%26aufirst%3DB.%2BA.%26aulast%3DAmberg%26aufirst%3DN.%26aulast%3DSmolle%26aufirst%3DV.%26aulast%3DSchrumpf%26aufirst%3DH.%26aulast%3DBoelke%26aufirst%3DE.%26aulast%3DAnsari%26aufirst%3DP.%26aulast%3DMacKenzie%26aufirst%3DC.%26aulast%3DWollenberg%26aufirst%3DA.%26aulast%3DKislat%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DJ.%2BW.%26aulast%3DRoeck%26aufirst%3DK.%26aulast%3DHarder%26aufirst%3DJ.%26aulast%3DSchroeder%26aufirst%3DJ.%2BM.%26aulast%3DHomey%26aufirst%3DB.%26aulast%3DSibilia%26aufirst%3DM.%26atitle%3DEpidermal%2520EGFR%2520controls%2520cutaneous%2520host%2520defense%2520and%2520prevents%2520inflammation%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26issue%3D199%26spage%3D199ra111%26doi%3D10.1126%2Fscitranslmed.3005886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Mascia, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keith, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garber, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinberg, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kohn, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuspa, S. H.</span><span> </span><span class="NLM_article-title">Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy</span> <span class="citation_source-journal">Sci. Transl. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x"> (</span><span class="NLM_issue">199</span><span class="NLM_x">) </span> <span class="NLM_fpage">199ra110</span><div class="note"><p class="first last">(13 pp).</p></div><span class="refDoi"> DOI: 10.1126/scitranslmed.3005773</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1126%2Fscitranslmed.3005773" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=23966299" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=199ra110&issue=199&author=F.+Masciaauthor=G.+Lamauthor=C.+Keithauthor=C.+Garberauthor=S.+M.+Steinbergauthor=E.+Kohnauthor=S.+H.+Yuspa&title=Genetic+ablation+of+epidermal+EGFR+reveals+the+dynamic+origin+of+adverse+effects+of+anti-EGFR+therapy&doi=10.1126%2Fscitranslmed.3005773"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3005773&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3005773%26sid%3Dliteratum%253Aachs%26aulast%3DMascia%26aufirst%3DF.%26aulast%3DLam%26aufirst%3DG.%26aulast%3DKeith%26aufirst%3DC.%26aulast%3DGarber%26aufirst%3DC.%26aulast%3DSteinberg%26aufirst%3DS.%2BM.%26aulast%3DKohn%26aufirst%3DE.%26aulast%3DYuspa%26aufirst%3DS.%2BH.%26atitle%3DGenetic%2520ablation%2520of%2520epidermal%2520EGFR%2520reveals%2520the%2520dynamic%2520origin%2520of%2520adverse%2520effects%2520of%2520anti-EGFR%2520therapy%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26issue%3D199%26spage%3D199ra110%26doi%3D10.1126%2Fscitranslmed.3005773" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Yu, H. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rekhtman, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sima, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zakowski, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kris, M. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span> </span><span class="NLM_article-title">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x"> (</span><span class="NLM_issue">8</span><span class="NLM_x">) </span> <span class="NLM_fpage">2240</span><span class="NLM_x">–</span> <span class="NLM_lpage">2247</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&issue=8&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+Tumor+Specimens+at+the+Time+of+Acquired+Resistance+to+EGFR-TKI+Therapy+in+155+Patients+with+EGFR-Mutant+Lung+Cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0lhOrU6OM9MRrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520Tumor%2520Specimens%2520at%2520the%2520Time%2520of%2520Acquired%2520Resistance%2520to%2520EGFR-TKI%2520Therapy%2520in%2520155%2520Patients%2520with%2520EGFR-Mutant%2520Lung%2520Cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26issue%3D8%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ten Eyck, L. F.</span><span> </span><span class="NLM_article-title">A helix scaffold for the assembly of active protein kinases</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x"> (</span><span class="NLM_issue">38</span><span class="NLM_x">) </span> <span class="NLM_fpage">14377</span><span class="NLM_x">–</span> <span class="NLM_lpage">14382</span><span class="refDoi"> DOI: 10.1073/pnas.0807988105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1073%2Fpnas.0807988105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=18787129" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD1cXht1SgtrnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=14377-14382&issue=38&author=A.+P.+Kornevauthor=S.+S.+Taylorauthor=L.+F.+Ten+Eyck&title=A+helix+scaffold+for+the+assembly+of+active+protein+kinases&doi=10.1073%2Fpnas.0807988105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">A helix scaffold for the assembly of active protein kinases</span></div><div class="casAuthors">Kornev, Alexandr P.; Taylor, Susan S.; Ten Eyck, Lynn F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">38</span>),
    <span class="NLM_cas:pages">14377-14382,S14377/1-S14377/12</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Structures of set of serine-threonine and tyrosine kinases were investigated by the recently developed bioinformatics tool Local Spatial Patterns (LSP) alignment.  We report a set of conserved motifs comprised mostly of hydrophobic residues.  These residues are scattered throughout the protein sequence and thus were not previously detected by traditional methods.  These motifs traverse the conserved protein kinase core and play integrating and regulatory roles.  They are anchored to the F-helix, which acts as an organizing "hub" providing precise positioning of the key catalytic and regulatory elements.  Consideration of these discovered structures helps to explain previously inexplicable results.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoU7MdhKf3Ul7Vg90H21EOLACvtfcHk0lhOrU6OM9MRrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXht1SgtrnJ&md5=238b0ae88119a68784849994e2f21a78</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0807988105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0807988105%26sid%3Dliteratum%253Aachs%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DTen%2BEyck%26aufirst%3DL.%2BF.%26atitle%3DA%2520helix%2520scaffold%2520for%2520the%2520assembly%2520of%2520active%2520protein%2520kinases%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26issue%3D38%26spage%3D14377%26epage%3D14382%26doi%3D10.1073%2Fpnas.0807988105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Kornev, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, S. S.</span><span> </span><span class="NLM_article-title">Defining the conserved internal architecture of a protein kinase</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1804</span><span class="NLM_x"> (</span><span class="NLM_issue">3</span><span class="NLM_x">) </span> <span class="NLM_fpage">440</span><span class="NLM_x">–</span> <span class="NLM_lpage">444</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2009.10.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2Fj.bbapap.2009.10.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=19879387" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1ynu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1804&publication_year=2010&pages=440-444&issue=3&author=A.+P.+Kornevauthor=S.+S.+Taylor&title=Defining+the+conserved+internal+architecture+of+a+protein+kinase&doi=10.1016%2Fj.bbapap.2009.10.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Defining the conserved internal architecture of a protein kinase</span></div><div class="casAuthors">Kornev, Alexandr P.; Taylor, Susan S.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1804</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">440-444</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Protein kinases constitute a large protein family of important regulators in all eukaryotic cells.  All of the protein kinases have a similar bilobal fold, and their key structural features have been well studied.  However, the recent discovery of non-contiguous hydrophobic ensembles inside the protein kinase core shed new light on the internal organization of these mols.  Two hydrophobic "spines" traverse both lobes of the protein kinase mol., providing a firm but flexible connection between its key elements.  The spine model introduces a useful framework for anal. of intramol. communications, mol. dynamics, and drug design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1YnTs23RLkrVg90H21EOLACvtfcHk0lhrEkpghh2Y9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1ynu74%253D&md5=275cf28f3883575b737639edfc2f454b</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2009.10.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2009.10.017%26sid%3Dliteratum%253Aachs%26aulast%3DKornev%26aufirst%3DA.%2BP.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26atitle%3DDefining%2520the%2520conserved%2520internal%2520architecture%2520of%2520a%2520protein%2520kinase%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2010%26volume%3D1804%26issue%3D3%26spage%3D440%26epage%3D444%26doi%3D10.1016%2Fj.bbapap.2009.10.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Taylor, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kannan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornev, A. P.</span><span> </span><span class="NLM_article-title">Integration of signaling in the kinome: Architecture and regulation of the αC Helix</span> <span class="citation_source-journal">Biochim. Biophys. Acta, Proteins Proteomics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">1854</span><span class="NLM_x">, </span> <span class="NLM_fpage">1567</span><span class="refDoi"> DOI: 10.1016/j.bbapap.2015.04.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2Fj.bbapap.2015.04.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=25891902" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmvVyrtb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1854&publication_year=2015&pages=1567&author=S.+S.+Taylorauthor=A.+S.+Shawauthor=N.+Kannanauthor=A.+P.+Kornev&title=Integration+of+signaling+in+the+kinome%3A+Architecture+and+regulation+of+the+%CE%B1C+Helix&doi=10.1016%2Fj.bbapap.2015.04.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Integration of signaling in the kinome: Architecture and regulation of the αC Helix</span></div><div class="casAuthors">Taylor, Susan S.; Shaw, Andrey S.; Kannan, Natarajan; Kornev, Alexandr P.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Proteins and Proteomics</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">1854</span>
        (<span class="NLM_cas:issue">10_Part_B</span>),
    <span class="NLM_cas:pages">1567-1574</span>CODEN:
                <span class="NLM_cas:coden">BBAPBW</span>;
        ISSN:<span class="NLM_cas:issn">1570-9639</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B. V.</span>)
        </div><div class="casAbstract">A review.  Eukaryotic protein kinases have evolved to be highly regulated and dynamic mol. switches that are typically kept in an inactive state and then activated in response to extracellular signals.  The hallmark signature of an active kinase is a hydrophobic spine called the regulatory (R) spine, which consists of four residues, two in the N-lobe and two in the C-lobe.  RS1 is in the catalytic loop, RS2 is the Phe in the DFG motif, RS3 is at the C-terminus of the αC-Helix, and RS4 is at the beginning of β4.  Assembly of the R-spine is typically facilitated by phosphorylation of the Activation Loop.  The assembled R-spine brings together all of the functional motifs that are essential for transferring the phosphate from ATP to a tethered protein substrate.  This includes the G-Loop, which anchors the ATP, the catalytic loop, the DFG motif fused to the Activation Loop, and the αC-Helix.  We focus here on the properties of the αC-Helix showing (1) how residues communicate with different parts of the mol., (2) how it is recruited to the active site as a consequence of assembling of the R-spine, and (3) how it is regulated by linkers/motifs/proteins that lie outside the conserved kinase core.  This article is part of a Special Issue entitled: Inhibitors of Protein Kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfWj2cGcicALVg90H21EOLACvtfcHk0lhrEkpghh2Y9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmvVyrtb8%253D&md5=524f8bd4ac5cc60d04cd4758bfe737f2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.bbapap.2015.04.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbapap.2015.04.007%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26aulast%3DShaw%26aufirst%3DA.%2BS.%26aulast%3DKannan%26aufirst%3DN.%26aulast%3DKornev%26aufirst%3DA.%2BP.%26atitle%3DIntegration%2520of%2520signaling%2520in%2520the%2520kinome%253A%2520Architecture%2520and%2520regulation%2520of%2520the%2520%25CE%25B1C%2520Helix%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Proteins%2520Proteomics%26date%3D2015%26volume%3D1854%26spage%3D1567%26doi%3D10.1016%2Fj.bbapap.2015.04.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Barf, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaptein, A.</span><span> </span><span class="NLM_article-title">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">6243</span><span class="NLM_x">–</span> <span class="NLM_lpage">6262</span><span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&issue=14&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+Protein+Kinase+Inhibitors%3A+Balancing+the+Benefits+and+Risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lhrEkpghh2Y9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520Protein%2520Kinase%2520Inhibitors%253A%2520Balancing%2520the%2520Benefits%2520and%2520Risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D14%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabnis, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buhrlage, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, L. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span> <span class="citation_source-journal">Chem. Biol. (Oxford, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">146</span><span class="NLM_x">–</span> <span class="NLM_lpage">159</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2012.12.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2Fj.chembiol.2012.12.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=23438744" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2013&pages=146-159&issue=2&author=Q.+Liuauthor=Y.+Sabnisauthor=Z.+Zhaoauthor=T.+Zhangauthor=S.+J.+Buhrlageauthor=L.+H.+Jonesauthor=N.+S.+Gray&title=Developing+Irreversible+Inhibitors+of+the+Protein+Kinase+Cysteinome&doi=10.1016%2Fj.chembiol.2012.12.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Developing Irreversible Inhibitors of the Protein Kinase Cysteinome</span></div><div class="casAuthors">Liu, Qingsong; Sabnis, Yogesh; Zhao, Zheng; Zhang, Tinghu; Buhrlage, Sara J.; Jones, Lyn H.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">146-159</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Protein kinases are a large family of approx. 530 highly conserved enzymes that transfer a γ-phosphate group from ATP to a variety of amino acid residues, such as tyrosine, serine, and threonine, that serves as a ubiquitous mechanism for cellular signal transduction.  The clin. success of a no. of kinase-directed drugs and the frequent observation of disease causing mutations in protein kinases suggest that a large no. of kinases may represent therapeutically relevant targets.  To date, the majority of clin. and preclin. kinase inhibitors are ATP competitive, noncovalent inhibitors that achieve selectivity through recognition of unique features of particular protein kinases.  Recently, there has been renewed interest in the development of irreversible inhibitors that form covalent bonds with cysteine or other nucleophilic residues in the ATP-binding pocket.  Irreversible kinase inhibitors have a no. of potential advantages including prolonged pharmacodynamics, suitability for rational design, high potency, and ability to validate pharmacol. specificity through mutation of the reactive cysteine residue.  Here, we review recent efforts to develop cysteine-targeted irreversible protein kinase inhibitors and discuss their modes of recognizing the ATP-binding pocket and their biol. activity profiles.  In addn., we provided an informatics assessment of the potential "kinase cysteinome" and discuss strategies for the efficient development of new covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVGD7TX3oIeLVg90H21EOLACvtfcHk0lhCV3nrVkdXsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtFWitbs%253D&md5=cef80823123bae88362e816a0a638133</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2012.12.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2012.12.006%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DSabnis%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DBuhrlage%26aufirst%3DS.%2BJ.%26aulast%3DJones%26aufirst%3DL.%2BH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDeveloping%2520Irreversible%2520Inhibitors%2520of%2520the%2520Protein%2520Kinase%2520Cysteinome%26jtitle%3DChem.%2520Biol.%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2013%26volume%3D20%26issue%3D2%26spage%3D146%26epage%3D159%26doi%3D10.1016%2Fj.chembiol.2012.12.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Flanagan, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramite, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aulabaugh, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahal, U. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryder, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuff, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uccello, D. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noe, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Philippe, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanmugasundaram, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Starr, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stroh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Che, Y.</span><span> </span><span class="NLM_article-title">Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">10072</span><span class="NLM_x">–</span> <span class="NLM_lpage">10079</span><span class="refDoi"> DOI: 10.1021/jm501412a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501412a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=10072-10079&issue=23&author=M.+E.+Flanaganauthor=J.+A.+Abramiteauthor=D.+P.+Andersonauthor=A.+Aulabaughauthor=U.+P.+Dahalauthor=A.+M.+Gilbertauthor=C.+Liauthor=J.+Montgomeryauthor=S.+R.+Oppenheimerauthor=T.+Ryderauthor=B.+P.+Schuffauthor=D.+P.+Uccelloauthor=G.+S.+Walkerauthor=Y.+Wuauthor=M.+F.+Brownauthor=J.+M.+Chenauthor=M.+M.+Haywardauthor=M.+C.+Noeauthor=R.+S.+Obachauthor=L.+Philippeauthor=V.+Shanmugasundaramauthor=M.+J.+Shapiroauthor=J.+Starrauthor=J.+Strohauthor=Y.+Che&title=Chemical+and+Computational+Methods+for+the+Characterization+of+Covalent+Reactive+Groups+for+the+Prospective+Design+of+Irreversible+Inhibitors&doi=10.1021%2Fjm501412a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors</span></div><div class="casAuthors">Flanagan, Mark E.; Abramite, Joseph A.; Anderson, Dennis P.; Aulabaugh, Ann; Dahal, Upendra P.; Gilbert, Adam M.; Li, Chao; Montgomery, Justin; Oppenheimer, Stacey R.; Ryder, Tim; Schuff, Brandon P.; Uccello, Daniel P.; Walker, Gregory S.; Wu, Yan; Brown, Matthew F.; Chen, Jinshan M.; Hayward, Matthew M.; Noe, Mark C.; Obach, R. Scott; Philippe, Laurence; Shanmugasundaram, Veerabahu; Shapiro, Michael J.; Starr, Jeremy; Stroh, Justin; Che, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">10072-10079</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Interest in drugs that covalently modify their target is driven by the desire for enhanced efficacy that can result from the silencing of enzymic activity until protein resynthesis can occur, along with the potential for increased selectivity by targeting uniquely positioned nucleophilic residues in the protein.  However, covalent approaches carry addnl. risk for toxicities or hypersensitivity reactions that can result from covalent modification of unintended targets.  Here we describe methods for measuring the reactivity of covalent reactive groups (CRGs) with a biol. relevant nucleophile, glutathione (GSH), along with kinetic data for a broad array of electrophiles.  We also describe a computational method for predicting electrophilic reactivity, which taken together can be applied to the prospective design of thiol-reactive covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAzTSCv_Nj6bVg90H21EOLACvtfcHk0lhCV3nrVkdXsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVyjtLbM&md5=3ccf59ab7a494655185e5eb5becf8c48</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1021%2Fjm501412a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501412a%26sid%3Dliteratum%253Aachs%26aulast%3DFlanagan%26aufirst%3DM.%2BE.%26aulast%3DAbramite%26aufirst%3DJ.%2BA.%26aulast%3DAnderson%26aufirst%3DD.%2BP.%26aulast%3DAulabaugh%26aufirst%3DA.%26aulast%3DDahal%26aufirst%3DU.%2BP.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DMontgomery%26aufirst%3DJ.%26aulast%3DOppenheimer%26aufirst%3DS.%2BR.%26aulast%3DRyder%26aufirst%3DT.%26aulast%3DSchuff%26aufirst%3DB.%2BP.%26aulast%3DUccello%26aufirst%3DD.%2BP.%26aulast%3DWalker%26aufirst%3DG.%2BS.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DBrown%26aufirst%3DM.%2BF.%26aulast%3DChen%26aufirst%3DJ.%2BM.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DNoe%26aufirst%3DM.%2BC.%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DPhilippe%26aufirst%3DL.%26aulast%3DShanmugasundaram%26aufirst%3DV.%26aulast%3DShapiro%26aufirst%3DM.%2BJ.%26aulast%3DStarr%26aufirst%3DJ.%26aulast%3DStroh%26aufirst%3DJ.%26aulast%3DChe%26aufirst%3DY.%26atitle%3DChemical%2520and%2520Computational%2520Methods%2520for%2520the%2520Characterization%2520of%2520Covalent%2520Reactive%2520Groups%2520for%2520the%2520Prospective%2520Design%2520of%2520Irreversible%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D10072%26epage%3D10079%26doi%3D10.1021%2Fjm501412a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Allen, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span> </span><span class="NLM_article-title">CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x"> (</span><span class="NLM_issue">5, Suppl. 16</span><span class="NLM_x">) </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span><span class="refDoi"> DOI: 10.1053/j.seminoncol.2003.08.009</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1053%2Fj.seminoncol.2003.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=14613028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2003&pages=65-78&issue=5%2C+Suppl.+16&author=L.+F.+Allenauthor=I.+A.+Eisemanauthor=D.+W.+Fryauthor=P.+F.+Lenehan&title=CI-1033%2C+an+irreversible+pan-erbB+receptor+inhibitor+and+its+potential+application+for+the+treatment+of+breast+cancer&doi=10.1053%2Fj.seminoncol.2003.08.009"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer</span></div><div class="casAuthors">Allen, Lee F.; Eiseman, Irene A.; Fry, David W.; Lenehan, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  The erbB family of cell surface receptor proteins consists of four members, all of which play a role in the development and growth of the normal breast.  The activity of this signaling pathway is normally tightly controlled, and dysregulation has been shown to play a significant role in the pathogenesis and progression of breast and other cancers.  The potent transforming potential of these receptors is further enhanced by the coexpression of multiple members of this receptor family, which worsens prognosis.  Therapeutic blockade of erbB-2 receptor signaling has to date been shown to be effective in only a subset of chemotherapy-resistant breast cancer patients.  CI-1033 is a highly potent and selective pan-erbB inhibitor that efficiently blocks signal transduction through all four members of the erbB receptor family.  In addn., it covalently binds to these receptors, irreversibility inhibiting them, and thereby provides for prolonged suppression of erbB receptor-mediated signaling.  Clin., it has been shown to have an acceptable side effect profile at potentially therapeutic doses and schedules.  Biomarker studies have shown target inhibition in patients, and evidence of antitumor activity has also been obsd. in phase I studies.  Given the broad expression pattern of the erbB family of receptors in solid tumors, and the important proliferative effect of co-expression of multiple erbB receptors, CI-1033, as an irreversible, pan-erbB inhibitor, has the potential to have an important role in the future treatment of breast and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnHJoa4ri9ObVg90H21EOLACvtfcHk0lhCV3nrVkdXsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrF&md5=13e9d00d8a20f3c79b4f7fe1032f07b5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2003.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2003.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DL.%2BF.%26aulast%3DEiseman%26aufirst%3DI.%2BA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26atitle%3DCI-1033%252C%2520an%2520irreversible%2520pan-erbB%2520receptor%2520inhibitor%2520and%2520its%2520potential%2520application%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2003%26volume%3D30%26issue%3D5%252C%2520Suppl.%252016%26spage%3D65%26epage%3D78%26doi%3D10.1053%2Fj.seminoncol.2003.08.009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zejnullahu, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gale, C.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lifshits, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gonzales, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimamura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naumov, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradner, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Althaus, I. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaenne, P. A.</span><span> </span><span class="NLM_article-title">PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x"> (</span><span class="NLM_issue">24</span><span class="NLM_x">) </span> <span class="NLM_fpage">11924</span><span class="NLM_x">–</span> <span class="NLM_lpage">11932</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-1885</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1158%2F0008-5472.CAN-07-1885" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=11924-11932&issue=24&author=J.+A.+Engelmanauthor=K.+Zejnullahuauthor=C.-M.+Galeauthor=E.+Lifshitsauthor=A.+J.+Gonzalesauthor=T.+Shimamuraauthor=F.+Zhaoauthor=P.+W.+Vincentauthor=G.+N.+Naumovauthor=J.+E.+Bradnerauthor=I.+W.+Althausauthor=L.+Gandhiauthor=G.+I.+Shapiroauthor=J.+M.+Nelsonauthor=J.+V.+Heymachauthor=M.+Meyersonauthor=K.-K.+Wongauthor=P.+A.+Jaenne&title=PF00299804%2C+an+Irreversible+Pan-ERBB+Inhibitor%2C+Is+Effective+in+Lung+Cancer+Models+with+EGFR+and+ERBB2+Mutations+that+Are+Resistant+to+Gefitinib&doi=10.1158%2F0008-5472.CAN-07-1885"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-1885&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-1885%26sid%3Dliteratum%253Aachs%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DZejnullahu%26aufirst%3DK.%26aulast%3DGale%26aufirst%3DC.-M.%26aulast%3DLifshits%26aufirst%3DE.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DZhao%26aufirst%3DF.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26aulast%3DNaumov%26aufirst%3DG.%2BN.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DJaenne%26aufirst%3DP.%2BA.%26atitle%3DPF00299804%252C%2520an%2520Irreversible%2520Pan-ERBB%2520Inhibitor%252C%2520Is%2520Effective%2520in%2520Lung%2520Cancer%2520Models%2520with%2520EGFR%2520and%2520ERBB2%2520Mutations%2520that%2520Are%2520Resistant%2520to%2520Gefitinib%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26issue%3D24%26spage%3D11924%26epage%3D11932%26doi%3D10.1158%2F0008-5472.CAN-07-1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadranel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.-M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.-C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.-H.</span><span> </span><span class="NLM_article-title">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">528</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span><span class="refDoi"> DOI: 10.1016/S1470-2045(12)70087-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&issue=5&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.-M.+Chenauthor=K.+Parkauthor=S.-W.+Kimauthor=C.+Zhouauthor=W.-C.+Suauthor=M.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.-H.+Tanauthor=T.-Y.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.-H.+Yang&title=Afatinib+versus+placebo+for+patients+with+advanced%2C+metastatic+non-small-cell+lung+cancer+after+failure+of+erlotinib%2C+gefitinib%2C+or+both%2C+and+one+or+two+lines+of+chemotherapy+%28LUX-Lung+1%29%3A+a+phase+2b%2F3+randomised+trial&doi=10.1016%2FS1470-2045%2812%2970087-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0lgWyxS4t9petQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.-M.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.-W.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DW.-C.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.-H.%26aulast%3DChao%26aufirst%3DT.-Y.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.-H.%26atitle%3DAfatinib%2520versus%2520placebo%2520for%2520patients%2520with%2520advanced%252C%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520after%2520failure%2520of%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%252C%2520and%2520one%2520or%2520two%2520lines%2520of%2520chemotherapy%2520%2528LUX-Lung%25201%2529%253A%2520a%2520phase%25202b%252F3%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26issue%3D5%26spage%3D528%26epage%3D538%26doi%3D10.1016%2FS1470-2045%2812%2970087-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature (London, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x"> (</span><span class="NLM_issue">7276</span><span class="NLM_x">) </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span><span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&issue=7276&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.-H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.-K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lgWyxS4t9petQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.-H.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.-K.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%2520%2528London%252C%2520U.%2520K.%2529%26date%3D2009%26volume%3D462%26issue%3D7276%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Walter, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjin, R. T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haringsma, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labenski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">St. Martin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karp, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kalken, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chaturvedi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaw-Tsai, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raponi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Dyke, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Etter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weaver, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simmons, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allen, A.</span><span> </span><span class="NLM_article-title">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x"> (</span><span class="NLM_issue">12</span><span class="NLM_x">) </span> <span class="NLM_fpage">1404</span><span class="NLM_x">–</span> <span class="NLM_lpage">1415</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&issue=12&author=A.+O.+Walterauthor=R.+T.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St.+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+Mutant-Selective+Covalent+Inhibitor+of+EGFR+that+Overcomes+T790M-Mediated+Resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lgWyxS4t9petQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt.%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520Mutant-Selective%2520Covalent%2520Inhibitor%2520of%2520EGFR%2520that%2520Overcomes%2520T790M-Mediated%2520Resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26issue%3D12%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghiorghiu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nebhan, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spitzler, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rahi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacobs, V. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brewer, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichihara, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Al-Kadhimi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowlinson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G. H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cantarini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D.-W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranson, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pao, W.</span><span> </span><span class="NLM_article-title">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1061</span><span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&issue=9&author=D.+A.+E.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+V.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+P.+Richmondauthor=M.+Cantariniauthor=D.-W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+Irreversible+EGFR+TKI%2C+Overcomes+T790M-Mediated+Resistance+to+EGFR+Inhibitors+in+Lung+Cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0ljB7MK3fcVuvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%2BP.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.-W.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520Irreversible%2520EGFR%2520TKI%252C%2520Overcomes%2520T790M-Mediated%2520Resistance%2520to%2520EGFR%2520Inhibitors%2520in%2520Lung%2520Cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26issue%3D9%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ballard, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bradbury, R. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Currie, G. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassall, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kemmitt, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lamont, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mellor, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perkins, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richmond, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whittaker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wells, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wrigley, G. L.</span><span> </span><span class="NLM_article-title">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">8249</span><span class="NLM_x">–</span> <span class="NLM_lpage">8267</span><span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&issue=20&author=M.+R.+V.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+E.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+Potent+and+Selective+EGFR+Inhibitor+%28AZD9291%29+of+Both+Sensitizing+and+T790M+Resistance+Mutations+That+Spares+the+Wild+Type+Form+of+the+Receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0ljB7MK3fcVuvg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520Potent%2520and%2520Selective%2520EGFR%2520Inhibitor%2520%2528AZD9291%2529%2520of%2520Both%2520Sensitizing%2520and%2520T790M%2520Resistance%2520Mutations%2520That%2520Spares%2520the%2520Wild%2520Type%2520Form%2520of%2520the%2520Receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D20%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Ward, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderton, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ashton, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bethel, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Box, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butterworth, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chorley, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuaqui, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, D. A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dakin, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Debreczeni, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberlein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finlay, M. R. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grist, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klinowska, T. C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lane, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orme, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waring, M. J.</span><span> </span><span class="NLM_article-title">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">7025</span><span class="NLM_x">–</span> <span class="NLM_lpage">7048</span><span class="refDoi"> DOI: 10.1021/jm400822z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&issue=17&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+E.+Crossauthor=L.+A.+Dakinauthor=J.+E.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+V.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+M.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+Reactivity-Based+Development+of+Covalent+Inhibitors+of+the+Activating+and+Gatekeeper+Mutant+Forms+of+the+Epidermal+Growth+Factor+Receptor+%28EGFR%29&doi=10.1021%2Fjm400822z"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%2BE.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%2BV.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%2BM.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520Reactivity-Based%2520Development%2520of%2520Covalent%2520Inhibitors%2520of%2520the%2520Activating%2520and%2520Gatekeeper%2520Mutant%2520Forms%2520of%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D17%26spage%3D7025%26epage%3D7048%26doi%3D10.1021%2Fjm400822z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">6</span><span class="NLM_x">) </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span><span class="refDoi"> DOI: 10.1021/jm201591k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&issue=6&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+Novel+Conformationally+Constrained+Inhibitors+Targeting+Epidermal+Growth+Factor+Receptor+Threonine790+%E2%86%92+Methionine790+Mutant&doi=10.1021%2Fjm201591k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%2520Novel%2520Conformationally%2520Constrained%2520Inhibitors%2520Targeting%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Threonine790%2520%25E2%2586%2592%2520Methionine790%2520Mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D6%26spage%3D2711%26epage%3D2723%26doi%3D10.1021%2Fjm201591k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, Synthesis, and Biological Evaluation of 2-Oxo-3,4-dihydropyrimido[4,5 d]pyrimidinyl Derivatives as New Irreversible Epidermal Growth Factor Receptor Inhibitors with Improved Pharmacokinetic Properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">21</span><span class="NLM_x">) </span> <span class="NLM_fpage">8803</span><span class="NLM_x">–</span> <span class="NLM_lpage">8813</span><span class="refDoi"> DOI: 10.1021/jm4012388</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4012388" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=8803-8813&issue=21&author=S.+Xuauthor=T.+Xuauthor=L.+Zhangauthor=Z.+Zhangauthor=J.+Luoauthor=Y.+Liuauthor=X.+Luauthor=Z.+Tuauthor=X.+Renauthor=K.+Ding&title=Design%2C+Synthesis%2C+and+Biological+Evaluation+of+2-Oxo-3%2C4-dihydropyrimido%5B4%2C5+d%5Dpyrimidinyl+Derivatives+as+New+Irreversible+Epidermal+Growth+Factor+Receptor+Inhibitors+with+Improved+Pharmacokinetic+Properties&doi=10.1021%2Fjm4012388"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm4012388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4012388%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520Synthesis%252C%2520and%2520Biological%2520Evaluation%2520of%25202-Oxo-3%252C4-dihydropyrimido%255B4%252C5%2520d%255Dpyrimidinyl%2520Derivatives%2520as%2520New%2520Irreversible%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520Inhibitors%2520with%2520Improved%2520Pharmacokinetic%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D21%26spage%3D8803%26epage%3D8813%26doi%3D10.1021%2Fjm4012388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ku, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span> </span><span class="NLM_article-title">Discovery of Pteridin-7(8H)one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x"> (</span><span class="NLM_issue">20</span><span class="NLM_x">) </span> <span class="NLM_fpage">7821</span><span class="NLM_x">–</span> <span class="NLM_lpage">7837</span><span class="refDoi"> DOI: 10.1021/jm401045n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401045n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7821-7837&issue=20&author=W.+Zhouauthor=X.+Liuauthor=Z.+Tuauthor=L.+Zhangauthor=X.+Kuauthor=F.+Baiauthor=Z.+Zhaoauthor=Y.+Xuauthor=K.+Dingauthor=H.+Li&title=Discovery+of+Pteridin-7%288H%29one-Based+Irreversible+Inhibitors+Targeting+the+Epidermal+Growth+Factor+Receptor+%28EGFR%29+Kinase+T790M%2FL858R+Mutant&doi=10.1021%2Fjm401045n"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm401045n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401045n%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DKu%26aufirst%3DX.%26aulast%3DBai%26aufirst%3DF.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DDing%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520Pteridin-7%25288H%2529one-Based%2520Irreversible%2520Inhibitors%2520Targeting%2520the%2520Epidermal%2520Growth%2520Factor%2520Receptor%2520%2528EGFR%2529%2520Kinase%2520T790M%252FL858R%2520Mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D20%26spage%3D7821%26epage%3D7837%26doi%3D10.1021%2Fjm401045n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Xia, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qi, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span> </span><span class="NLM_article-title">A Chemical Tuned Strategy to Develop Novel Irreversible EGFR-TK Inhibitors with Improved Safety and Pharmacokinetic Profiles</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x"> (</span><span class="NLM_issue">23</span><span class="NLM_x">) </span> <span class="NLM_fpage">9889</span><span class="NLM_x">–</span> <span class="NLM_lpage">9900</span><span class="refDoi"> DOI: 10.1021/jm5014659</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm5014659" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9889-9900&issue=23&author=G.+Xiaauthor=W.+Chenauthor=J.+Zhangauthor=J.+Shaoauthor=Y.+Zhangauthor=W.+Huangauthor=L.+Zhangauthor=W.+Qiauthor=X.+Sunauthor=B.+Liauthor=Z.+Xiangauthor=C.+Maauthor=J.+Xuauthor=H.+Dengauthor=Y.+Liauthor=P.+Liauthor=H.+Miaoauthor=J.+Hanauthor=Y.+Liuauthor=J.+Shenauthor=Y.+Yu&title=A+Chemical+Tuned+Strategy+to+Develop+Novel+Irreversible+EGFR-TK+Inhibitors+with+Improved+Safety+and+Pharmacokinetic+Profiles&doi=10.1021%2Fjm5014659"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm5014659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm5014659%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShao%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DQi%26aufirst%3DW.%26aulast%3DSun%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DB.%26aulast%3DXiang%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DC.%26aulast%3DXu%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DMiao%26aufirst%3DH.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DYu%26aufirst%3DY.%26atitle%3DA%2520Chemical%2520Tuned%2520Strategy%2520to%2520Develop%2520Novel%2520Irreversible%2520EGFR-TK%2520Inhibitors%2520with%2520Improved%2520Safety%2520and%2520Pharmacokinetic%2520Profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26issue%3D23%26spage%3D9889%26epage%3D9900%26doi%3D10.1021%2Fjm5014659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Engel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richters, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Getlik, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomassi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keul, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Termathe, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lategahn, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mayer-Wrangowski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruetter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlenbrock, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kruell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaumann, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eppmann, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kibies, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffgaard, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heil, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menninger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortiz-Cuaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuckmann, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tinnefeld, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zahedi, R. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sos, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kast, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rauh, D.</span><span> </span><span class="NLM_article-title">Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x"> (</span><span class="NLM_issue">17</span><span class="NLM_x">) </span> <span class="NLM_fpage">6844</span><span class="NLM_x">–</span> <span class="NLM_lpage">6863</span><span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01082</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01082" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6844-6863&issue=17&author=J.+Engelauthor=A.+Richtersauthor=M.+Getlikauthor=S.+Tomassiauthor=M.+Keulauthor=M.+Termatheauthor=J.+Lategahnauthor=C.+Beckerauthor=S.+Mayer-Wrangowskiauthor=C.+Gruetterauthor=N.+Uhlenbrockauthor=J.+Kruellauthor=N.+Schaumannauthor=S.+Eppmannauthor=P.+Kibiesauthor=F.+Hoffgaardauthor=J.+Heilauthor=S.+Menningerauthor=S.+Ortiz-Cuaranauthor=J.+M.+Heuckmannauthor=V.+Tinnefeldauthor=R.+P.+Zahediauthor=M.+L.+Sosauthor=C.+Schultz-Fademrechtauthor=R.+K.+Thomasauthor=S.+M.+Kastauthor=D.+Rauh&title=Targeting+Drug+Resistance+in+EGFR+with+Covalent+Inhibitors%3A+A+Structure-Based+Design+Approach&doi=10.1021%2Facs.jmedchem.5b01082"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01082%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DTomassi%26aufirst%3DS.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DTermathe%26aufirst%3DM.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DMayer-Wrangowski%26aufirst%3DS.%26aulast%3DGruetter%26aufirst%3DC.%26aulast%3DUhlenbrock%26aufirst%3DN.%26aulast%3DKruell%26aufirst%3DJ.%26aulast%3DSchaumann%26aufirst%3DN.%26aulast%3DEppmann%26aufirst%3DS.%26aulast%3DKibies%26aufirst%3DP.%26aulast%3DHoffgaard%26aufirst%3DF.%26aulast%3DHeil%26aufirst%3DJ.%26aulast%3DMenninger%26aufirst%3DS.%26aulast%3DOrtiz-Cuaran%26aufirst%3DS.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DTinnefeld%26aufirst%3DV.%26aulast%3DZahedi%26aufirst%3DR.%2BP.%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DKast%26aufirst%3DS.%2BM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DTargeting%2520Drug%2520Resistance%2520in%2520EGFR%2520with%2520Covalent%2520Inhibitors%253A%2520A%2520Structure-Based%2520Design%2520Approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D17%26spage%3D6844%26epage%3D6863%26doi%3D10.1021%2Facs.jmedchem.5b01082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Cheng, H.; Johnson, T. O.,  Jr.; Kath, J. C.; Liu, K. K.-C.; Lunney, E. A.; Nagata, A.; Nair, S. K.; Planken, S. P.; Sutton, S. C.</span><span> </span><span class="NLM_article-title">Preparation of pyrrolopyrimidine and purine derivatives for the treatment of abnormal cell growth</span>. WO2013042006,<span class="NLM_x"> </span><span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=H.+Cheng&author=T.+O.+Johnson&author=J.+C.+Kath&author=K.+K.-C.+Liu&author=E.+A.+Lunney&author=A.+Nagata&author=S.+K.+Nair&author=S.+P.+Planken&author=S.+C.+Sutton&title=Preparation+of+pyrrolopyrimidine+and+purine+derivatives+for+the+treatment+of+abnormal+cell+growth"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DH.%26atitle%3DPreparation%2520of%2520pyrrolopyrimidine%2520and%2520purine%2520derivatives%2520for%2520the%2520treatment%2520of%2520abnormal%2520cell%2520growth%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Planken, S.; Nair, S. K.; Kath, J. C.; Lafontaine, J.; Weinrich, S.; Cheng, H.; Sutton, S. C.; Johnson, T. O.; Zientek, M.; Nagata, A.; Gajiwala, K.; Solowiej, J.; Murray, B. W.; Yin, M.-J.; Hemkens, M.</span><span> </span><span class="NLM_article-title">Discovery and development of a series of irreversible EGFR_T790M 7H-pyrrolo[2,3-d]pyrimidine inhibitors with high selectivity over EGFR wild type</span>.  <span class="citation_source-book">Abstracts of Papers</span>, 249th National Meeting and Exposition of the American Chemical Society, Denver, CO, U.S., March 22–26, 2015; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>MEDI-320.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=S.+Planken&author=S.+K.+Nair&author=J.+C.+Kath&author=J.+Lafontaine&author=S.+Weinrich&author=H.+Cheng&author=S.+C.+Sutton&author=T.+O.+Johnson&author=M.+Zientek&author=A.+Nagata&author=K.+Gajiwala&author=J.+Solowiej&author=B.+W.+Murray&author=M.-J.+Yin&author=M.+Hemkens&title=Abstracts+of+Papers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPlanken%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520a%2520series%2520of%2520irreversible%2520EGFR_T790M%25207H-pyrrolo%255B2%252C3-d%255Dpyrimidine%2520inhibitors%2520with%2520high%2520selectivity%2520over%2520EGFR%2520wild%2520type%26btitle%3DAbstracts%2520of%2520Papers%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Schwartz, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuzmic, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solowiej, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergqvist, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bolanos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Almaden, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagata, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalvie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span> </span><span class="NLM_article-title">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">111</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">173</span><span class="NLM_x">–</span> <span class="NLM_lpage">178</span><span class="refDoi"> DOI: 10.1073/pnas.1313733111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1073%2Fpnas.1313733111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=24347635" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2014&pages=173-178&issue=1&author=P.+A.+Schwartzauthor=P.+Kuzmicauthor=J.+Solowiejauthor=S.+Bergqvistauthor=B.+Bolanosauthor=C.+Almadenauthor=A.+Nagataauthor=K.+Ryanauthor=J.+Fengauthor=D.+Dalvieauthor=J.+C.+Kathauthor=M.+Xuauthor=R.+Waniauthor=B.+W.+Murray&title=Covalent+EGFR+inhibitor+analysis+reveals+importance+of+reversible+interactions+to+potency+and+mechanisms+of+drug+resistance&doi=10.1073%2Fpnas.1313733111"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance</span></div><div class="casAuthors">Schwartz, Phillip A.; Kuzmic, Petr; Solowiej, James; Bergqvist, Simon; Bolanos, Ben; Almaden, Chau; Nagata, Asako; Ryan, Kevin; Feng, Junli; Dalvie, Deepak; Kath, John C.; Xu, Meirong; Wani, Revati; Murray, Brion William</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">173-178</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Covalent inhibition is a reemerging paradigm in kinase drug design, but the roles of inhibitor binding affinity and chem. reactivity in overall potency are not well-understood.  To characterize the underlying mol. processes at a microscopic level and det. the appropriate kinetic consts., specialized exptl. design and advanced numerical integration of differential equations are developed.  Previously uncharacterized investigational covalent drugs reported here are shown to be extremely effective epidermal growth factor receptor (EGFR) inhibitors (kinact/Ki in the range 105-107 M-1s-1), despite their low specific reactivity (kinact ≤ 2.1 × 10-3 s-1), which is compensated for by high binding affinities (Ki < 1 nM).  For inhibitors relying on reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor dissocn. and bond formation is central.  Interestingly, reversible binding affinity of EGFR covalent inhibitors is highly correlated with antitumor cell potency.  Furthermore, cellular potency for a subset of covalent inhibitors can be accounted for solely through reversible interactions.  One reversible interaction is between EGFR-Cys797 nucleophile and the inhibitor's reactive group, which may also contribute to drug resistance.  Because covalent inhibitors target a cysteine residue, the effects of its oxidn. on enzyme catalysis and inhibitor pharmacol. are characterized.  Oxidn. of the EGFR cysteine nucleophile does not alter catalysis but has widely varied effects on inhibitor potency depending on the EGFR context (e.g., oncogenic mutations), type of oxidn. (sulfinylation or glutathiolation), and inhibitor architecture.  These methods, parameters, and insights provide a rational framework for assessing and designing effective covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrTpPuRq8MwCLVg90H21EOLACvtfcHk0lhTrZJ_V6dwdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXps1eluw%253D%253D&md5=47197c5e7876a238eefb2e8e7de305ea</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1313733111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1313733111%26sid%3Dliteratum%253Aachs%26aulast%3DSchwartz%26aufirst%3DP.%2BA.%26aulast%3DKuzmic%26aufirst%3DP.%26aulast%3DSolowiej%26aufirst%3DJ.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DBolanos%26aufirst%3DB.%26aulast%3DAlmaden%26aufirst%3DC.%26aulast%3DNagata%26aufirst%3DA.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DDalvie%26aufirst%3DD.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWani%26aufirst%3DR.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26atitle%3DCovalent%2520EGFR%2520inhibitor%2520analysis%2520reveals%2520importance%2520of%2520reversible%2520interactions%2520to%2520potency%2520and%2520mechanisms%2520of%2520drug%2520resistance%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2014%26volume%3D111%26issue%3D1%26spage%3D173%26epage%3D178%26doi%3D10.1073%2Fpnas.1313733111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Kuzmic, P.</span><span> </span><span class="NLM_article-title">Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase</span> <span class="citation_source-journal">Anal. Biochem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1996</span><span class="NLM_x">, </span> <span class="NLM_volume">237</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">273</span><span class="refDoi"> DOI: 10.1006/abio.1996.0238</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1006%2Fabio.1996.0238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=8660575" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADyaK28XjtlOktL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=237&publication_year=1996&pages=260-273&issue=2&author=P.+Kuzmic&title=Program+DYNAFIT+for+the+analysis+of+enzyme+kinetic+data%3A+application+to+HIV+proteinase&doi=10.1006%2Fabio.1996.0238"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Program DYNAFIT for the analysis of enzyme kinetic data: application to HIV proteinase</span></div><div class="casAuthors">Kuzmic, Petr</div><div class="citationInfo"><span class="NLM_cas:title">Analytical Biochemistry</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">237</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">260-273</span>CODEN:
                <span class="NLM_cas:coden">ANBCA2</span>;
        ISSN:<span class="NLM_cas:issn">0003-2697</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">A computer program with the code name DYNAFIT was developed for fitting either the initial velocities or the time course of enzyme reactions to an arbitrary mol. mechanism represented symbolically by a set of chem. equations.  Seven numerical tests and five graphical tests are applied to judge the goodness of fit.  Exptl. data on the inhibition of the dissociative dimeric proteinase from HIV were used in four test examples.  A set of initial velocities was analyzed to see if a tight-binding inhibitor could bind to the HIV proteinase monomer.  Three different sets of progress curves were analyzed (i) to det. the kinetic properties of an irreversible inhibitor, (ii) to investigate the dissocn. and denaturation mechanism for the protease dimer, and (iii) to investigate the inhibition mechanism for a transient inhibitor.  The program is available by anonymous ftp via uwmml.pharmacy.wisc.edu and on the World Wide Web via http://uwmml.pharmacy.wisc. edu.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGa_hR-OebWLVg90H21EOLACvtfcHk0lhTrZJ_V6dwdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XjtlOktL4%253D&md5=71b4b01a4d81d3e38490b1124fe836b4</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1006%2Fabio.1996.0238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fabio.1996.0238%26sid%3Dliteratum%253Aachs%26aulast%3DKuzmic%26aufirst%3DP.%26atitle%3DProgram%2520DYNAFIT%2520for%2520the%2520analysis%2520of%2520enzyme%2520kinetic%2520data%253A%2520application%2520to%2520HIV%2520proteinase%26jtitle%3DAnal.%2520Biochem.%26date%3D1996%26volume%3D237%26issue%3D2%26spage%3D260%26epage%3D273%26doi%3D10.1006%2Fabio.1996.0238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Kuzmic, P.</span><span> </span><span class="NLM_article-title">DynaFit—a software package for enzymology</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">247</span><span class="NLM_x">–</span> <span class="NLM_lpage">280</span><span class="refDoi"> DOI: 10.1016/S0076-6879(09)67010-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2FS0076-6879%2809%2967010-5" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2009&pages=247-280&author=P.+Kuzmic&title=DynaFit%E2%80%94a+software+package+for+enzymology&doi=10.1016%2FS0076-6879%2809%2967010-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2FS0076-6879%2809%2967010-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0076-6879%252809%252967010-5%26sid%3Dliteratum%253Aachs%26aulast%3DKuzmic%26aufirst%3DP.%26atitle%3DDynaFit%25E2%2580%2594a%2520software%2520package%2520for%2520enzymology%26jtitle%3DMethods%2520Enzymol.%26date%3D2009%26volume%3D467%26spage%3D247%26epage%3D280%26doi%3D10.1016%2FS0076-6879%2809%2967010-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span> </span><span class="NLM_article-title">Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition</span> <span class="citation_source-journal">Structure (Oxford, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x"> (</span><span class="NLM_issue">2</span><span class="NLM_x">) </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span><span class="refDoi"> DOI: 10.1016/j.str.2012.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1016%2Fj.str.2012.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFeq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=209-219&issue=2&author=K.+S.+Gajiwalaauthor=J.+Fengauthor=R.+Ferreauthor=K.+Ryanauthor=O.+Brodskyauthor=S.+Weinrichauthor=J.+C.+Kathauthor=A.+Stewart&title=Insights+into+the+Aberrant+Activity+of+Mutant+EGFR+Kinase+Domain+and+Drug+Recognition&doi=10.1016%2Fj.str.2012.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition</span></div><div class="casAuthors">Gajiwala, Ketan S.; Feng, Junli; Ferre, RoseAnn; Ryan, Kevin; Brodsky, Oleg; Weinrich, Scott; Kath, John C.; Stewart, Al</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-219</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The oncogenicity of the L858R mutant form of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer is thought to be due to the constitutive activation of its kinase domain.  The selectivity of the marketed drugs gefitinib and erlotinib for L858R mutant is attributed to their specific recognition of the active kinase and to weaker ATP binding by L858R EGFR.  We present crystal structures showing that neither L858R nor the drug-resistant L858R+T790M EGFR kinase domain is in the constitutively active conformation.  Addnl. co-crystal structures show that gefitinib and dacomitinib, an irreversible anilinoquinazoline deriv. currently in clin. development, may not be conformation specific for the active state of the enzyme.  Structural data further reveal the potential mode of recognition of one of the autophosphorylation sites in the C-terminal tail, Tyr-1016, by the kinase domain.  Biochem. and biophys. evidence suggest that the oncogenic mutations impact the conformational dynamics of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi6kAQLM6h7LVg90H21EOLACvtfcHk0lhTrZJ_V6dwdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFeq&md5=439bfda2e4e33786a15742e53cc271bc</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DWeinrich%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DStewart%26aufirst%3DA.%26atitle%3DInsights%2520into%2520the%2520Aberrant%2520Activity%2520of%2520Mutant%2520EGFR%2520Kinase%2520Domain%2520and%2520Drug%2520Recognition%26jtitle%3DStructure%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2013%26volume%3D21%26issue%3D2%26spage%3D209%26epage%3D219%26doi%3D10.1016%2Fj.str.2012.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney-Pickett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Umland, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gebhard, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Federico, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davidson, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reyner, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kempshall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-kattan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liston, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Troutman, M. D.</span><span> </span><span class="NLM_article-title">Development of a new permeability assay using low-efflux MDCKII cells</span> <span class="citation_source-journal">J. Pharm. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x"> (</span><span class="NLM_issue">11</span><span class="NLM_x">) </span> <span class="NLM_fpage">4974</span><span class="NLM_x">–</span> <span class="NLM_lpage">4985</span><span class="refDoi"> DOI: 10.1002/jps.22674</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1002%2Fjps.22674" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=21766308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2011&pages=4974-4985&issue=11&author=L.+Diauthor=C.+Whitney-Pickettauthor=J.+P.+Umlandauthor=H.+Zhangauthor=X.+Zhangauthor=D.+F.+Gebhardauthor=Y.+Laiauthor=J.+J.+Federicoauthor=R.+E.+Davidsonauthor=R.+Smithauthor=E.+L.+Reynerauthor=C.+Leeauthor=B.+Fengauthor=C.+Rotterauthor=M.+V.+Varmaauthor=S.+Kempshallauthor=K.+Fennerauthor=A.+F.+El-kattanauthor=T.+E.+Listonauthor=M.+D.+Troutman&title=Development+of+a+new+permeability+assay+using+low-efflux+MDCKII+cells&doi=10.1002%2Fjps.22674"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a new permeability assay using low-efflux MDCKII cells</span></div><div class="casAuthors">Di, Li; Whitney-Pickett, Carrie; Umland, John P.; Zhang, Hui; Zhang, Xun; Gebhard, David F.; Lai, Yurong; Federico, James J.; Davidson, Ralph E.; Smith, Russ; Reyner, Eric L.; Lee, Caroline; Feng, Bo; Rotter, Charles; Varma, Manthena V.; Kempshall, Sarah; Fenner, Katherine; El-kattan, Ayman F.; Liston, Theodore E.; Troutman, Matthew D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4974-4985</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Permeability is an important property of drug candidates.  The Madin-Darby canine kidney cell line (MDCK) permeability assay is widely used and the primary concern of using MDCK cells is the presence of endogenous transporters of nonhuman origin.  The canine P-glycoprotein (Pgp) can interfere with permeability and transporter studies, leading to less reliable data.  A new cell line, MDCKII-LE (low efflux), has been developed by selecting a subpopulation of low-efflux cells from MDCKII-WT using an iterative fluorescence-activated cell sorting technique with calcein-AM as a Pgp and efflux substrate.  MDCKII-LE cells are a subpopulation of MDCKII cells with over 200-fold lower canine Pgp mRNA level and fivefold lower protein level than MDCKII-WT.  MDCKII-LE cells showed less functional efflux activity than MDCKII-WT based on efflux ratios.  Notably, MDCKII-MDR1 showed about 1.5-fold decreased expression of endogenous canine Pgp, suggesting that using the net flux ratio might not completely cancel out the background endogenous transporter activities.  MDCKII-LE cells offer clear advantages over the MDCKII-WT by providing less efflux transporter background signals and minimizing interference from canine Pgp.  The MDCKII-LE apparent permeability values well differentiates compds. from high to medium/low human intestinal absorption and can be used for Biopharmaceutical Classification System.  The MDCKII-LE permeability assay (4-in-1 cassette dosing) is high throughput with good precision, reproducibility, robustness, and cost-effective. © 2011 Wiley-Liss, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTVtRmYnbF17Vg90H21EOLACvtfcHk0liSGGQVbfJgyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXovFGltb8%253D&md5=97f647fc215ea6d04882351ffc912a1e</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1002%2Fjps.22674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.22674%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGebhard%26aufirst%3DD.%2BF.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DFederico%26aufirst%3DJ.%2BJ.%26aulast%3DDavidson%26aufirst%3DR.%2BE.%26aulast%3DSmith%26aufirst%3DR.%26aulast%3DReyner%26aufirst%3DE.%2BL.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DFeng%26aufirst%3DB.%26aulast%3DRotter%26aufirst%3DC.%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DKempshall%26aufirst%3DS.%26aulast%3DFenner%26aufirst%3DK.%26aulast%3DEl-kattan%26aufirst%3DA.%2BF.%26aulast%3DListon%26aufirst%3DT.%2BE.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26atitle%3DDevelopment%2520of%2520a%2520new%2520permeability%2520assay%2520using%2520low-efflux%2520MDCKII%2520cells%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2011%26volume%3D100%26issue%3D11%26spage%3D4974%26epage%3D4985%26doi%3D10.1002%2Fjps.22674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Varma, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gardner, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steyn, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nkansah, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rotter, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitney-Pickett, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fenner, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">El-Kattan, A. F.</span><span> </span><span class="NLM_article-title">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span> <span class="citation_source-journal">Mol. Pharmaceutics</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x"> (</span><span class="NLM_issue">5</span><span class="NLM_x">) </span> <span class="NLM_fpage">1199</span><span class="NLM_x">–</span> <span class="NLM_lpage">1212</span><span class="refDoi"> DOI: 10.1021/mp2004912</span> </span><div class="citationLinks">[<a href="/doi/10.1021/mp2004912" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1199-1212&issue=5&author=M.+V.+Varmaauthor=I.+Gardnerauthor=S.+J.+Steynauthor=P.+Nkansahauthor=C.+J.+Rotterauthor=C.+Whitney-Pickettauthor=H.+Zhangauthor=L.+Diauthor=M.+Cramauthor=K.+S.+Fennerauthor=A.+F.+El-Kattan&title=pH-Dependent+solubility+and+permeability+criteria+for+provisional+biopharmaceutics+classification+%28BCS+and+BDDCS%29+in+early+drug+discovery&doi=10.1021%2Fmp2004912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery</span></div><div class="casAuthors">Varma, Manthena V.; Gardner, Iain; Steyn, Stefanus J.; Nkansah, Paul; Rotter, Charles J.; Whitney-Pickett, Carrie; Zhang, Hui; Di, Li; Cram, Michael; Fenner, Katherine S.; El-Kattan, Ayman F.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmaceutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1199-1212</span>CODEN:
                <span class="NLM_cas:coden">MPOHBP</span>;
        ISSN:<span class="NLM_cas:issn">1543-8384</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The Biopharmaceutics Classification System (BCS) is a scientific framework that provides a basis for predicting the oral absorption of drugs.  These concepts have been extended in the Biopharmaceutics Drug Disposition Classification System (BDDCS) to explain the potential mechanism of drug clearance and understand the effects of uptake and efflux transporters on absorption, distribution, metab., and elimination.  The objective of present work is to establish criteria for provisional biopharmaceutics classification using pH-dependent passive permeability and aq. soly. data generated from high throughput screening methodologies in drug discovery settings.  The apparent permeability across monolayers of clonal cell line of Madin-Darby canine kidney cells, selected for low endogenous efflux transporter expression, was measured for a set of 105 drugs, with known BCS and BDDCS class.  The permeability at apical pH 6.5 for acidic drugs and at pH 7.4 for nonacidic drugs showed a good correlation with the fraction absorbed in human (Fa).  Receiver operating characteristic (ROC) curve anal. was utilized to define the permeability class boundary.  At permeability ≥5 × 10-6 cm/s, the accuracy of predicting Fa of ≥0.90 was 87%.  Also, this cutoff showed more than 80% sensitivity and specificity in predicting the literature permeability classes (BCS), and the metab. classes (BDDCS).  The equil. soly. of a subset of 49 drugs was measured in pH 1.2 medium, pH 6.5 phosphate buffer, and in FaSSIF medium (pH 6.5).  Although dose was not considered, good concordance of the measured soly. with BCS and BDDCS soly. class was achieved, when soly. at pH 1.2 was used for acidic compds. and FaSSIF soly. was used for basic, neutral, and zwitterionic compds.  Using a cutoff of 200 μg/mL, the data set suggested a 93% sensitivity and 86% specificity in predicting both the BCS and BDDCS soly. classes.  In conclusion, this study identified pH-dependent permeability and soly. criteria that can be used to assign provisional biopharmaceutics class at early stage of the drug discovery process.  Addnl., such a classification system will enable discovery scientists to assess the potential limiting factors to oral absorption, as well as help predict the drug disposition mechanisms and potential drug-drug interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr84irw4TD15rVg90H21EOLACvtfcHk0liSGGQVbfJgyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xlt1Ont74%253D&md5=2bcb29ea512d2e0665973292e4a4a0a3</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Fmp2004912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fmp2004912%26sid%3Dliteratum%253Aachs%26aulast%3DVarma%26aufirst%3DM.%2BV.%26aulast%3DGardner%26aufirst%3DI.%26aulast%3DSteyn%26aufirst%3DS.%2BJ.%26aulast%3DNkansah%26aufirst%3DP.%26aulast%3DRotter%26aufirst%3DC.%2BJ.%26aulast%3DWhitney-Pickett%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DCram%26aufirst%3DM.%26aulast%3DFenner%26aufirst%3DK.%2BS.%26aulast%3DEl-Kattan%26aufirst%3DA.%2BF.%26atitle%3DpH-Dependent%2520solubility%2520and%2520permeability%2520criteria%2520for%2520provisional%2520biopharmaceutics%2520classification%2520%2528BCS%2520and%2520BDDCS%2529%2520in%2520early%2520drug%2520discovery%26jtitle%3DMol.%2520Pharmaceutics%26date%3D2012%26volume%3D9%26issue%3D5%26spage%3D1199%26epage%3D1212%26doi%3D10.1021%2Fmp2004912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dube, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoffman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jalaie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, G. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koenig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vojkovsky, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, Y.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aguirre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span> </span><span class="NLM_article-title">Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x"> (</span><span class="NLM_issue">18</span><span class="NLM_x">) </span> <span class="NLM_fpage">8091</span><span class="NLM_x">–</span> <span class="NLM_lpage">8109</span><span class="refDoi"> DOI: 10.1021/jm300967g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300967g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8091-8109&issue=18&author=J.+J.+Cuiauthor=M.+McTigueauthor=M.+Nambuauthor=M.+Tran-Dubeauthor=M.+Pairishauthor=H.+Shenauthor=L.+Jiaauthor=H.+Chengauthor=J.+Hoffmanauthor=P.+Leauthor=M.+Jalaieauthor=G.+H.+Goetzauthor=M.+Koenigauthor=T.+Vojkovskyauthor=F.-J.+Zhangauthor=S.+Doauthor=I.+Botrousauthor=K.+Ryanauthor=N.+Grodskyauthor=Y.-l.+Dengauthor=M.+Parkerauthor=S.+Timofeevskiauthor=B.+W.+Murrayauthor=S.+Yamazakiauthor=S.+Aguirreauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensen&title=Discovery+of+a+Novel+Class+of+Exquisitely+Selective+Mesenchymal-Epithelial+Transition+Factor+%28c-MET%29+Protein+Kinase+Inhibitors+and+Identification+of+the+Clinical+Candidate+2-%284-%281-%28Quinolin-6-ylmethyl%29-1H-%5B1%2C2%2C3%5Dtriazolo%5B4%2C5-b%5Dpyrazin-6-yl%29-1H-pyrazol-1-yl%29ethanol+%28PF-04217903%29+for+the+Treatment+of+Cancer&doi=10.1021%2Fjm300967g"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm300967g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300967g%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DTran-Dube%26aufirst%3DM.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DCheng%26aufirst%3DH.%26aulast%3DHoffman%26aufirst%3DJ.%26aulast%3DLe%26aufirst%3DP.%26aulast%3DJalaie%26aufirst%3DM.%26aulast%3DGoetz%26aufirst%3DG.%2BH.%26aulast%3DKoenig%26aufirst%3DM.%26aulast%3DVojkovsky%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DF.-J.%26aulast%3DDo%26aufirst%3DS.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DDeng%26aufirst%3DY.-l.%26aulast%3DParker%26aufirst%3DM.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DAguirre%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520a%2520Novel%2520Class%2520of%2520Exquisitely%2520Selective%2520Mesenchymal-Epithelial%2520Transition%2520Factor%2520%2528c-MET%2529%2520Protein%2520Kinase%2520Inhibitors%2520and%2520Identification%2520of%2520the%2520Clinical%2520Candidate%25202-%25284-%25281-%2528Quinolin-6-ylmethyl%2529-1H-%255B1%252C2%252C3%255Dtriazolo%255B4%252C5-b%255Dpyrazin-6-yl%2529-1H-pyrazol-1-yl%2529ethanol%2520%2528PF-04217903%2529%2520for%2520the%2520Treatment%2520of%2520Cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26issue%3D18%26spage%3D8091%26epage%3D8109%26doi%3D10.1021%2Fjm300967g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Chein, R.-J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corey, E. J.</span><span> </span><span class="NLM_article-title">Strong Conformational Preferences of Heteroaromatic Ethers and Electron Pair Repulsion</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">132</span><span class="NLM_x">–</span> <span class="NLM_lpage">135</span><span class="refDoi"> DOI: 10.1021/ol9025364</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol9025364" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFSnurnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=132-135&issue=1&author=R.-J.+Cheinauthor=E.+J.+Corey&title=Strong+Conformational+Preferences+of+Heteroaromatic+Ethers+and+Electron+Pair+Repulsion&doi=10.1021%2Fol9025364"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Strong Conformational Preferences of Heteroaromatic Ethers and Electron Pair Repulsion</span></div><div class="casAuthors">Chein, Rong-Jie; Corey, E. J.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">132-135</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Electron-pair repulsion in 2-methoxyheteroarenes is important for N, but not for O or S heteroatoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgArLQp_Bpl7Vg90H21EOLACvtfcHk0lhfsOGqg246fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFSnurnJ&md5=f558c5f754f1610e85bab3a0f556b0db</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1021%2Fol9025364&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol9025364%26sid%3Dliteratum%253Aachs%26aulast%3DChein%26aufirst%3DR.-J.%26aulast%3DCorey%26aufirst%3DE.%2BJ.%26atitle%3DStrong%2520Conformational%2520Preferences%2520of%2520Heteroaromatic%2520Ethers%2520and%2520Electron%2520Pair%2520Repulsion%26jtitle%3DOrg.%2520Lett.%26date%3D2010%26volume%3D12%26issue%3D1%26spage%3D132%26epage%3D135%26doi%3D10.1021%2Fol9025364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Perola, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Charifson, P. S.</span><span> </span><span class="NLM_article-title">Conformational Analysis of Drug-Like Molecules Bound to Proteins: An Extensive Study of Ligand Reorganization upon Binding</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x"> (</span><span class="NLM_issue">10</span><span class="NLM_x">) </span> <span class="NLM_fpage">2499</span><span class="NLM_x">–</span> <span class="NLM_lpage">2510</span><span class="refDoi"> DOI: 10.1021/jm030563w</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm030563w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVans78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=2499-2510&issue=10&author=E.+Perolaauthor=P.+S.+Charifson&title=Conformational+Analysis+of+Drug-Like+Molecules+Bound+to+Proteins%3A+An+Extensive+Study+of+Ligand+Reorganization+upon+Binding&doi=10.1021%2Fjm030563w"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Conformational Analysis of Drug-Like Molecules Bound to Proteins: An Extensive Study of Ligand Reorganization upon Binding</span></div><div class="casAuthors">Perola, Emanuele; Charifson, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2499-2510</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">This paper describes a large-scale study on the nature and the energetics of the conformational changes drug-like mols. experience upon binding.  Ligand strain energies and conformational reorganization were analyzed with different computational methods on 150 crystal structures of pharmaceutically relevant protein-ligand complexes.  The common knowledge that ligands rarely bind in their lowest calcd. energy conformation was confirmed.  Addnl., the authors found that over 60% of the ligands do not bind in a local min. conformation.  While approx. 60% of the ligands were calcd. to bind with strain energies lower than 5 kcal/mol, strain energies over 9 kcal/mol were calcd. in at least 10% of the cases regardless of the method used.  A clear correlation was found between acceptable strain energy and ligand flexibility, while there was no correlation between strain energy and binding affinity, thus indicating that expensive conformational rearrangements can be tolerated in some cases without overly penalizing the tightness of binding.  On the basis of the trends obsd., thresholds for the acceptable strain energies of bioactive conformations were defined with consideration of the impact of ligand flexibility.  An anal. of the degree of folding of the bound ligands confirmed the general tendency of small mols. to bind in an extended conformation.  The results suggest that the unfolding of hydrophobic ligands during binding, which exposes hydrophobic surfaces to contact with protein residues, could be one of the factors accounting for high reorganization energies.  Finally, different methods for conformational anal. were evaluated, and guidelines were defined to maximize the prevalence of bioactive conformations in computationally generated ensembles.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMrN0dFKglcbVg90H21EOLACvtfcHk0lhfsOGqg246fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVans78%253D&md5=8f54a8285ef1ffc5e1a19f748f4674bf</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1021%2Fjm030563w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm030563w%26sid%3Dliteratum%253Aachs%26aulast%3DPerola%26aufirst%3DE.%26aulast%3DCharifson%26aufirst%3DP.%2BS.%26atitle%3DConformational%2520Analysis%2520of%2520Drug-Like%2520Molecules%2520Bound%2520to%2520Proteins%253A%2520An%2520Extensive%2520Study%2520of%2520Ligand%2520Reorganization%2520upon%2520Binding%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26issue%3D10%26spage%3D2499%26epage%3D2510%26doi%3D10.1021%2Fjm030563w" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Lanning, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitby, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dix, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Douhan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilbert, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hett, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, T. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joslyn, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niessen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hulce, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whiteley, L. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayward, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x"> (</span><span class="NLM_issue">9</span><span class="NLM_x">) </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">767</span><span class="refDoi"> DOI: 10.1038/nchembio.1582</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1038%2Fnchembio.1582" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=25038787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2014&pages=760-767&issue=9&author=B.+R.+Lanningauthor=L.+R.+Whitbyauthor=M.+M.+Dixauthor=J.+Douhanauthor=A.+M.+Gilbertauthor=E.+C.+Hettauthor=T.+O.+Johnsonauthor=C.+Joslynauthor=J.+C.+Kathauthor=S.+Niessenauthor=L.+R.+Robertsauthor=M.+E.+Schnuteauthor=C.+Wangauthor=J.+J.+Hulceauthor=B.+Weiauthor=L.+O.+Whiteleyauthor=M.+M.+Haywardauthor=B.+F.+Cravatt&title=A+road+map+to+evaluate+the+proteome-wide+selectivity+of+covalent+kinase+inhibitors&doi=10.1038%2Fnchembio.1582"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors</span></div><div class="casAuthors">Lanning, Bryan R.; Whitby, Landon R.; Dix, Melissa M.; Douhan, John; Gilbert, Adam M.; Hett, Erik C.; Johnson, Theodore O.; Joslyn, Chris; Kath, John C.; Niessen, Sherry; Roberts, Lee R.; Schnute, Mark E.; Wang, Chu; Hulce, Jonathan J.; Wei, Baoxian; Whiteley, Laurence O.; Hayward, Matthew M.; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">760-767</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinases are principal components of signal transduction pathways and the focus of intense basic and drug discovery research.  Irreversible inhibitors that covalently modify non-catalytic cysteines in kinase active sites have emerged as valuable probes and approved drugs.  Many protein classes, however, have functional cysteines, and therefore understanding the proteome-wide selectivity of covalent kinase inhibitors is imperative.  Here, we accomplish this objective using activity-based protein profiling coupled with quant. MS to globally map the targets, both specific and nonspecific, of covalent kinase inhibitors in human cells.  Many of the specific off-targets represent nonkinase proteins that, notably, have conserved active site cysteines.  We define windows of selectivity for covalent kinase inhibitors and show that, when these windows are exceeded, rampant proteome-wide reactivity and kinase target-independent cell death conjointly occur.  Our findings, taken together, provide an exptl. road map to illuminate opportunities and surmount challenges for the development of covalent kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMAiUlEg9R5rVg90H21EOLACvtfcHk0lhfsOGqg246fA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtFygs7nO&md5=6f17b0d1b00e088f37c511eea577d290</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.1582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.1582%26sid%3Dliteratum%253Aachs%26aulast%3DLanning%26aufirst%3DB.%2BR.%26aulast%3DWhitby%26aufirst%3DL.%2BR.%26aulast%3DDix%26aufirst%3DM.%2BM.%26aulast%3DDouhan%26aufirst%3DJ.%26aulast%3DGilbert%26aufirst%3DA.%2BM.%26aulast%3DHett%26aufirst%3DE.%2BC.%26aulast%3DJohnson%26aufirst%3DT.%2BO.%26aulast%3DJoslyn%26aufirst%3DC.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DNiessen%26aufirst%3DS.%26aulast%3DRoberts%26aufirst%3DL.%2BR.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DHulce%26aufirst%3DJ.%2BJ.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DWhiteley%26aufirst%3DL.%2BO.%26aulast%3DHayward%26aufirst%3DM.%2BM.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DA%2520road%2520map%2520to%2520evaluate%2520the%2520proteome-wide%2520selectivity%2520of%2520covalent%2520kinase%2520inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2014%26volume%3D10%26issue%3D9%26spage%3D760%26epage%3D767%26doi%3D10.1038%2Fnchembio.1582" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Rostovtsev, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Green, L. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fokin, V. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharpless, K. B.</span><span> </span><span class="NLM_article-title">A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes</span> <span class="citation_source-journal">Angew. Chem., Int. Ed.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">41</span><span class="NLM_x"> (</span><span class="NLM_issue">14</span><span class="NLM_x">) </span> <span class="NLM_fpage">2596</span><span class="NLM_x">–</span> <span class="NLM_lpage">2599</span><span class="refDoi"> DOI: 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;key=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=2002&pages=2596-2599&issue=14&author=V.+V.+Rostovtsevauthor=L.+G.+Greenauthor=V.+V.+Fokinauthor=K.+B.+Sharpless&title=A+stepwise+Huisgen+cycloaddition+process%3A+copper%28I%29-catalyzed+regioselective+%22ligation%22+of+azides+and+terminal+alkynes&doi=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3773%252820020715%252941%253A14%253C2596%253A%253AAID-ANIE2596%253E3.0.CO%253B2-4%26sid%3Dliteratum%253Aachs%26aulast%3DRostovtsev%26aufirst%3DV.%2BV.%26aulast%3DGreen%26aufirst%3DL.%2BG.%26aulast%3DFokin%26aufirst%3DV.%2BV.%26aulast%3DSharpless%26aufirst%3DK.%2BB.%26atitle%3DA%2520stepwise%2520Huisgen%2520cycloaddition%2520process%253A%2520copper%2528I%2529-catalyzed%2520regioselective%2520%2522ligation%2522%2520of%2520azides%2520and%2520terminal%2520alkynes%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2002%26volume%3D41%26issue%3D14%26spage%3D2596%26epage%3D2599%26doi%3D10.1002%2F1521-3773%2820020715%2941%3A14%3C2596%3A%3AAID-ANIE2596%3E3.0.CO%3B2-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Muchowski, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solas, D. R.</span><span> </span><span class="NLM_article-title">Protecting groups for the pyrrole and indole nitrogen atom. The [2-(trimethylsilyl)ethoxy]methyl moiety. Lithiation of 1-[[2-(trimethylsilyl)ethoxy]methyl]pyrrole</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1984</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x"> (</span><span class="NLM_issue">1</span><span class="NLM_x">) </span> <span class="NLM_fpage">203</span><span class="NLM_x">–</span> <span class="NLM_lpage">5</span><span class="refDoi"> DOI: 10.1021/jo00175a053</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00175a053" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=1984&pages=203-5&issue=1&author=J.+M.+Muchowskiauthor=D.+R.+Solas&title=Protecting+groups+for+the+pyrrole+and+indole+nitrogen+atom.+The+%5B2-%28trimethylsilyl%29ethoxy%5Dmethyl+moiety.+Lithiation+of+1-%5B%5B2-%28trimethylsilyl%29ethoxy%5Dmethyl%5Dpyrrole&doi=10.1021%2Fjo00175a053"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjo00175a053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00175a053%26sid%3Dliteratum%253Aachs%26aulast%3DMuchowski%26aufirst%3DJ.%2BM.%26aulast%3DSolas%26aufirst%3DD.%2BR.%26atitle%3DProtecting%2520groups%2520for%2520the%2520pyrrole%2520and%2520indole%2520nitrogen%2520atom.%2520The%2520%255B2-%2528trimethylsilyl%2529ethoxy%255Dmethyl%2520moiety.%2520Lithiation%2520of%25201-%255B%255B2-%2528trimethylsilyl%2529ethoxy%255Dmethyl%255Dpyrrole%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1984%26volume%3D49%26issue%3D1%26spage%3D203%26epage%3D5%26doi%3D10.1021%2Fjo00175a053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG7" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG7','PDB','5HG7'); return false;">PDB: 5HG7</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG5','PDB','5HG5'); return false;">PDB: 5HG5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG8" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG8','PDB','5HG8'); return false;">PDB: 5HG8</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG9','PDB','5HG9'); return false;">PDB: 5HG9</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i50"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01633">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_58020"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01633">10.1021/acs.jmedchem.5b01633</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Methods to estimate reversible binding affinities of covalent inhibitors, experimental procedures, and spectral data for compounds <b>14</b>–<b>22</b> and relevant intermediates, additional data on proteome wide selectivity for compound <b>1</b>, kinase selectivity data for compound <b>1</b>, ligand torsional strain energy analysis for <b>15</b> and <b>16</b>, ligand strain energy analysis for bound conformation of compound <b>1</b> in EGFR DM, and modeling of compound <b>10</b> in EGFR WT protein (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings for <b>1</b>, <b>10</b>–<b>23</b>, canertinib (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_002.csv">CSV</a>)</p></li><li><p class="inline">Molecular formula strings for <b>1</b>, rociletinib, osimertinib, erlotinib (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_003.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_001.pdf">jm5b01633_si_001.pdf (1.22 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_002.csv">jm5b01633_si_002.csv (1.54 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01633/suppl_file/jm5b01633_si_003.csv">jm5b01633_si_003.csv (0.63 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">PDB codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG7">5HG7</a> for compound <b>1</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG5">5HG5</a> for compound <b>10</b>, <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG8">5HG8</a> for compound <b>12</b>, and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5HG9">5HG9</a> for compound <b>14</b>.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01633&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-5%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01633" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01633" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                3MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a63184c763c82","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
